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Abstract
Blood cells are crucial to human physiology, with functions in oxygen transport, infection
control, and wound healing. Molecular mechanisms endogenous to blood cells have
been implicated in the aetiologies of cancer, infection and inflammatory and immune
disorders. The genetic determinants of blood cell function have not been comprehensively
characterised, because it is too difficult to perform direct assays of cell function in large
population samples. High-throughput flow cytometry can be used to measure functionally
relevant phenotypes such as cell granulation, nucleic acid content, and cell size. Many
of these phenotypes are important for the diagnosis of diseases such as sepsis, Szary
disease, toxic granulation, and myelodysplastic syndromes, or correlate with assessments
of cell morphology from blood smear images. Here, I report the results of my genome-
wide association study of 63 previously genetically unstudied blood cell flow cytometry
phenotypes. I have identified associated variants in loci containing genes coding for
established drug targets with known roles in white cell function and immunity. I have
colocalised the association signals with blood cell transcriptomic, blood proteomic, and
disease risk, identifying possible causal roles for molecular mechanisms endogenous to white
cells in the aetiology of a range of immune disorders, including atopic dermatitis, multiple
sclerosis and celiac disease. My results have utility in drug design and therapeutic target
selection, demonstrated by examples including the replication of the mechanism of action
of Daclizumab, a treatment for multiple sclerosis, and evidence for the role of IL-18R1 in
aetiology of celiac disease. Furthermore, mendelian randomisation analyses suggest a causal
role for blood cell flow cytometry phenotypes in the aetiology of coronary artery disease,
lung cancer, and asthma. In addition to my work on flow cytometry traits, I report a major
contribution to the largest ever GWAS meta-analysis of routine clinical haematological
phenotypes, including 563,085 individuals. I performed primary and conditional analyses,
identifying parsimonious sets of independently associated variants. This is the largest
genome-wide association study study of clinical haematological phenotypes to date and
identifies 7,122 association signals.
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Chapter 1
Introduction
Cells are a primary unit of biology and cell behaviour such as cell count, protein production
and exocytosis, mitosis, and signalling are important biological functions. Underpinning
these cell phenotypes are proteins which are encoded by translation from the genome.
Changes in cellular behaviour, protein structure, or expression of proteins can lead to
downstream and knock-on effects throughout the organism. The motivation for my thesis
is to understand the association between variation in the genome and variation in blood
cell phenotypes. This analysis can implicate potential genes, transcripts, or proteins in
blood cell behaviour and inform further biological experimentation and drug development.
In this chapter I will give an introduction to blood cell types, blood cell function, and
the fundamentals of a genome wide association study (GWAS) which can identify genetic
variations that influence phenotypes of interest. Following this, I will discuss automated
haematology analysers and explain how flow cytometry and electrical impedance may be
used to derive blood cell phenotypes from whole blood samples. Finally, I will review
previous work in the study of haematological genetics and present my contribution to the
field, the first ever GWAS of functionally relevant haematological phenotypes, and the
largest ever GWAS of previously studied haematological measurements.
1.1 Haematology and the study of blood cells
Blood cells permeate most tissues and organs in the human body and are implicated in the
aetiology of many rare and common diseases. All blood cells originate from haematopoietic
stem cells (HSCs), differentiation of HSCs resulting in the generation of new blood cells
is termed haematopoiesis. Haematopoiesis occurs in the medullary cavity of the bone
which contains bone marrow. Bone marrow is semi-solid tissue composed of non-cellular
connective tissue and cells such as adipose tissue and haematopoietic cells. HSCs are
multipotent meaning they are able to differentiate into multiple specialised cell types and
self-renew. Haematopoiesis begins with generation of myeloid or lymphoid progenitor
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Figure 1.1: Haematological cell lineage and differentiation into cell types.
Pluripotent stem cells in the bone marrow produce haematopoietic cells which differentiate into
progenitors to create increasingly specialised cells. Immature erythrocytes develop into red cells,
thrombocytes or platelets are generated from megakaryocytes. White cells include basophils,
neutrophils, eosinophils, monocytes, and lymphocytes which includes natural killer cells and T
or B lymphocytes (Figure source: [140]).
cells from the division of HSCs. Progenitor cells differentiate into specialised blood cells:
platelets, reticulocytes, and white cells which are released into circulation (Fig. 1.1). Cells
can develop further following release from the medullary cavity, for example, circulating
reticulocytes mature in circulation to become red blood cells.
Blood cells are broadly categorised into platelets, red blood cells, and white blood
cells. These categories are based on structural differences observable with microscopy.
Unsurprisingly, categorisation based on structure also delineates functional differences
between these cell categories:
• Platelets also known as thrombocytes are cytoplasmic fragments of megakaryocyte
cells. Being up to 2 - 3 µm in diameter, platelets are smaller in comparison to other
blood cells [135]. Platelets are responsible for coagulation preventing blood loss from
damaged vessels.
• Red blood cells are the most common blood cell, responsible for oxygen transport
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through the circulatory system to tissues. Red blood cells do not contain a nucleus,
and their cytoplasm is rich in haemoglobin, an oxygen binding molecule. Observed
with microscopy these cells appear as discoid shaped distinguishing them from other
cell types.
• White blood cells are also known as leukocytes and include neutrophils, monocytes,
eosinophils, basophils, and lymphocyte cell types. These cells are distinguished from
red blood cells and platelets by the presence of a nucleus. This category includes a
broad range of immune cells responsible for clearing infectious agents and pathogens.
Staining and microscopy of white blood cell nuclei and granules results in further
sub-categorisation (Section 1.1.3).
The phenotypes studied in my analysis are often blood cell type specific, platelets, red
blood cells, and each of the five white blood cell types discussed above. These blood cell
types were historically delineated with staining and microscopy, in particular, differences in
nuclear structure (polynuclear or mononucleuar cells) and presence of granules (granulocyte
or agranulocyte cells) (Section 1.1.3). I utilise these categories because high throughput
blood cell assay technology based on flow cytometry or electrical impedance can differentiate
between the aforementioned categories. However, within this categorisation more specific
cell types have been identified, such as T or B lymphocytes. T lymphocytes perform cell-
mediated immunity activating phagocytes and releasing cytokines. B lymphocytes perform
humoural immunity generating macromolecules such as antibodies. Such sub-categories
are not currently easily identified by available high throughput blood cell assay technology.
This is a major drawback of high-throughput assay technology for the study of blood cells.
1.1.1 Platelets
Platelets (also known as thrombocytes) are blood cells produced in the bone marrow from
cytomplasmic fragments of megakaryocytes. Platelet formation begins with cytoplasmic
extensions on megakaryocytes which fragment to form platelet cells, each megakaryocyte
can generate 1000 - 5000 platelets [81, p. 316]. Platelets have no nucleus but contain
subcellular components such as mitochondria and granules which contribute to the primary
function of platelets: to generate a haemostatic plug or thrombus to prevent loss of blood
through a perforation in the vessel wall (Fig. 1.2). Dormant platelets circulate in the blood
and show a dramatic response when activated following vessel injury. Platelet response
to vessel injury begins with adhesion to the site of perforation, followed by activation
and aggregation of platelet cells. Finally aggregated platelet cells are bound by a fibrin
mesh, this body of aggregated platelets is termed a thrombus (Fig. 1.2). The fibrin
mesh is created by catalytic conversion of fibrinogen to fibrin by the enzyme thrombin.
Thrombin is activated by the blood coagulation cascade, which is initiated by release of
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tissue factor or exposure of collagen (described below) and amplified by a positive feedback
loop involving the sequential activation of a number of protease enzymes resulting in
cleavage of prothombin to thrombin.
Internally, blood vessels are lined by endothelial cells attached to subendothelial collagen
which under normal circumstances is not exposed to blood. Attachment of endothelial cells
to collagen is maintained by von Willebrand factor (VWF). VWF is a glycoprotein which
plays a number of roles in hemostasis, VWF is also found in the granules of platelets and
endothelial cells being released during thrombus formation. Normally, endothelial cells
provide a non-adhesive surface to platelets. However, if the endothelial layer is damaged
or the blood vessel is perforated, collagen fibrils and VWF are exposed to platelets.
Platelet cell membranes contain a number of receptors such as GPIb (Glycoprotein Ib) and
GPIIb/IIIa which bind to VWF and GPIa which binds to collagen. Numerous platelets
bind to long chains of VWF and collagen, localising platelets to the site of rupture, this
initial adhesion is the first step of thrombus formation [81, p. 318].
Adhesion also initiates platelet activation, firstly, platelets will undergo a dramatic
shape change from smooth discoid cells to spheres with extending filopodia [122, p. 446].
Adhered platelets will also release contents of their α and dense granules [122, p. 443].
Both granule types contain a number of important molecules which promotes thrombus
formation. α-granules contain VWF and fibrinogen, VWF promotes platelet adhesion as
previously described [122, p. 443]. Similarly, fibrinogen localises pairs of activated platelets
by binding to the GPIIb/IIIa receptor on the platelet cell membrane. In addition fibrinogen
can be converted to fibrin, a key component for thrombus formation which is described
later [122, p. 448]. Dense granules contain molecules such as ADP and serotonin which
promote further platelet activation [122, p. 443]. This creates a feedback loop recruiting
further platelets which adhere to the growing thrombus and are activated. A crucial step
in the positive feedback loop of platelet activation is the generation of thromboxane A2
by activated platelets [122, p. 448]. Thromboxane A2 binds to the thromboxane receptor
on nearby platelets promoting activation and further thromboxane A2 production [122,
p. 448].
Thrombin is a key component in thrombus formation, thrombin catalyses the conversion
of fibrinogen to fibrin. Fibrin molecules crosslink creating a binding mesh which holds
aggregated platelets together creating a thrombus. Thrombin is produced by cleavage
of prothrombin, this is the last step in the coagulation cascade which is initiated by
the intrinsic and extrinsic pathways [122, p. 448]. The intrinsic pathway begins with
formation of an activating complex initiated by collagen, the extrinsic pathway is activated
by tissue factor, a protein present on subendothelial tissue [130]. In addition to thrombus
formation vasoconstriction reduces blood flow through the injured vessel [122, p. 443].
Vasoconstriction is promoted by thromboxane A2 produced catalytically by activated
4
platelets and serotonin which is released from platelet dense granules.
1.1.2 Red Blood Cells
Red blood cells (also known as erythrocytes) form up to 45% of blood volume [81, p. 25]
being the most frequently observed cells and appear red under microscopy following
application of Wright’s stain (Fig 1.3). Red blood cells are described as having a dougnut
shape and have structural flexibility allowing them to pass through narrow capillaries
which permeate tissues. Up to 1012 red blood cells are generated each day through a
process called erythropoiesis [81, p. 16]. Differentiation begins with HSC, as with the
generation of all blood cells (Fig. 1.1). Red blood cells differentiate in two stages, firstly
in the bone marrow leading to generation of reticulocytes which are released and undergo
final maturation in circulation. Reticulocytes originate from erythroid precursor cells,
which differentiate into pronormoblasts which generate early normoblasts leading to late
normoblasts which differentiate into reticulocytes that exit the bone marrow (Fig. 1.4).
Given the large numbers of red blood cells which need to be produced, a substantial degree
of amplification occurs from the differentiation of a HSC to the generation of a red blood
cell. Mitosis of intermediate and late normoblasts increases the number of unipotent stem
cells reducing the requirement for division of multipotent HSCs (Fig. 1.4). Unipotent stem
cells are those which can differentiate into only one lineage, in contrast to multipotent
stem cells which can differentiate into many.
Once reticulocytes are released from bone marrow they will gradually mature into red
blood cells. The absence of a nucleus allows extra space in the cytoplasm for additional
haemoglobin molecules which enables the primary function of red blood cells which
is transport oxygen throughout the organism. Haemoglobin consists of four globular
proteins each with a haem iron metalloprotein complex, which can bind oxygen molecules.
Oxyhaemoglobin is formed by binding of oxygen to haemoglobin molecules which occurs
in pulmonary capillaries of the lungs. When red blood cells flow to the periphery of
the organism, a lower oxygen concentration encourages a dissociation of oxygen from
haemoglobin and diffusion of oxygen into tissues where oxygen molecules contribute to
metabolism. Thus, oxyhaemoglobin is converted to deoxyhaemoglobin. Red blood cells
containing deoxyhaemoglobin then circulate back through to the pulmonary capillaries of
the lungs where they are once again oxygenated.
1.1.3 White Blood Cells
The primary function of white blood cells (also known as leukocytes) is to clear infection
by pathogens. White cells can be categorised based on the presence or absence of granules
(granulocytes or agranulocytes), by lineage (myeloid or lymphoid) (Fig. 1.1), and by nuclear
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Figure 1.2: Platelet generation of haemostatic plug (thrombus) following ves-
sel injury.
Multiple factors contribute to the generation of a stable haemostatic plug (thrombus). Firstly, a
primary haemostatic plug is generated by aggregated platelets. Collagen and VWF exposure
promotes platelet adhesion to the site of injury and subsequent activation. Activated platelets
release thromboxane A2 recruiting further platelets to the site of injury forming a primary
haemostatic plug. The primary haemostatic plug is bound by a fibrin mesh to create a stable
haemostatic plug. Fibrin is generated by thrombin produced by the blood coagulation cascade.
The blood coagulation cascade is initiated by tissue factor release following vessel injury and
platelet phospholipid release. Finally, activated platelets release serotonin resulting in
vasoconstriction reducing blood flow through the injured vessel (Figure source [81, p. 315]).
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Figure 1.3: Stained red blood cell observed by microscopy.
Red blood cells are visibly distinct from other blood cells by their smaller size and doughnut
shape, they form the largest proportion of blood by volume and are the most numerous when
observed with Wright-Gimesa stain and microscopy. (Figure source [122, p. 26]).
structure (polynuclear or mononuclear). Blood cells were initially studied by extraction of
blood samples and microscopy following application of Wright-Giemsa stain, a mixture of
red and methylene blue dyes [57]. This leads to the delineation of five white blood cell type
categories, listed in order of abundance: neutrophils, lymphocytes, monocytes, eosinophils,
and basophils (Table 1.1). These categories are based on differences easily observable
with microscopy which also correspond to functional differences. However, this method of
classification is limiting. Firstly, the staining of white cells to observe granules results in
a agranulocyte classification for monocytes. This is incorrect, as monocytes do contain
granules at lower quantities not easily observable under microscopy. Furthermore, as the
study of haematology has progressed, it is now clear that functionally important subtypes
exist within the previously defined categories. This is especially true for lymphocyte cells
which contain a number of functionally heterogeneous subclasses which are discussed later.
Neutrophils
Neutrophils are short lived cells with a lifespan of only 6 - 10 hours in circulation and are
part of the innate immune system which is the first to react in response to pathogenic
assault [81, p. 110]. Neutrophils are highly abundant forming up to half the population of
white blood cells (Table 1.1) being distinguished by their multilobed nucleus and granulated
cytoplasm (Fig. 1.5). Neutrophils flowing through the circulatory system are recruited to
a site of infection by endothelial cells. This allows neutrophils to leave the blood vessel and
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Figure 1.4: Erythropoiesis of red blood cells from pronormoblasts.
Red blood cells originate from the common myeloid progenitor which differentiates into
pronormoblast cells, then early, intermediate, and late normoblasts (precursor cells of red blood
cells) finally becoming reticulocytes which mature into red blood cells. Unipotent early and
intermediate normoblasts can undergo mitosis resulting in a greater number of red cells
produced from a single pronormoblast (Figure source [81, p. 17]).
Category
Abundance
(Cells/Litre blood)
Progenitor Nuclear Structure Granulation
Neutrophils 4.00 - 11.00 x 109 Myeloid Multilobed Granulocyte
Lymphocytes 1.5 - 3.5 x 109 Lymphoid Mononuclear (round) Agranulocyte
Monocytes 0.2 - 0.8 x 109 Myeloid Unilobed Agranulocyte*
Eosinophils 0.04 - 0.4 x 109 Myeloid Bilobed Granulocyte
Basophils 0.01 - 0.1 x 109 Myeloid Bilobed Granulocyte
Table 1.1: White blood cell categories, their abundance in circulation and
features of categorisation.
Neutrophils are by far the most abundant white cell type in circulation with basophils rarely found
in circulation (see table). Cell types are categorised based on progenitor, or structural differences
in nuclear structure, and granulation. Myeloid cells differentiate from myeloid progenitors, and
lymphoid cells from lymphoid progenitor cells. * Monocyte cells contain granules, however these
granules are fine and not easily observable by staining and microscopy - thus leading to the
agranulocyte classification. Abundance statistics from [81, p. 109].
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Figure 1.5: Neutrophil cell observed by microscopy following staining.
Neutrophils are differentiated by their multilobed nucleus, in this case containing roughly 4 lobes
and the presence of granules (pink stain) in the cytoplasm. The cell is surrounded by discoid
shaped red blood cells which are highly abundant in blood plasma (Figure source [81, p. 109]).
Figure 1.6: Neutrophil cell recruitment to the site of infection
Steps in neutrophil recruitment begin with circulating neutrophils adhering to endothelial cells
presenting the selectin receptor which binds to the selectin ligand on the neutrophil cell
membrane. Following recruitment, neutrophils roll towards the source of chemoattractant
molecules, rolling is arrested by binding of integrins leading to eventual extraversion through the
endothelial wall (Figure source [40]).
begin migrating to the site of infection. Recruitment begins by interaction of P-selectin
ligand on neutrophil cells with P or E-selectin receptors presented by endothelial cells
(Fig. 1.6) [99]. Following recruitment, neutrophils will begin to migrate towards the source
of chemokines produced at the site of infection. This migration along the concentration
gradient of attractant molecules is termed chemotaxis and is performed by rolling along
the endothelial wall. Eventually, rolling is arrested by binding of the integrin ligand on
neutrophil cells to integrin receptor on endothelial cells. Leading to passing of neutrophils
through the endothelial wall towards the site of infection in the surrounding tissue (Fig.
1.6) [185].
Once circulating neutrophils are recruited, adhere, and move to the site of infection
they engage and destroy pathogens. This can occur by degranulation, phagocytosis,
and generation of neutrophil extracellular traps (NETs). Key to all these responses are
neutrophil granules which contain cytotoxic compounds such as defensin peptides and
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bactericidal permeability increasing protein (BPI). Straightforward degranulation results
in the release of granule contents onto pathogenic cells in order to induce cell death.
This may occur, for example, by release of defensin peptides which permeabalise the
pathogen membrane. Phagocytosis engulfs and digests pathogen cells which have been
bound by antibodies. During phagocytosis neutrophils generate cytotoxic reactive oxygen
species by a process termed respiratory burst, and granules enable digestion by releasing
their contents as the pathogenic cell is engulfed. Finally, generation of NETs entangles
pathogens with a fibre of chromatin from neutrophil DNA and serine proteases such as
neutrophil elastase and cathepsin G which are released from granules.
Neutrophil granules consist of primary granules, more common secondary granules,
and a smaller number of gelatinase granules. The contents of these granules has been
studied extensively by separation on a density gradient and proteome profiling with mass
spectrometry [144]:
• Primary (azurophilic) granules contain antibacterial compounds such as defensin
peptides and serine proteases. Primary granules are distinguished by the presence of
myeloperoxidase (MPO) protein.
• Secondary (specific) granules are most numerous and contain further cytotoxic
compounds such as lysozyme and lactoferrin.
• Gelatinase granules contain matrix metalloproteinase proteins allowing neutrophils
to pass the endothelial wall [123].
In addition to cytotoxic action, neutrophil signalling following pathogen detection
can further activate the immune system. Presentation of antigens by neutrophils to
lymphocytes informs the adaptive immune system, and release of cytokines activates
nearby macrophages which assist in phagocytosis [178].
Eosinophils
Similar to neutrophils, eosinophils are derived from myeloid progenitor cells and contain
a granulated cytoplasm when observed with staining and microscopy. Unlike neutrophil
cells, eosinophils are far less abundant in circulation (Table. 1.1), have a maximum of
two nuclear lobes, and display orange-red granules following application of Wright-Giemsa
stain [122, p. 239]. Wright-Giemsa stain consists of a mixture of red and methylene blue
dyes. The red dyes, also known as eosin compounds preferentially bind to eosinophils
due to the high amount of basic arginine rich proteins in their granules [122, p. 239].
Arginine is an amino acid which is negatively charged and described as ‘basic’ in contrast
to positively charged ‘acidic’ amino acids. The purpose of the arginine rich proteins
packaged in eosinophil granules is to destroy pathogenic cells, particularly parasite cells.
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Figure 1.7: Eosinophil cell observed by microscopy following staining.
Eosinophils are differentiated by their bilobed nucleus and the presence of granules (pink stain)
in the cytoplasm. The cell is surrounded by discoid shaped red blood cells which are highly
abundant in blood plasma (Figure source [81, p. 109]).
Examples include the negatively charged major basic protein (MBP) which permeabilises
cell membranes of parasites and other targets, and eosinophil cationic protein (ECP) a
cytotoxic protein with ribonuclease activity which also signals to nearby immune cells
[122, p. 239]. Eosinophils are notable for their role in the destruction of parasites which
are differentiated from other pathogens by being multicellular pathogenic organisms [93].
Furthermore, eosinophil function has been implicated in patients with allergic disease
and related immune disorders such as asthma [15] [93]. Mild eosinophilia (an abundance
of eosinophils) is observed in patients with allergic diseases such as asthma and allergic
rhinitis [93].
Basophils
Basophils are the least common of all leukocyte cell categories, identified by their bilobed
nucleus and a cytoplasm rich in granules which are stained dark purple by Wright-Gimesa
dye and can often conceal the nucleus itself [122, p. 241]. Functionally, basophil cells are
known for their high affinity for immunoglobulin E (IGE), a class of antibody primarily
targeted to antigens present on parasite cells [161]. The binding of basophils to IGE
is facilitated by the high affinity IGE receptor FcεRI, where expression of this receptor
correlates with circulating IGE concentration [161]. IGE binding results in phosphorylation
of tyrosine kinase Syk, leading to intracellular calcium release (Syk mediated signalling
cascade), resulting in exocytosis of granules and their contents [108]. Basophils known for
their highly granular cytoplasm will degranulate secreting large amounts of cytokines (IL-4,
IL-13) and histamine [161]. Release of chemokines by basophils leads to characteristic
allergic responses such as increased blood flow, itching of the skin (puritis), and sneezing
(if in the respiratory tract) [161]. These are immune responses which aim to expel the
parasite which cannot be easily destroyed by other immune functions such as phagocytosis
or release cytotoxic proteins. Basophil activation contributes to allergic responses to
allergens such as pollen when antibodies are binding these antigens [161].
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Figure 1.8: Basophil cell observed by microscopy following staining
Basophils are differentiated by their bilobed nucleus and the abundance of granules stained dark
purple in the cytoplasm. The cell is surrounded by discoid shaped red blood cells which are
highly abundant in blood plasma (Figure source [81, p. 109]).
Monocytes
Monocytes are short lived cells with a lifespan of 2 - 3 days in blood [122, p. 242] and
are distinguished by their c-shaped nucleus and fine vacuoles in the cytoplasm which
often stain blue [81, p. 111] (Fig. 1.9). Granules are present at a lower abundance
than that of neutrophils, eosinophils, or basophils [122, p. 242]. In particular monocytes
harbour primary (azurophil) granules [122, p. 242]. Most circulating monocytes are known
to be classical monocytes which are differentiated by high expression of the CD14 cell
surface receptor, a smaller number of monocytes are termed non-classical monocytes with
higher CD16 and lower expression of CD14 receptor [187]. It is difficult to determine a
specific boundary between the classical and non-classical population because non-classical
monocytes develop from classical monocytes which change their expression of cell surface
receptors [187]. Furthermore, an intermediate monocyte subpopulation has also been
proposed with high CD14 and low CD16 expression [187]. Classical monocytes are the
abundant subpopulation and modulate inflammatory responses at the site of infection.
Non-classical monocytes are less characterised and thought to interact with endothelial
cells in the vascular lumen [90]. The intermediate monocyte population is known to expand
during infection, however their function is not well characterised [187].
Neutrophils are usually the first cells responding to infection followed by monocytes
which support neutrophil cells in removal of pathogens [122, p. 242]. Furthermore, once
monocytes enter the tissue they also convert into tissue resident macrophages which
undergo a limited number of cell divisions resulting in mature macrophages. Macrophages
can respond to pathogenic attack by phagocytosis of pathogens and release of signalling
proteins. Macrophages also help return the tissue to homoeostasis following resolution
of infection by clearance of cellular debris and contribution to wound closure [53]. Most
macrophages in the human organism originate from a pool of self-renewing tissue resident
macrophages. However, monocytes enable further production of macrophage cells at sites
of infection [138].
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Figure 1.9: Monocyte cell observed by microscopy following staining.
Monocytes appear larger than other blood leukocytes with a large oval or indented nucleus, the
cytoplasm contains many small vacuoles and is stained blue by Wright-Gimesa stain with a
‘ground-glass’ appearance (Figure source [81, p. 109]).
Figure 1.10: Lymphocyte cell observed by microscopy following staining.
Lymphocytes are distinguished by their large rounded nucleus surrounded by a thin cytoplasm.
Some lymphocyte subtypes (not pictured above) may also be granular (Figure source [81,
p. 109]).
Lymphocytes
Lymphocyte cells are the second most abundant white cell after neutrophils, they are
distinguished by a round nucleus and can be variable in size (Fig. 1.10) [81, p. 127] .
Lymphocytes are the most heterogeneous of white cell categories and include, listed by
order of abundance: T cells, B cells, and large granular lymphocytes (LGLs) (which includes
natural killer (NK) cells). Roughly 75% of lymphocytes are T cells with the remaining
25% consisting of a roughly equal proportion of B cells and LGLs [122, p. 244]. Within the
lymphocyte subtypes further heterogenity emerges during lymphocyte maturation which
begins in the primary lymphoid organs: the medulla of the bone marrow and the thymus
[81, p. 127].
Fundamental to lymphocyte maturation is the major histocompatibility complex (MHC)
cell surface protein encoded in the human leukocyte antigen (HLA) locus. MHC presents
antigens on the cell surface. These can be self antigens which are peptide fragments
encoded in the genome, or foreign antigens, peptide fragments from pathogenic cells or
viruses. There are two classes of MHC, class I presents antigens existing inside the cell,
class II presents antigens collected from pathogens by antigen presenting cells (APCs)
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which include neutrophils and macrophages. Healthy cells expressing MHC class I will
present self-antigens, however MHC class I on virus infected cells may present viral antigens
- thus signalling that cell for destruction. During maturation lymphocyte cells are guided
to ensure that they interact with the MHC molecule generally, but crucially that they do
not react in situations where MHC is presenting self-antigens.
T cells mature in the thymus from precursor cells which originate from the bone marrow
[81, p. 129]. A crucial part of maturation is development of the T cell receptor (TCR)
which is expressed on the cell surface of T cells and should have a high affinity for MHC,
but low affinity if MHC is presenting self antigens [81, p. 129]. The TCR gene contains a
hypervariability region, in this region point mutations occur often leading to heterogeneous
TCR proteins even between T cells in the same individual [122, p. 246]. Maturation occurs
in the thymus by positive and negative selection. Positive selection promotes expansion of
T cell populations with TCR which have affinity for MHC, this is important to enable T
cells to bind to MHC in order to carry out their immune function. Subsequently negative
selection removes T cells which bind to native antigens presented by MHC [163] (Fig. 1.11).
Negative selection is achieved by presentation of self-antigens to maturing T cells, ensuring
that T cells which react to these antigens are not permitted to survive [122, p. 249]. T
cells which develop with affinity to MHC class I become cytotoxic T cells and those with
affinity to MHC class II become T helper cells [163]. Cytotoxic T cells are responsible for
lysis of virus infected cells which are presenting foreign antigens by MHC class I. T helper
cells are responsible for detection of foreign antigens when presented by APCs by MHC
class II [122, p. 249]. If a helper or cytotoxic T cell is activated by a foreign peptide it will
proliferate and signal for further immune responses. Cytotoxic T cells contain granules
which release perforin peptides and serine proteases upon contact with a virus infected
cell [122, p. 249].
Unlike T cells expressing TCR with general specificity to recognise foreign antigens
presented by MHC, B cells produce antibodies which recognise a specific antigen directly
[79]. B cell maturation begins in the bone marrow where cells initiate expression of B cell
receptor (BCR), a dimer of immunoglobulin molecules. Immunoglobulins are membrane
bound surface molecules with constant Fc regions and variable antigen binding Fab regions
[81, p. 131]. In the bone marrow, B cells undergo positive and negative selection for BCR
molecules that bind to MHC, but not self-antigens [122, p. 246]. Following selection, naive
B cells leave the bone marrow and move to the secondary lymphoid organs, the spleen or
lymph nodes where pathogenic antigens are collected by immune cells such as T cells or
by the passive flow of lymphatic fluid [79]. In the secondary lymphoid organs antigens are
stored and concentrated by follicular dendritic cells (FDCs) located in germinal centres
[79]. Naive B cells move into the germinal centre and proliferate undergoing somatic
mutations of the BCR encoding genes (Fig. 1.12). B cells compete for binding with an
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Figure 1.11: Positive and negative selection during T lymphocyte maturation.
This figure shows maturation of T lymphocytes which are selected such that their TCR receptor
binds HLA and secondly such that they do not bind to HLA presenting self-antigens, this is
termed positive and negative selection respectively (Figure source [74]).
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Figure 1.12: B cell maturation in the germinal centre
B cell maturation occurs in the germinal centres within secondary lymphoid organs. B cells
move into the germinal centre and proliferate with somatic hypermutation which results in
heterogeneous BCR. B cells which bind to dendritic cells presenting antigens are promoted to
proliferate, this results in generation of BCR which binds to antigens. (Figure source [81,
p. 137]).
antigen presented by the FDC, those that outcompete are encouraged to proliferate [81,
p. 137]. This leads to production of B cells which can generate antibodies with specificity
for an antigen. Surviving B cells differentiate into plasma cells responsible for high volume
antibody secretion, or memory B cells which have a long lifespan and when activated by
presentation of their antigen will rapidly proliferate and instantiate an immune response
[113]. Plasma cells produce and secrete soluble antibodies based on their BCR generated
by the previously described positive and negative selection.
LGL cells consist of two major classes, the previously described cytotoxic T cells and
NK cells which are known for their response to virus infected and tumour cells. NK cells
recognise their targets both by binding to the constant Fc region of antibodies or by
detecting a lack of MHC class I expression, common in virus infected or malignant cells
[81, p. 130]. Similar to cytotoxic T cells NK cells initiate destruction of their target by
exocytosis of granule contents which includes proteases and other cytotoxic compounds
[122, p. 249].
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1.2 Haematological analysers
GWAS studies require collection of phenotype and genotype data in a cohort of individuals
large enough to power identification of associations with statistical confidence (Section
1.5). This requires high-throughput measurement of phenotypes with limited measurement
error. Automated haematological analysers are designed to rapidly count cell types and
measure other cell properties from a blood sample. The measurements routinely obtained
by haematological analysers can be condensed as follows: cell counts for the seven primary
blood cell types (platelets, red cells, neutrophils, eosinophils, basophils, monocytes, and
lymphocytes), red cell and platelet volumes, and red cell haemoglobin measurements. I
will introduce the two major techniques for automated haematological analysis: impedance
electrometry and flow cytometry and show that additional blood cell properties can be
derived by flow cytometry.
1.2.1 Impedance flow cytometry (Coulter principle)
The origin of automated haematology analysers began in October 1953 with a patent for
automated cell counting by flow cytometry and impedance electrometry also known as the
Coulter principle, filed by Wallace H. Coulter and his brother Joseph R. Coulter, Jr [72]
[50]. Historically, erythrocyte counting was routinely performed with manual microscopy,
a process taking a haematologist up to 30 minutes per sample [72]. There was a pressing
need for the development of an automated solution. A publication in 1934 by Canadian
Andrew Moldavan proposed automated counting of ‘microscopical cells’ in solution using a
capillary tube [120]. Here, cells in solution are forced to process through a capillary tube
observed by a microscope and photoelectric apparatus which registers the passing of cells.
Intriguingly this concept seems to have originally been proposed in a French publication by
Marcandier, Bideau, and Dubreuil in 1928 [111]. Regardless, the publication by Andrew
Moldavan is noted as being the inspiration for the development of the first flow cytometry
and electrical impedance based automated cell counter by Wallace H. Coulter and his
brother Joseph R. Coulter, Jr [72], their work being published in the aforementioned
patent and referred to as the ‘Coulter principle’. The Coulter based counter obtains an
electrical contrast between cells and surrounding solution which is ten times higher than
those identified by the photoelectric method proposed by Andrew Moldavan [72].
The Coulter principle relies on the changes in conductivity when cells pass through
an aperture and displace surrounding solution. A container filled with fluid holds an
electrode, inside this container a smaller tube is placed inside which an electrode of opposite
charge is placed (Fig. 1.13). A microscopic aperture is made in the smaller tube allowing
electrical current to flow from one electrode to the next. When fluid is drawn through the
aperture, the observed current will not change as the conductance through the aperture is
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Figure 1.13: Schematic of the Coulter principle of electrical impedance.
Schematic showing the Coulter principle for counting cells in solution. A conductive solution
flows through an aperture with an electrical current also passing through the aperture. As a cell
passes through the aperture the electrical current is disrupted because the conductive solution is
displaced by a cell. The magnitude of the disruption of electrical current will depend on the size
of the cell. Analysis of the disruptions in electrical current allow blood cells to be identified
(Figure source [125]).
not changing. However, if a cell is drawn through the aperture the current is disrupted,
because the conductance of a cell is different to that of fluid [72]. By studying the waveform
of current flowing through the aperture the concentration and size distribution of cells can
be measured. The Coulter principle is utilised in many modern automated haematological
analysers, such analysers have also been utilised to phenotype large population cohorts
empowering a number of GWAS studies of blood cell count [15] [162] [66].
1.2.2 Fluorescence flow cytometry
Fluorescence flow cytometry began with a patent filed by Go¨hde and Dittrich in 1968
[177]. The use of light for cell counting is based on work by George Oliver in 1896 who
proposed counting blood cells by measuring the loss of light passing through a test tube
caused by scattering and absorption by suspended cells [128]. This loss of light will be
correlated not just to cell count, but also with cell size and haemoglobin content. To make
this method of fluorescence flow cytometry a reality, it was required to separate individual
cells. In 1965 Mark Fulwyler published an article in Science utilising the Coulter principle
to separate cells by volume which proved to be the enabling factor which paved the way
to fluorescence flow cytometry [63] [73]. Go¨hde and Dittrich utilised this technique with a
laser beam to create the first fluorescence cytometer [177].
Flow cytometry relies on the scatter of laser light incident upon cells which flow
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Figure 1.14: Schematic of fluorescence flow cytometry.
Cells flow single file through the Sysmex flow cytometry channel and are hit by a laser beam,
light is scattered or fluoresced by dyes in the cell and this is recorded resulting in three readings
(SSC, SFL, and FSC) per cell. * SFL is an index of nucleic acid content also influenced by
membrane composition of cells which affects the rate of absorption of nucleic acid staining dye
into the cell (Figure source [4]).
through the cytometer in single file and the fluorescence of dyes which stain the cell (Fig.
1.14). In most modern flow cytometers fluorescent nucleic acid stains are applied to cells
based on nucleic acid binding dyes such as acridine orange and membrane perforating
agents, although the exact formulation of stains usually remains proprietary [73]. Three
parameters are derived from cells flowing through a standard flow cytometer: side scatter
(SSC), forward scatter (FSC), side fluorescence (SFL) (Table 1.2). These parameters
represent cellular properties, cell structure or granularity, cell size, and cell nucleic acid
content respectively. Plotting these parameters results in a scattergram with clusters of
cells corresponding to different cell types (Fig. 1.15). Not only can individual cell types be
identified from the scattergram, position of cells within a certain cell type in the three axes
(SSC, FSC, SFL) represents important properties about the state of the haematological
system which varies between individuals. Further discussion of flow cytometry parameters,
their derivation from scattergram information, and clinical relevance is made in Section
3.2.2.
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Property Abbreviation Description
Side Scatter SSC Cell internal structure and granularity
Forward Scatter FSC Cell size
Side Fluorescence SFL
Fluorescence of stain, usually nucleic acid stain.
Measurement also influenced by membrane composition
which influences progression of stain into cell.
Table 1.2: Properties measured by standard cell flow cytometery.
A standard flow cytometer measures: SSC, FSC, and SFL. These measurements are representative
of important cell properties such as cell size, cell structure or granularity, and cell nucleic acid
content.
Figure 1.15: White blood cell differential channel scattergram.
This plot represents results obtained from the white blood cell differential channel (WDF) from
analysis of a blood sample. Each data point represents a blood cell for which SSC, SFL, and
FSC values are derived - only SSC and SFL axes are drawn. Cell types are identified using
bounds set across the axes, for each cluster of cells representing a cell type cells are counted.
Furthermore, phenotypes are derived from the median position of each cell type in the axes. The
example drawn represents the SSC and SFL values for eosinophil cells and distribution width
values are also calculated from the width of the cluster. Cell types observed from the WDF
scattergram are highlighted. LY: lymphocytes, RE-LYMP: reactive lymphocytes, AS-LYMP:
antibody synthesising lymphocytes, MONO: monocytes, IG: immature granulocytes, NEUT:
neutrophils, BASO: basophils, EO: eosinophils.
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1.3 Variation in the human genome
The human genome consists of 23 pairs of chromosomes located in the nucleus where
each chromosome is a DNA molecule containing genetic information of the organism.
DNA is formed of base pairs of ‘nucleotides’ of which there are four types: adenine (A),
cytosine (C), guanine (G), and thymine (T). Across all 23 chromosomes, DNA consists
of 6 billion base pairs of nucleotides. Genetic variations are changes in DNA sequence
which exist between individuals. Fundamentally, it is genetic variation which underpins
almost all the heritable differences in phenotypes between individuals. The total number of
observable variations in the human genome has not been determined and depends greatly
on the reference sequence used and population being studied. Genetic variants include
single nucleotide polymorphisms (SNPs), the substitution of a single nucleotide in the
genome, or inversions, copy number variations, insertions, and deletions. Copy number
variations are regions larger than 1000 base-pairs which appear a variable number of times
within the genome [141]. Copy number variations are a type of structural variation which
includes other alterations such as inversion or translocation of segments of DNA larger than
1000 base-pairs [62]. Variants can be genotyped directly using microarray or sequencing
technology, or imputed using a scaffold of nearby genotyped variations. Imputation relies
on linkage disequilibrium (LD) calculations from a reference population to infer genetic
variations which have not been genotyped and exist near to genotyped variations in the
genome (Section 3.1.3). Genotyping arrays are designed to detect genetic variations target
smaller variations such as SNPs, or small insertions and deletions and cannot identify
larger structural variants such as copy number variations.
The inheritance of genetic variation was first determined by Mendel who described
the ‘law of segregation’ and ‘independent assortment’ in inheritance of a phenotype from
parent to offspring [176]. Mendel observed segregation of alleles on different chromosomes
from parent to offspring, and independent assortment of those chromosomes. The laws of
inheritance as described by Mendel cannot easily describe the inheritance of polygenic (or
complex) traits which depend on multiple genetic loci across the genome [143]. Therefore,
to characterise the genetics of a complex trait we must systematically test genetic variants
across the genome for association with the phenotype. This type of analysis, a systematic
search for genetic associations across the genome is termed a genome wide association
study (GWAS), and requires a large population sample on which genetic and phenotypic
data has been recorded.
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Figure 1.16: Recombination exchanges of information between chromosomes.
Exchange of information between chromosomes during homologous recombination. This effect
results in chromosomes inherited by offspring being different from those parental chromosomes.
Recombination means that variants located physically close on chromosomes are more likely to
be inherited together (Figure source: [127]).
1.4 Genetic recombination and linkage disequilibrium
Genetic inheritance relies on chromosomes, which are continuous coiled segments of DNA
that are passed from parent to offspring. Every human individual normally inherits 23
chromosomes from each parent, resulting in a genome of 46 chromosomes. However,
chromosomes are not an indivisible unit of genetic information. Recombination can
occur during formation of gametes which pass genetic information to offspring, thus
allowing exchange of DNA segments between each chromosome in the pair, this is termed
homologous recombination (Fig. 1.16).
The result of genetic recombination is that alleles which are physically located close
together on a chromosome are more likely to be inherited together. Therefore, in the
population sample, the correlation between two alleles on the same chromosome reduces
as the physical distance between their variants in the genome increases (Fig. 1.17). This
also creates challenges in the context of GWAS as it is difficult to distinguish whether a
variant is associated with a phenotype due to a true mechanistic effect, or because the
variant is located close to, and is therefore often inherited with a variant which is the
true mechanistic variant. In Figure 1.18 a single association signal with the blood cell
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Figure 1.17: Linkage to a point in the genome across a chromosome.
Alleles of genes which are physically closer to gene three are more likely to be inherited with
gene three, this is defined as a greater degree of linkage. Similarly, proximal alleles are also more
likely to be inherited together (Figure source: [127]).
phenotype H-IPF a measure of immature platelets (a platelet parameter described further
Section 3.2.2) is identified on chromosome 8, and there are multiple highly correlated
variants with low P-values for association with the phenotype. It is not immediately clear
which (if any) of these highly correlated and associated variants is the causal variant for
the observed signal. Therefore, GWAS analyses are often followed by methods to identify
the number of independent association signals identified accounting for correlation or
LD between alleles. Methods to address this are discussed including multiple stepwise
conditional analysis (Section 2.2.8.1) and LD based clumping methods (Section 2.2.9).
1.5 Genome wide association study
A GWAS analysis can identify genetic variants which are associated with changes in a
phenotype, for example: transcript level, protein concentration, or some other biological
property. The phenotype is measured in a sample of individuals which are also genotyped
to determine genetic variations. A GWAS analysis estimates the magnitude of the effects
variants have on the phenotype and the standard error of this estimation. This analysis
highlights regions of the genome which influence the phenotype being studied. GWAS
analyses are subject to confounding factors such as population stratification which are
discussed in more detail in Section 2.2.6.
GWAS analyses are categorised into those studying case-control outcomes such as
diagnosis of disease, or quantitative outcome such as height, weight, or the value of a
haematological measurement. If the outcome in question is binary (case-control) a logistic
model will most often be used to generate test statistics, alternatively a linear regression
is used to model quantitative outcomes. Each SNP is tested individually with adjustment
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for covariates which can include participant factors such as age, weight or height which
could also effect the phenotype. A quantitative phenotype is studied as follows, where y is
a vector of phenotype values, xc represents a matrix of covariate values across individuals,
x represents the genotype of the individual coded as 0, 1, or 2 for homozygous reference
allele, heterozygous, or homozygous alternate allele respectively, and α, β, βc represent the
intercept and effect sizes of the genotype and covariates to be estimated:
E[y] = α + xcβc + xβ (1.1)
y ∼ N (µ, σ2) (1.2)
Alternatively, working with a case-control GWAS where phenotype values are binary
outcomes y ∈ {0, 1}, Equation 2.1 is modified as follows using a sigmoid function to fit a
logisitc regression:
E[y] =
1
1 + e−(α + xcβc + xβ + )
(1.3)
y ∼ B(p) (1.4)
Population stratification and relatedness are effects which may lead to false positive
results and are discussed in more detail in Section 2.2.6. Briefly, covariates are included
in the model such as population principal componentss (PCs) or an additional genetic
relationship matrix (GRM) term which accounts for relatedness amongst the sample
population to help account for population stratification. A GRM requires modelling of
random effects, in which case the linear model above is modified to a linear mixed model
(LMM) (Section 2.2.7). At its basis, a GWAS study utilises a linear model or a LMM.
Therefore, the primary assumptions of linear regression still apply which are discussed
with more detail in Section 2.2.4.
1.5.1 The history of GWAS analysis
The history of GWAS necessarily begins with that of the human genome project which
formally began in October 1990. The goal of the human genome project was to determine
the sequence of nucleotide base pairs in DNA and map all the genes within the human
genome. The first genome to be sequenced was that of bacterial virus φX174 with 5400
nucleotides by Fred Sanger in 1977 [147]. For many years the prospect of sequencing
the human genome was met with incredulity and disbelief [158]. In May 1985 Robert
Sinsheimer organised a workshop to propose sequencing the human genome and wrote
the following about the response of his audience: “The sources of hesitation ranged from
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concerns over the introduction of Big Science into biology to arguments that most of the
human DNA is junk” [158]. In response to arguments about “junk DNA” Sinsheimer would
retort that “one man’s garbage is another’s treasure” and used the example of large projects
in physics and astronomy such as the Hubble space telescope to argue for the benefits of
“Big science” [158]. Unfortunately, Sinsheimers proposal to sequence the human genome
was not pursued at that time. However, subsequent workshops proposing sequencing of the
human genome by Charles DeLisi [54], James Watson [75], and a publication in Science by
Renato Dulbecco [56] began to turn the tide. Of particular importance was New Mexico
US Senator Peter Domenici, a friend of DeLisi who offered political support to proposals
to dedicate money from various government organisations to fund the prospective genome
project. Efforts culminated with approval for funding from the Senate Committee on
Energy and Natural Resources chaired by Senator Domenici and an act of Congress in
January 1987, both of which committed money for the purpose of sequencing the human
genome. The act was a budget submission signed by US President Ronald Reagan himself,
and thus began the era of ‘Big Science’ proposed by Sinsheimer which continues to this
day. The remaining history of the human genome project is well documented in a number
of sources [1] [54]. Laboratories in the United States, United Kingdom, Germany, Japan,
and China would eventually contribute to the project in addition to (and often competing
with) private organisations in particular Celera Genomics finally leading to publication of
the draft human genome sequence in 2001.
Publication of the human genome sequence enabled creation of the Japanese single-
nucleotide polymorphisms (JSNP) database of 190,652 variants in the Japanese population.
It is from this database that the first GWAS for myocardial infarction in Japanese
participants was performed [86]. From JSNP, 92,788 variants were selected which the
authors assumed would account for each of the 100,000 genes expected in the genome. Of
course, we now know that the estimation of 100,000 genes in the genome is incorrect and
the number is closer to 30,000. The chosen variants were genotyped in 1,133 individuals
affected by myocardial infarction and 1,006 controls [129]. This analysis, which is now
known to be the first ever GWAS identified only a single association locus composed of 5
SNPs on chromosome six [129] [86]. Although, it could be argued that 92,788 variants
studied in this analysis hardly cover the entire genome. In the same regard even modern
GWAS studies do not cover the entire genome often missing regions which are difficult
to genotype or impute such as the MHC locus. Regardless, since the first study in 2002
[129], GWAS Catalog, a repository for results of GWAS analyses has collected over 3,000
GWAS results [34]. Almost all major common diseases have been subject to GWAS, often
in sample sizes of hundreds of thousands of individuals.
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Figure 1.18: GWAS identifies a large number of significant variants but only
one signal at this locus.
This plot represents an association signal on chromosome eight with haematological trait H-IPF,
a measure of immature platelets (Section 2.1.3). Each data point represents a genetic variant
with the position of the data point on the x axis corresponding to the physical location of that
variant on chromosome eight. The position of each variant in the y axis is the -log10(P ) for
association with H-IPF. Variants are coloured based on their LD to the conditionally significant
variant (rs6558405) which is identified with multiple stepwise conditional analysis to be the best
statistical candidate for this association signal, although this does not imply that rs6558405 is
the causal variant for this association signal. Variants in high LD to the conditionally significant
variant show significant association with the phenotype H-IPF, however conditional analysis
shows only one independent signal at this locus, suggesting only one variant is mechanistically
associated with changes in the phenotype.
26
1.5.2 Genotyping of genetic variants
Genotyping is a biological assay which allows the determination of alleles in DNA. The two
primary classes of genotyping technology utilised in GWAS analysis are DNA microarrays
and whole genome sequencing. In my analysis I utilise DNA microarray based technology
which at the time of study recruitment and genotyping (2012 - 2015) was affordable enough
to enable genetic analysis of a large cohort of individuals as required for GWAS.
The most common DNA microarray technique for GWAS genotyping is one-channel
detection utilised by the Affymetrix Gene Chip and Illumina Bead Chip systems. This
system allows determination of hundreds of thousands of genetic variants in a single sample.
Here, a DNA microarray contains a number of probes, each of which can assay for the
presence of an allele in a sample. A probe is a fragment of single stranded DNA encoded
to hybridise to a piece of DNA which contains the variant in question. The probe is fixated
to the silicon wafer by a covalent bond which forms the body of the microarray. Probes
can be designed as required, selection of probes is discussed in more detail in Section 2.2.1.
A sample of DNA is fragmented and washed over the silicon wafer containing the probes.
If fragments contain the genetic variant of interest it will form a strong hybridisation with
the corresponding probe. The silicon wafer is washed to remove DNA fragments which
are not hybridised with an appropriate probe. The DNA microarray is designed such
that specific coordinates on the array are dedicated to detecting a particular variant. A
fluorescent dye is added which binds to double stranded DNA and a laser is used to query
coordinates along the DNA microarray to identify probes which have hybridised. Thus it
is possible to deduce which alleles exist in the DNA sample by identifying which probes
are fluorescent. However, only a limited number of variants can be genotyped. In the
case of my analysis a Affymetrix Axiom array including 820,967 probes was utilised. It
is known that variants across the genome are correlated depending on physical distance
between them (Section 1.4). Utilising this linkage (correlation) structure which can be
determined by whole genome sequencing of a reference population, it is possible to further
impute the existence of millions more genetic variants.
Imputation of genetic variants
Imputation allows prediction of genotypes which were not directly measured. Imputation is
performed using the correlation structure (LD) between variants in the genome estimated
from a reference population. To ensure similar LD structure, the reference population
must have similar ancestry as the genotyped individuals. All imputation methods begin
by phasing genotyped variants to estimate ‘haplotype blocks’ along the genome (Fig.
1.19). Haplotype blocks are contiguous regions of DNA which show little evidence of
recombination in the reference population thus the genetic variants in a haplotype block are
very likely to be inherited together. Once haplotypes have been estimated, haplotypes from
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the reference population are used to impute missing variants in the sample population (Fig.
1.19). Imputed alleles are estimated with a degree of uncertainty, this is often represented
with the information (INFO) score metric which is between 0 and 1. The INFO score for
an imputed variant multiplied by the total sample size represents the equivalent effective
sample size for the power of an association test, a perfectly imputed variant will have
an INFO score of 1 [25]. Given this uncertainty, if genotyped variants are encoded as
follows: 0 for homozygote reference, 1 for heterozygote, and 2 homozygote alternate alleles,
imputed variants will have values closer to 0 if the likelihood of homozygote reference
alleles is high and closer to 2 in the reverse scenario. Examples of reference populations
include the European ancestry populations from the UK10K [46] and haplotype reference
consortium (HRC) which combines data from multiple cohorts including UK10K and the
1000 Genomes project [167]. These data were utilised by the UK Biobank consortium to
impute nearly 96 million variants in their cohort of 500,000 British volunteers [38].
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Figure 1.19: Schematic of steps for imputation of genotype data to estimate
missing variants
a) Genotype data from the sample population with missing genotypes represented by question
marks. b) Testing for an association signal using genotype data alone results in no association
peak. c) Using a set of reference haplotypes from d) genotype data is phased to determine
haplotypes present at each position along the genome. Three phased individuals are represented
in the figure, each genome is a mosaic of haplotypes from the reference population. d) Reference
haplotypes are defined from whole genome sequencing of a population with similar ancestry to
the sample population. e) Missing variants in the genotyped sample population are estimated
using the imputation procedure, with imputed variants highlighted in orange. f) In this
example, testing for association of genotyped and imputed SNPs results in an association signal
which was not identified before (Figure source [112]).
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1.6 Interpretation of GWAS results
Since the first GWAS of myocardial infarction in 2002 which found an association locus
on chromosome six [129], the number of identified associations has been increasing rapidly
[173]. As more associations are identified, there is a greater need for interpretation of
these results to generate relevant scientific insights. Large amounts of public money from
government agencies such as the National Institute of Health and charities such as the
Wellcome Trust have been and continue to be committed to GWAS studies on the promise
of great advances in our understanding of biology and disease. As we approach two decades
since the first GWAS study, questions still remain about how to use the results of GWAS
analysis to inform biological experimentation and clinical development. I will attempt to
address these questions by discussing the tools and techniques which have been developed
to query GWAS summary statistics and how these techniques aim to answer fundamental
biological questions. Some of the primary challenges regarding inference from GWAS
results can be categorised as follows:
• Confident identification of the genes mediating each genetic association, a starting
point for further inference.
• Understanding the mechanisms of biology which lead to emergence of a genetic
association and the tissue specificity of those mechanisms.
• Inferring a causal relationship between two measurements, for example a risk factor
and disease risk, and the implications of this for the consideration of the risk factor
as a target for therapeutic modulation.
Fundamentally, all these questions are proposed in context of the same overarching
goal: “how can we interpret the results of GWAS analysis to infer causal underlying
biological mechanisms”. However, inferring causal mechanisms is difficult, analysis such
as annotation of associations to genes can get closer to this goal. In an attempt to
make biological and aetiological inferences from GWAS analysis I utilise many tools and
techniques. Here I will provide an overview of these techniques within the context of
broader biological questions, with more detailed methodological reviews in the relevant
chapters.
1.6.1 From genetic associations to genes
GWAS can provide insight into the genes which contribute to the studied phenotype.
However, inferring a mediating gene from an associated variant is not trivial. In some
cases, the associated variant may be near or overlapping several genes, in other cases
the associated variant is located megabases away from the nearest gene. This problem is
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encapsulated in the wider challenge of identifying a causal biological mechanism which
is leading to associations identified by a GWAS study. For many associated variants it
is not even clear which tissues the mechanism of action occurs in and how this leads
to changes in the phenotype which is detected by GWAS. Understanding the biological
mechanism causal for the genetic associations must necessarily include the gene which is
being modulated. Broadly, two solutions exist to annotate genetic variants to probable
mediating genes:
• Physical overlap or physical distance of the variant with genes, this is implemented
by software packages such as variant effect predictor (VEP).
• By integrating (colocalising) loci of associations from GWAS with gene or protein
expression data.
Studying which genes and genetic elements the variant in question is overlapping can
be misleading, a variant may overlap with multiple genes some of which may not even
be expressed in the relevant tissue. Colocalisation of genetic associations with gene or
protein expression GWAS results is a more reliable method for annotation, discussed in
detail below (Section 1.6.2).
1.6.2 Understanding genetic associations with colocalisation anal-
ysis
Genetic colocalisation analysis can determine if different phenotypes with a genetic
association in the same locus are being mediated by the same underlying causal variant.
The context of my work is to better understand genetic associations with haematological
phenotypes derived from a haematological analyser. I utilise colocalisation to explore the
following questions about genetic associations with haematological measurements:
• Which blood cell transcripts are modulated by the genetic association? This will
suggest genes which may be participating in the biological mechanism leading to
changes in the haematological measurement.
• The concentration of which blood plasma proteins are modulated by the genetic
association? This analysis could identify which haematological cells are producing
particular blood plasma proteins, or which haematological cells are modulated by
particular blood plasma proteins.
• Does this genetic association, which is modulating a haematological phenotype, also
influence disease risk? This is a starting point for more detailed analysis to study
the effect of haematological cells on disease aetiology.
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It is crucial to emphasise, colocalisation analysis cannot determine causal relationships
between the phenotypes being studied, and neither can it determine the direction of
causality between the two phenotypes. In the case were two phenotypes both have an
association signal in a locus, colocalisation analysis determines if those signals are caused
by a common variant. The interpretation of colocalisation analysis depends on the specific
nature of the phenotypes being colocalised. Haematological phenotypes studied in my
analysis are discussed in Section 2.1.3 and 3.2.2, colocalising expression quantitative trait
loci (eQTL), protein quantitative trait loci (pQTL), and disease risk phenotypes are
described further in Chapter 5.
1.6.3 Causal inference with mendelian randomisation
Mendelian randomisation (MR) allows determination of a causal relationship between an
exposure and outcome using genetic variants across the population sample. A population
level causal association is a relationship where if across the entire population the exposure
is modulated, this will cause a concomitant change in the outcome. An example of this
is low density lipoprotein and heart disease, low density lipoprotein is known to cause
heart disease and is modulated in the population by statin medication to reduce the risk
of heart disease. It is known that there is a causal association between this risk factor
and outcome. In this context, genetic associations are instrumental variables (IVs) used
to assess the influence of the exposure on the outcome. This helps avoid the pervasive
problem of confounding in epidemiological studies. Confounding factors influence both
the exposure and outcome and can therefore induce a correlation between them. Often,
confounding factors are unlikely to be measured or even known, therefore epidemiologists
may never know if identified correlations are driven by confounding factors or result from
a true causative mechanism. In MR studies the confounding effect is greatly ameliorated
as it is not likely for confounding factors to affect genetic variants which are randomised
at birth. Therefore, we are able to assess causality without the risk of our inferences being
unduly influenced by confounding factors.
MR studies are often termed ‘naturally randomised trials’, as properly chosen exposures
can be used as proxies for clinically relevant biomarkers or modifiable exposures. Genetic
evidence for efficacy of drug targets can be tested using MR (Fig. 1.20). For example,
instrumental variables in LDLR have demonstrated LDL-c is a risk factor for coronary
heart disease (CHD) (Fig. 1.21). However, MR relies on a large number of assumptions
which must be met for the analysis to be reliable. These assumptions and suggestions for
sensitivity analysis are described in Section 5.2.2.
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Figure 1.20: Mendelian Randomisation and a ‘naturally randomised control
trial’.
MR analysis as an analogy of a conventional randomised control trial, in this case the
relationship between LDL-C and cardiovascular (CV) events is studied by genetic instrumental
variables associated with a reduction in LDL-C. Assuming the genetic instruments meet
assumptions of validity (Section 5.2.2), MR can be used to assess the causal relationship
between LDL-C and cardiovascular events and thus predict whether LDL-C is a causal factor in
modulation of cardiovascular risk. This is relevant to clinical trials of LDL-C lowering therapies
such as statins (Figure source: [22]).
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Figure 1.21: Mendelian Randomisation to test causal association between
LDL-c and chronic heart disease.
A diagram representing the framework of a MR analysis, instrumental variables are selected
from genetic variants located in the LDL Receptor (LDLR) gene which raises LDL-C levels.
Instrumental variables are used to assess for causal association between LDLR (exposure) and
CHD (outcome), allowing estimation of a causal effect between LDL-C and CHD without
influence of confounding factors (Figure adapted from: [119]).
1.6.4 Intermediate traits for the study of disease aetiology
GWAS of disease outcomes identifies many associated variants, however a primary challenge
is understanding which genes, proteins, and cellular behaviours are influenced by disease
associations. An example of this is identifying which genes are modulated by an association,
a problem which is described in detail above (Section 1.6.1). Measurements of gene
expression, protein concentration, and cellular properties are often termed intermediate
traits. GWAS of intermediate traits identifies associations which influence those phenotypes.
Colocalisation analysis can identify cases where an intermediate trait association and
a disease association is driven by the same underlying causal variant. Furthermore, a
causal relationship between the intermediate trait and disease risk can be identified with
MR. Individuals with asthma often have increased eosinophil count, does asthma cause
increases in eosinophil count or are individuals with higher eosinophil count at greater risk
of asthma? A MR study using GWAS of eosinophil count and GWAS of asthma suggests
the causal relationship is driven by higher eosinophil count which in turn increases the risk
of asthma [15]. In this way my GWAS of haematological phenotypes including functionally
relevant phenotypes can help increase understanding of disease aetiology.
1.6.5 Genetic analysis to inform drug development
In recent decades there has been rapid progress in scientific advances including sequencing
of the human genome, emergence of new therapeutic modalities such as antibodies and
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RNAi, and advances in combinatorial chemistry allowing synthesis of thousands of small
molecule compounds. Given these developments it could be expected that the rate of
approval of new drugs to be higher relative to historical averages. However, approval of
new drugs is not only taking longer and getting more expensive, candidates are also now
more likely to fail at late stage clinical trials than in the past [159] [91]. In response to
this unfavourable outlook AstraZeneca undertook a “major revision of its R&D strategy”
in 2011. Part of this revision was the publication of a systematic longitudinal analysis of
its drug development portfolio for all projects between 2005 - 2010 [47]. Notably, their
analysis identified that that failure at late stages of clinical trails (Phase II and III) were
more likely to be due to drug efficacy than any other factor, reaching up to 88% in Phase
IIb trials (Fig. 1.22), where smaller Phase IIa trials (<200 patients) are distinguished
from larger Phase IIb trials (<400 patients). In 40% of cases, the reason for failure due to
efficacy was cited to be “target linkage to disease not established or no validated models
available”, this is in contrast to other reasons such as the dose of drug being limited by
compound characteristics (Fig. 1.23).
These results show that many drug compounds pass all the early milestones of drug
discovery only to fail at the latest stages of clinical development due to no efficacious effect
in man (Fig. 1.22). A study of the costs of drug development shows that from a cost
per new launch of $1.78 billion, roughly $1 billion of costs are incurred prior to Phase II
clinical trials, the first real opportunity to assess clinical efficacy in man (Fig. 1.25) [134].
These analyses demonstrate a need to assess drug efficacy as early as possible, and that
experiments with tissue and mouse models are not providing accurate enough insights
into human biology. However, testing compounds in a clinical trial prior to passing all the
early development milestones which contribute to the aforementioned $1 billion of cost
would be deemed highly unethical.
Role of genetics in drug development
It has been shown that genes which are drug targets in a database of drug approvals in
the United States and European Union are significantly enriched with genetic variants
associated with human traits compared to other genes [124], and candidates with genetic
linkage evidence are 30% more likely to succeed (Fig. 1.24). Here, associated genetic
variants were assigned to genes using physical proximity and evidence that the genetic
association influences gene expression, for more details see Nelson et al [124]. A promise of
modern genetics is to use observational data collected from cohort level analysis to make
inferences about the aetiology of disease. In this context, the benefits of genetic analysis
are clear. GWAS of disease outcomes can identify associated variants which may implicate
a gene in disease aetiology and therefore indicate a potential drug target (Section 1.5).
Furthermore, using intermediate phenotypes (Section 1.6.4) one can generate a multiomic
35
Figure 1.22: Primary reasons for project closure in AstraZeneca pipeline 2005
- 2010.
Project closures were classified into the following categories: safety (toxicology or clinical safety),
efficacy (failure to achieve sufficient efficacy), pharmacokinetics/pharmacodynamics (PK/PD) or
closure due to oranisation strategic reasons. The percentage of projects failing due to each
category for each phase of development is indicated in the plot with the total number of projects
shown in brackets below the bars (Figure source: [47]).
picture of the consequences of variations using colocalisation analysis between multiple
phenotypes such as transcript levels, biomarker levels, and multiple disease outcomes
(Section 1.6.2). Finally, MR analysis can test purported causal relationships between risk
factors and disease outcomes (Section 1.6.3). However, such analyses must be performed
with awareness about the limitations of the ability of genetics and the challenges of
drug discovery as a whole. As previously described, the first GWAS study of myocardial
infarction was performed in 2002, since that time many complex common diseases have
been subject to GWAS. This has not lead to a substantial increase in the number of
therapeutic compounds being developed or approved. Indeed, very few genes implicated
by GWAS analysis as being associated with disease risk are also subject to therapeutic
intervention.
Limitations of genetics in drug development
In addition to examining reasons why drugs fail in clinical trials (see above), it may also be
helpful to ask how the pool of candidate drug targets is initially selected. Based on current
technology it is estimated that roughly 10% of proteins in the human organism can be
targeted by small molecule drugs, an additional 10% can be targeted with biologics such as
antibodies [171]. This estimation of the total pool of ‘druggable’ proteins shows that the
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Figure 1.23: Reasons for lack of efficacy in clinical trials in AstraZeneca
pipeline 2005 - 2011.
Project teams were surveyed to identify reasons for project failure due to lack of clinical efficacy
and answers were classified into one of four categories shown. Teams could report more than one
reason for lack of clinical efficacy. Percentages are shown in the bars with the total number of
projects failing due to the listed reason in brackets (Figure source: [47]).
Figure 1.24: Success rate of projects in Phase IIa stratified as those with or
without human genetic linkage evidence linking the target to disease.
Phase IIa is classified as Phase II projects with fewer than 200 patients. Projects in Phase IIa
were classified as those with or without human genetic linkage of the target to disease. Projects
were also classified as those still active or successful or closed. A higher closure rate is observed
for projects without human genetic evidence for linkage to disease. Percentages are shown in the
bars and total number of projects in the brackets below (Figure source: [47]).
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Figure 1.25: Flow chart of drug development showing costs at each stage of
development.
The size of the trapezium at each stage indicates the higher number of projects required to be
initiated for one successful project to reach launch with cost listed in US dollars. The phases of
drug discovery are defined as follows: ‘target-to-hit’: an initial screen to identify compounds
which perturb the target, ‘hit-to-lead’: high throughput process by which lead compounds which
bind the target are generated, ‘lead optimisation’: leads compounds are optimised for favourable
pharmacokinetic properties, ‘preclinical’: study to further understand pharmacokinetics of leads,
potential side effects of the lead, and determination of dose in man. Phases I - III: standard
phases for drugs in clinical trial (Figure source: [134]).
vast majority of proteins are not druggable with current technology. Many proteins which
are known to play critical roles in disease aetiology and are expected to be efficacious drug
targets are not pursued due to the technical difficulty perturbing those targets. Examples
include c-Myc, K-Ras and BCL-2 [171], where perturbation is limited by druggability or
fear of side effects, although efforts in this respect are ongoing [17] [104] [68].
Criticism of clinical pipelines that include drug targets for which genetic evidence does
not exist is possibly beyond the point in many cases. Standout targets which are known
to be involved in disease aetiology and for which genetic evidence exists are likely either
already subject to therapeutic intervention, or undruggable with current technology. It
could be argued that searching for genetic evidence linking genes to disease aetiology will
chiefly lead to targets for which therapeutic agents have already been developed or targets
for which therapeutic agents have not been developed due to the difficulty in perturbing
them in a safe way.
Therefore, perhaps simply increasing the sample size of GWAS studies and performing
more MR to find ever more ‘causal’ associations between risk factors and outcomes, or
utilising whole genome sequencing techniques to replace microarray based technology will
not yield to downstream advances in drug discovery and patient outcomes. As explained by
Cook et al who performed the aforementioned review of the drug pipeline at AstraZeneca
“industrialization of R&D” has lead to poor outcomes by encouraging “quantity-based
metrics to drive productivity” [47]. Simply increasing the number of drug candidates in
clinical development did not increase the number of successful outcomes. Optimising on
quantity based metrics suppresses the ability of scientific investigators to perform research
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which answers real questions about biology and disease aetiology.
1.7 Previous GWAS of haematological phenotypes
The first GWAS of a haematological phenotype published in 2007 and 2008 explained
nearly half the variation in fetal haemoglobin, identifying three major associated loci
[116] [169] [149]. This phenotype was considered important due to the ability of increased
fetal haemoglobin to ameliorate symptoms of sickle cell disease and β-thalassemia [148].
Since this time, GWAS of a number of other haematological phenotypes have been
performed, including the count of the major types of blood cells (platelets, red blood cells,
neutrophils, eosinophils, basophils, monocytes, and lymphocytes), and other measurements
such as mean corpuscular volume (MCV), hematocrit (percentage of blood volume made of
erythrocytes), red cell distribution width (RDW), and mean sphered cell volume (MSCV)
[15, 66, 162, 42, 23, 61, 71]. These studies with progressively increasing sample sizes
have identified more rare variants with higher effect sizes, and an increasing number of
common variants. Furthermore, there has been a growing complement of research into the
genetics of haematology in non-European ancestry individuals, including African American,
Hispanic, and east Asian individuals [170]. All such analyses have identified yet greater
numbers of genetic associations with haematological phenotypes. In tandem, there have
been genetic studies of other phenotypes such as disease risk [34], blood plasma proteins
[164], and blood or blood cell transcript levels [183]. Further analysis should not only
search additional genetic space: rare variants, or common variants with weaker effect sizes
to find new associations with haematological phenotypes, but also integrate information
from GWAS of other phenotypes to offer a more complete picture of the influence of
genetic variants. I aimed to address these challenges with my work, performing GWAS of
previously unstudied blood cell phenotypes, and contributing to a large meta-analysis of
full blood count (FBC) phenotypes in a meta-analysis of 563,085 individuals. Furthermore,
I performed broad integration of my association results by colocalisation with disease risk,
blood plasma proteome, and blood cell transcript GWAS results.
1.8 Aims and structure of thesis
Haematological cells are known to be important in the aetiology of disease including
cardiovascular and immune disorders. The aim of this thesis is use statistical genetic
analysis to derive biological insight into haematology and the role of blood cells in aetiology
of disease. Using a GWAS analysis I identify genetic determinants which influence blood
cell properties including cell count, volume, size, and other flow cytometric properties.
I use these results in a hypothesis generating approach to identify genes and proteins
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which contribute to haematological cell function and evidence for linkage with disease risk.
Finally, I perform MR analyses to identify causal relationships between haematological
cell properties and disease. The analysis outlined in this thesis contributes to the following
scientific outcomes:
1. Chapter 2: contribute to the largest ever GWAS of FBC haematological properties.
The summary statistics generated by this analysis will be shared with the scientific
community to enable further work.
2. Chapter 3: obtain and extract functionally relevant blood phenotypes (termed
Sysmex parameters) from Sysmex XN-1000 analysers used to study participants in
the INTERVAL cohort.
3. Chapter 3: adjust Sysmex parameters for environmental and technical variation thus
increasing power to detect association signals.
4. Chapter 4: Identify novel genetic determinants of haematological function using
Sysmex parameters which index functionally relevant haematological properties.
5. Chapter 5: better understand the biological implications of associations with haema-
tological properties on gene expression and blood plasma protein concentration.
6. Chapter 5: identify which associations with haematological properties also influence
disease risk. From these results generate biological hypotheses about the role of
haematological cells in aetiology of disease.
7. Chapter 5: study the direction of causality between haematological properties and
disease aetiology.
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Chapter 2
Discovery of genetic associations
with FBC haematological
phenotypes
2.1 Introduction
In this chapter I discuss my analysis of haematological phenotypes to identify new asso-
ciations with FBC haematological parameters. I perform conditional analysis on results
of a GWAS of 28 FBC haematological parameters from the UK Biobank cohort and
a meta-analysis of FBC phenotypes including 563,085 individuals. This is the largest
GWAS of haematological phenotypes compared to the previous largest including 173,480
individuals by Astle et al., [15]. The increased sample size enables identification of variants
with lower effect sizes than previous possible and rare variants with lower minor allele
frequency (MAF), the minimum MAF studied by Astle et al., was 0.01% compared to
0.005% in this analysis.
In this chapter I will firstly expand on my introduction to GWAS (Section 1.5) and
discuss challenges regarding multiple testing, population stratification and relatedness,
genotype and phenotype quality control (QC). Secondly, I discuss a protocol for conditional
analysis in meta-analysis and single cohort frameworks, in particular, my software enables
the largest ever exact conditional analysis of GWAS results with 500,000 individuals which
is a significant computational challenge. Finally, I present my results from the combined
meta-analysis of the UK Biobank cohort and 26 haematological GWAS studies collected
by Blood Cell Genetics Consortium (BCX). This meta-analysis allows a further increase
in sample size to 563,085 individuals.
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2.1.1 UK Biobank cohort
UK Biobank is a cohort of 500,000 individuals living in the United Kingdom recruited aged
between 40 and 69 at the time of recruitment. A large number of phenotypic outcomes have
been recorded including haematological measurements, lifestyle factors, biomarkers in urine,
and magnetic resonance imaging (MRI) imaging in a subset of individuals. Participants
have also been genotyped followed by phasing and imputation resulting in a total of 96
million variants [39]. The first release of genotype data from UK Biobank occurred in
May 2015 including 150,000 individuals [15], this was followed in 2018 by a full release of
500,000 individuals of which 403,112 were utilised in my genetic analysis. Haematological
phenotyping was performed with a Coulter full blood count analyser (Chapter 1.2) [39]
generating 28 blood cell phenotypes derived from red blood cells (RBC), platelets, and
white cells (Table 2.1.3). One primary advantage of the large UK Biobank cohort is the
ability to model associations of rare genetic variants reliably. Following the precedent set
by Astle et al., 2016, I excluded variants which did not have atleast 40 minor heterozygote
alleles in the dataset [15], this results in a MAF threshold of 0.005% in comparison to
0.04% in the smaller INTERVAL study.
2.1.2 Blood Cell Genetics consortium
The BCX is an international collaboration of geneticists, haematologists, and statisticians
with the goal of utilising genetic analyses to study and blood cell genetics. This large scale
collaborative effort has allowed sharing of data from 26 blood cell GWAS studies allowing
a meta-analysis of 14 blood cell phenotypes in 563,085 European ancestry individuals,
work which I contributed to and results which I present in this chapter.
2.1.3 Full blood count haematological phenotypes
FBC reports are used routinely in a clinical setting being one of the most common laboratory
tests [37]. The derivation of FBC parameters are described in detail in Section 1.2.1 and
1.2.2 from Coulter based impedance or fluorescence based measurements respectively.
In Table 2.1 I provide a description of the haematological FBC parameters which were
studied in analysis of phenotypes from the UK Biobank cohort or associated meta-analysis.
Phenotypes are determined in four ways: measurement from gating and counting of cells
following flow cytometry, impedance, light absorbance, or calculation from a combination
of the aforementioned directly measured phenotypes.
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2.2 Methods
2.2.1 Genotyping and quality control
Collection and QC of genotype data for the UK Biobank cohort which is utilised in my
analysis was collected by Bycroft et al., [38], this includes genotyping, imputation, and QC
on the UK Biobank cohort. Genotyping was performed on a total of 488,377 participants,
a subset of 49,950 individuals were genotyped with a UK BiLEVE Axiom array containing
807,411 probes, and the remaining 438,427 participants were genotyped using a custom
UK Biobank Axiom array with 825,927 probes [38]. The UK Biobank Axiom array was
designed with additional markers to assay more variants, in particular insertion deletion
variations, the two arrays share 95% of their probes. Probes were specifically selected to
assay for both common and low frequency variants and also variants previously suggested to
be important in other phenotypes such as autoimmune disease, cancer or blood phenotypes
[38]. Blood samples were collected from participants visiting a UK Biobank assessment
centre and samples shipped to Affymetrix for genotyping, sample retrieval and DNA
extraction which are described in Welsh et a., 2017 [175]. Of genotyped individuals 94%
reported their ancestry as ‘White’ with the remaining 6% as Asian, Black, Chinese, mixed
or unknown ancestry. Given the heterogeneous ancestry of the cohort many standard QC
tools will not be effective for this dataset. For example, deviations from Hardy-Weinberg
equilibrium (HWE), which in a cohort of homogeneous ancestry normally occurs due to
poor genotyping will be expected in a cohort of mixed ancestry [38]. QC was divided into
marker or probe based and sample based, I will discuss these separately.
Probe based quality control
In order to avoid the complications of heterogeneous ancestry, Bycroft et al performed
probe based QC only on participants with European ancestry [38]. European ancestry
individuals were identified by projecting samples on the two major PCs from the 1000
Genomes cohort [3] and selecting samples which fall in the European cluster (CEU)
identified by sequencing of European ancestry individuals by the 1000 Genomes project.
This analysis resulted in identification of 463,844 European ancestry individuals. The
following tests were performed to identify and exclude poorly genotyped variants:
• Test for batch and plate effects to check if the allele frequency of genotyped variants
significantly differs between genotype batch or sample plate.
• Test for departure from HWE on somatic chromosomes only to identify markers
which have been genotyped poorly.
• Test to see if variants on chromosome X have a consistently different allele frequency
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between males and females. This shows technical bias for that variant caused by the
use of different calling algorithms on autosomal chromosomes between males and
females.
• Test for array effects to exclude variants which show systematic differences depending
on if they were genotyped by the UK Biobank or UK BiLEVE Axiom array.
• Two wells on each plate were dedicated to two control samples which were loaded
on all plates. A discordance metric was designed [38] to exclude markers which are
significantly discordant between controls across different wells.
Sample based quality control
Poor quality samples were excluded using a set of 605,876 high quality autosomal markers
which were genotyped on both UK Biobank and UKBiLEVE arrays. High quality markers
were defined such that they meet the following criteria:
• Marker is a SNP and not an insertion / deletion variant.
• Marker passed QC in all genotyped batches.
• Marker has a MAF across all samples higher than 0.01%.
• Not in the list of SNPs listed by Affymetrix to be affected by an artefact in a small
subset of 300 individuals.
Tests to identify poor quality samples were performed using only the aforementioned
high quality markers. Heterozygosity was calculated as the ratio of heterozygous genotypes
divided by the total number of non-missing genotypes. Heterozygosity was then adjusted
for population ancestry effects by regressing out the first six PCs calculated from the
genotype data. Following this, individuals with with outlying heterozygosity or higher
than 5% missing genotype data were excluded [38]. Heterozygosity outliers were identified
using the R package abberant and a lambda value of 120, where lambda represents ratio of
the standard deviations of outlying and normal individuals [20]. Furthermore, samples
with mismatch between self reported and genotypic sex or with potential aneuploidy in
sex chromosomes were flagged, these individuals are excluded from my analysis.
2.2.2 Phasing and imputation of variants
As previously described, imputation utilises LD structure from a reference population to
enable identification of variants which have not been genotyped (Section 1.5.2). To ensure
reliable imputation across all samples Bycroft et al., phased a subset of genotyped variants,
45
chosen to ensure a high proportion are good quality in all individuals (for a description
of phasing and imputation see Section 1.5.2). Variants were excluded if they were not
genotyped in both arrays, failed QC in more than one batch, had a MAF of smaller than
0.01% across samples, or had a missingness of greater than 5%. Phasing was performed
using the SHAPEIT3 software [126].
The accuracy of imputation is also influenced by the reference panel, accuracy is higher
if the reference panel contains a higher number of haplotypes and is a close match to the
ancestry of the sample population [38]. Bycroft et al., used a combination of HRC [167]
and UK10K [46] reference panels, selected as they contain a high percentage of European
ancestry individuals and a small subset of individuals with diverse ancestry, thus having
a similar ancestry distribution to the UK Biobank cohort [38]. To perform imputation
Bycroft et al., modified the IMPUTE2 package [84] to perform only haploid imputation on
the pre-phased samples, their new software was termed IMPUTE4 and executes the same
hidden markov model (HMM) as IMPUTE2 and obtains identical results to IMPUTE2 [38].
Imputation estimated 92,693,895 variants in 487,442 individuals [38], it is this genotype
dataset which forms the basis of further analysis in this chapter.
2.2.3 Adjustment of phenotype values for influencing covariates
The outcome of a GWAS study is highly dependent on the quality of both phenotype and
genotype data used in the analysis. Technical and environmental factors which influence
phenotype values increase variation in phenotype values and decrease power to detect
associations. Therefore, phenotypes values are adjusted to account for the influence
of environmental and technical factors. Technical variables include: seasonal effects,
time dependent drift of equipment, sample decay, centre of sample collection, systematic
differences in equipment, and systematic changes resulting from calibration of equipment.
Adjustment is also made for participant environmental variables such as participant sex,
menopause status, age, height, weight, and lifestyle factors including smoking, alcohol
consumption, and diet. For more details regarding the adjustment of haematological
phenotypes for technical and environmental covariates refer to Section 3.2.7 and 3.2.8.
Adjustment for participant phenotypes such as weight and menopause status will
prevent detection genetic determinants which influence haematological traits mechanisti-
cally through these participant phenotypes. On the other hand, adjusting for participant
phenotypes such as weight and menopause status which cause a large degree in variation of
haematological trait values allows greater power to detect other genetic association signals.
In the case of participant phenotypes such as sex or menopause status, adjustment is
further required to ensure a similar distribution of phenotype values across all participants,
an assumption required for the linear modelling of GWAS (Section 2.2.4).
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2.2.4 Genome wide association study
As introduced in Section 1.5, a GWAS identifies genetic variants associated with changes
in a phenotype. In the context of this study GWAS analysis was utilised to test for
association of genetic variants in the UK Biobank cohort with recorded haematological
measurements. The analysis for N individuals was modelled as follows:
E[y] = α + xpcβpc + xβ + g (2.1)
Where xpc is a (N × 10) matrix including the top ten PCs, x is a (N × 1) genotype
matrix coded as described in Section 1.5, and g models genetic effects which contribute to
population stratification (Section 2.2.6) with a GRM matrix which is described in more
detail in Section 2.2.7. At its basis, a GWAS study utilises a linear model or a LMM.
Therefore, the primary assumptions of linear regression still apply. I will discuss these
individually and explain how these assumptions could be broken in the context of a GWAS
study.
Limited multicolinearity
I assume there is not a high correlation between the independent variables in the model, if
this is the case it will lead to poor estimates for the effect size of the correlated independent
variables. Therefore covariates should be selected to ensure they are not strongly correlated
with genetic variants which are being tested. Furthermore, multicolinearity can also occur
when identifying independent variants by multivariable analysis where multiple variants
are put in the same linear model, this is discussed in more detail in Chapter 2.2.8.
Samples drawn from an independent distribution
A core assumption of a linear regression is that under the null hypothesis samples are
independent and identically distributed given the covariates and the model. This assump-
tion is broken if there are related individuals within the sample population (relatedness).
Relatedness between can be estimated with the identity by descent (IBD) parameter and
related samples filtered out. In addition, a GRM can be used as a random effect covariate
to help account for relatedness and reduce the influence of this effect on the estimated
variant effect sizes. This is discussed in more detail in Chapter 2.2.6.
Homoscedasticity
The homoscedasticity assumption states that the variance of the outcome variable is
constant across the range of values for the independent variables (genotype and covariates).
Given the relatively low proportion of variance in the outcome explained by any single
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variant or covariate being modelled, GWAS is not likely to break the homoscedasticity
assumption.
Normal distribution of residuals
The residuals of the model are assumed to be normally distributed, in the context of my
analysis the dependent variable (phenotype to be tested) is transformed to be normally
distributed by an inverse-normal quantile transformation. This helps ensure normal
distribution of residuals assuming there is not a serious deviation from the homoscedasticity
assumption, which as previously explained is unlikely to be the case due to the low variance
explained by any one variant being tested.
2.2.5 Multiple testing
In a frequentist paradigm, statistical tests of a null hypothesis are considered to be
significant if the P-value of association falls below a threshold usually set to 5%. If the
assumptions of the statistical model are correct this procedure will incorrectly reject the
null hypothesis (false positive result) in 5% of cases. In a GWAS analysis each SNP is
tested separately for association. Therefore I perform a very large number of parallel tests
thus increasing the total number of false positives if I maintain the 5% P-value threshold.
To reduce the number of false positive results, I adjusted the 5% P-value threshold by
dividing the threshold by the number of effective independent tests, this is also known as
a bonferroni correction. A GWAS analysis testing a large number of imputed variants will
contain many variants which are highly correlated (Section 1.4). Therefore, the number of
effective independent tests is less than the total number of variants tested for association.
The number of effective independent tests has been found to vary greatly depending on the
MAF threshold. Studies which include many rare variants will perform more independent
tests as rare variants are less likely to be in LD with nearby variants (Table 2.2) [180]. My
analysis utilised a MAF threshold of 0.005%, thus according to the simulations performed
by Xu et al., it is appropriate to use the same P-value threshold of 8.31× 10−9 as that
utilised by Astle et al., 2016. This MAF threshold was set to ensure at least 40 minor
alleles per variant in the sample population, this is inline the threshold set by other studies
[15].
Alternatively it is possible to limit false positive findings using permutation to obtain
an empirical null distribution. With this approach the phenotype is permuted to ensure
that there is no true association between genotype and phenotype. All variants are tested
with the permuted data and the smallest P-value is recorded. This shuﬄing and testing
procedure is repeated to obtain an empirical null distribution of the smallest P-values
calculated by chance [155]. P-values calculated from analysis of the un-shuﬄed dataset are
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MAF Threshold
Range of Predicted
Independent Tests
Range of Appropriate
GWAS thresholds
0.05% 2, 746, 888− 4, 306, 272 1.16× 10−8 − 1.82× 10−8
0.01% 4, 412, 096− 6, 019, 458 1.13× 10−8 − 8.31× 10−9
0.005% 5, 933, 687− 8, 547, 380 5.85× 10−9 − 8.43× 10−9
Table 2.2: Range of appropriate GWAS thresholds.
Range of predicted GWAS thresholds depend on the MAF filter applied to the variants being
studied, calculated by Xu et al., 2014 who assume participants of European ancestry [180].
then compared to this empirical null distribution. This method relies on the assumption
that samples within the population are independent, this assumption can be broken by
relatedness in the population [105]. The influence of relatedness can be reduced by filtering
related individuals (Section 2.2.4), or using a permutation procedure which accounts for
relatedness in the sample population [105]. I did not employ the permutation procedure
due to the computational burden of calculating the null distribution.
2.2.6 Population stratification and relatedness
As described above, application of an appropriate P-value threshold will help limit false
positive results from GWAS studies. Confounding factors may also lead to inflated false
positive or false negative results. An example is population stratification, the presence of
correlated ancestry within a stratum of the population. This is problematic as a stratum
of the population may also have common environmental or genetic exposures. Population
stratification makes it difficult to distinguish between a variant is associated with an
outcome because of a genetically mediated mechanism, or because an allele of that variant
happens to be common in a stratum of the population where the presence of the measured
phenotypic outcome is common by chance. In addition to population stratification, closely
related individuals in the sample population (cryptic relatedness) can lead to similar
inflation in false positive or negative results. Linear models assume phenotype values are
independent given association with the test variant, relatedness in the population cohort
breaks this assumption (Section 1.5). There are multiple ways to account for population
stratification and relatedness which are used in combination as no single method can
sufficiently account for these confounding factors:
• Bycroft et al, filtered all samples to ensure to only include those of British ancestry
[38]. This was performed using self reported ancestry of individuals and PCs
generated from genotype data.
• Bycroft et al, removed all samples with a high degree of relatedness, as determined
by IBD analysis [38].
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• Regress the effect of clinic, a variable recording the location of blood donation against
the phenotype values and use the residuals for GWAS analysis.
• Include PCs as covariates in the GWAS model.
• Use a LMM model which allows including a GRM random-effect covariate in the
GWAS model (Section 2.2.7).
• Filter tested variants by MAF>0.005%.
Generation of PCs from genotype data provides information about participant ancestry
and is used in calculation of relatedness, heterozygosity and other sample quality metrics.
However, PCs should ideally be calculated from high-quality unrelated samples. To address
this problem Bycroft et al performed two rounds of principal component analysis (PCA),
firstly to identify unrelated high-quality samples, and secondly to compute PC adjusted
heterozygosity and measures of relatedness [38].
First calculation of principal components
Firstly, Bycroft et al estimated kinship coefficients up to third degree of relation between
all samples using the software package KING [109]. The kinship coefficient is calculated
pairwise between samples and is the probability that two randomly sampled alleles are
identical due to shared descent between the samples. A parent-offspring pair is expected to
have a kinship coefficient of 0.5, decreasing by a multiple of 0.5 for every additional degree
of relatedness, grandparent-grandchild pairs have a kinship coefficient of 1/8 [38]. From
the set of kinship coefficients calculated across the samples a maximal set of unrelated
individuals is calculated by pruning the relatedness graph of individuals using the i-graph
(v1.0.1) package [10] in R. Samples were then excluded based on the following properties:
• Missing rate of autosomes > 0.02.
• Mismatch between inferred and self-reported sex.
• Not in the set of unrelated individuals.
SNPs were also excluded based on the following properties before being pruned into a
set of independent markers by pairwise r2 > 0.1:
• Missing rate > 0.015.
• MAF > 0.01%.
• In regions of long-range LD such as regions of inversion, these are defined in Bycroft
et al [38].
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Application of filters to the genotype data resulted in a set of 147,551 SNPs and 406,257
samples which were used to compute PCs which are then utilised to generated adjusted
QC metrics as described below. Generation of PCs was performed with fastPCA [65] and
the top 8 components were extracted.
PC adjusted QC metrics
Heterozygosity and kinship metrics are sensitive to participant ancestry effects. For
example recent admixture can lead to inflation of kinship and heterozygosity estimates.
Therefore, kinship metrics are recalculated and heterozygosity using the first set of PCs.
Exclusion of samples was recalculated from the adjusted kinship and heterozygosity metrics
and a second round of PCs was calculated resulting in 40 components.
Kinship was recalculated as described but with a subset of SNPs which contribute
loads less than 0.0003 in the first three PCs. Bycroft et al chose this threshold to meet
the trade-off where inclusion of SNPs with high loads of contribution to the PCs will
inflate the kinship matrix due to recent admixture, but a stringent threshold would lead
to exclusion of too few SNPs would result in kinship estimates with high variance. In
total 93,511 SNPs were used for final kinship inference and from the kinship estimates
unrelated individuals identified as described above.
Heterozygosity is a ratio of genotypes which are not homogeneous in the population:
h =
Nnm −Nhom
Nnm
(2.2)
Where Nnm is the number of non-missing genotypes and Nhom is the number of homozygous
genotypes. However, heterozygosity is influenced by ancestry effects, therefore heterozy-
gosity was adjusted for the top 6 PCs x = (x1, x2, x3, x4, x5, x6), features which correlate
with ancestry:
h(x) = h0 + β(x) (2.3)
Where h(x) is the raw heterozygosity, β(x) is a function of the bias due to population
structure, and h0 which is the ancestry adjusted heterozygosity. β(x) has a quadratic form
and includes all linear and quadratic terms xi and x
2
i and cross terms xixj where i and j
index over the six features in x [38]. The fitted value for ancestry adjusted heterozygosity
hˆ0 identified with ordinary least squares is utilised in sample QC to exclude samples with
outlying heterozygosity. Samples with outlying heterozygosity are identified and excluded
with the aberrant R package [21] from the logit transformed missing rate and ancestry
adjusted heterozygosity hˆ0 and a λ value of 120. Aberrant is a clustering algorithm which
uses a mixture model to identify outlying data point where outliers are defined as those
which have standard deviation (SD) λ times higher than that of the sample distribution
which is inferred from the data by the aberrant package.
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With the QC metrics adjusted for ancestry effects with PCs as described above,
exclusion of samples were performed with the following criteria:
• Missing rate on autosomes > 0.02.
• Not in a set of unrelated individuals as identified by kinship estimates.
• In the list of outliers based on heterozygosity and missing rates.
• Mismatch between inferred and self-reported sex.
This exclusion resulted in a set of 147,606 SNPs and 407,599 samples which were used
to compute a second round of PCs. The top 40 PCs were computed with fastPCA [65], the
top 10 PCs were included in the LMM model to account for population ancestry effects
(Section 2.2.7).
2.2.7 Linear mixed model GWAS
GWAS analyses are traditionally modelled using linear regression with a set of fixed
effect independent variables such as PCs and the genotype of the variant (Section 1.5).
Relatedness in the sample population can be represented with a GRM and included as
a covariate (Section 2.2.6). The GRM covariate is necessarily a random effect as it will
not have a consistent effect size across all individuals in the sample population, some
individuals may have more relatedness to model than others [106]. Therefore, a fixed
effects linear model will not suffice, inclusion of a GRM requires construction of a LMM.
Using the BOLT-LMM application by Loh et al., I constructed a LMM with GRM and
the top ten PCs as covariates [106]:
y = xPCsβPCs + xβ + u+ e (2.4)
Where y is a vector of phenotype values across all individuals N , xPCs is a matrix
where columns are one of ten PCs calculated from the genotype data (N × 10), and x is a
genotype vector for the variant being modelled as a fixed effect with coefficient βtest. The
effect of relatedness is included in the model with the u term and environmental effects
with e ∼ N (0, σ2eI). The effect of relatedness is modelled with a GRM matrix containing
a subset of MGRM SNPs across all N individuals: XGRM (N ×MGRM):
u = XGRMβGRM (2.5)
Here βGRM is a vector (length MGRM ) of random effect sizes drawn a normal distribution
thus resulting in the requirement for a LMM to estimate these effects.
u ∼ N (0, σ2gXGRMX ′GRM/MGRM) (2.6)
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It is evident that the SNP being tested and its proxies in the genotype vector x defined
above should not be included in u, as this would lead to deflation of the test statistic
for that SNP. This is effect is also known as ‘proximal contamination’ and is avoided in
the BOLT-LMM implementation by removing all SNPs on the same chromosome as that
being tested, this defines the ‘MGRM subset of SNPs’ mentioned above.
A LMM analysis is computationally expensive to fit with time complexity O(MN2)
or O(M2N), where N is the number of samples and M the number of tests [182]. The
BOLT-LMM algorithm uses a series of approximations to achieve a O(MN1.5) time
complexity [182]. BOLT-LMM achieves this by estimating variance parameters using a
stochastic approximation algorithm which avoids ‘spectral decomposition’, a time expensive
operation where the matrix of genotype values is represented in terms of its eigenvalues
and eigenvectors.
BOLT-LMM also allows modelling of associations with a non-infinitesimal prior on
the SNP effect size coefficient β, which is in contrast to the infinitesimal prior used in
standard LMM. The infinitesimal model assumes that all variants have effect sizes drawn
from a Gaussian (or normal) distribution. In reality traits usually have a few associated
variants with large effect sizes compared to many associations with smaller effect sizes.
Therefore empirically, effect sizes are not Gaussian distributed. To enable reductions
in computational time complexity BOLT-LMM uses a ‘spike-and-slab’ mixture of two
Gaussian distributions. One to model the few causally associated variants with large effect
sizes, and a second Gaussian distribution to model the higher number of more weakly
associated variant [106].
2.2.8 Conditional analysis to identify independent associations
Due to LD between variants it is not clear from a GWAS analysis alone how many
independent association signals are present in a locus. Conditional analysis determines how
many association signals are present in a locus and which variants are the good statistical
representatives for those signals. However, conditional analysis cannot determine which
variants are casual for the association signal. Causality only be truly determined with a
downstream follow up experiment, although statistical methods such as FINEMAP can
build a credible set of variants which are likely to contain the causal variant.
Methods for conditional analysis are split between those which utilise summary statistics
to perform analysis such as genome-wide complex trait analysis (GCTA) [181], and those
which rely on availability of participant level genotype and phenotype data. Summary
statistics based methods rely on LD calculated from a reference population resulting in
less accurate results. Therefore, I utilise the multiple step-wise conditional analysis using
phenotype and genotype data from the study population (Section 2.2.8.1).
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2.2.8.1 Multiple stepwise conditional analysis algorithm
Stepwise multiple regression is an algorithm which identifies a parsimonious set of condi-
tionally independent genetic variants, which represent the underlying association signals for
each phenotype. Principally, a series of joint models are utilised to test for independence
of genetic variants in association to the phenotype, constructed as follows:
y = xPCsβ + xVAR1βVAR1 + xVAR2βVAR2 + ...xVARnβVARn (2.7)
Where y is the phenotype value across individuals, xVARi is a vector of genotypes for
the ith variant being tested across individuals, and βVARi represents the effect size for that
variant. If the estimated effect size for a particular variant has a P-value below that of
genome-wide significance, that variant is considered to be independently significant from
the other variants in the model. To avoid collinearity between predictors a variant is never
put in the model if it has a squared correlation higher than 0.9 with any other variant in
the model. In these cases it is assumed that the entering variant would not be independent
from its correlated variant.
In order to find a parsimonious set of independent variants from all the genome-
wide significant variants, a multiple-stepwise regression algorithm is run which tests many
combinations of variants in a joint model. This is Efroymsons stepwise regression algorithm
which has been shown to be convergent in most cases to a global minimum across the
search space of variant combinations which would best explain the association signal [117].
To limit the search space and make the algorithm computationally tractable the genome
is initially subsetted into blocks. Variants within those blocks are tested separately using
the multiple-stepwise regression algorithm and independently associated variants are put
forward into a larger chromosome wide pool on which a second multiple-stepwise regression
algorithm is executed.
For each phenotype, I split the genome into blocks of variants associated at genome-
wide significance threshold with the phenotype so that each block is not larger than
2,500 variants, and there are no genome-wide significant variants 5 Mb on either side of
each block. I then performed the multiple stepwise conditional analysis procedure on
genome-wide significant variants within each block (Fig. 2.1):
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Figure 2.1: Flowchart of multiple-stepwise conditional analysis algorithm.
Protocol for the conditional analysis algorithm where P is the joint P-value of the variant and
PThreshold is the genome-wide significance threshold. The multiple-stepwise conditional analysis
algorithm creates multiple joint models including different subsets of variants to identify a
parsimonious set of independently associated variants. The algorithm begins by addition of
variant with the smallest P-value and proceeds to test all other variants sequentially in a joint
model. Here the algorithm alternates between ‘adding’ and ‘dropping’. Adding: sequentially test
all remaining variants in the joint model, then add the variant with lowest joint P-value.
Dropping: run the joint model with all currently included variants and drop the variant with the
lowest joint P-value if it is below the threshold. The algorithm will terminate if it cannot add or
drop any variants to the model. * Uncorrelated variants are defined as those not in LD r2 > 0.9
with any variants already in the joint model.
1. START: The variant with the lowest univariate P-value in the block is put in the
linear model.
2. All other variants in the block are sequentially tested in the model if they are not
r2 > 0.9 with any other variant in the model.
3. Of the variants tested in Step 2, the variant with the lowest conditional P-value is
put in the linear model.
4. The joint model is fitted again, and variants in the model with conditional P-value
above the genome-wide association threshold are dropped. Dropped variants continue
to be tested in Step 2 and could re-enter the model.
5. Repeat Step 4 until no more variants can be dropped from the model.
6. Iterate through Steps 2 - 4 until there are no other variants which can be added or
dropped from the model.
Given the computational challenges of executing a multiple-stepwise regression algo-
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rithm on a dataset of up to 403,112 individuals an additional filter was utilised to reduce
the number of iterations. If a variant reaches -log10(P ) < 2 for association in the addition
phase, this variant is excluded from all further analysis. Once a parsimonious set of
conditionally significant variants is identified for each block, those variants are brought
forward into a chromosome-wide multiple-stepwise conditional analysis procedure including
all blocks. The resultant set of variants are labelled as ‘conditionally significant’ and
are identified independently for each phenotype. Practical implementation of the block
level and chromosome-wide conditional analysis procedure is explained further in Section
2.2.8.2.
2.2.8.2 Software pipeline for large-scale individual level conditional analysis
The storage and manipulation of genetic data, including up to 90 million variants in 403,112
individuals is a significant computational challenge. Therefore, I developed a software
pipeline which subsets BGEN files and converts them into smaller and more easily readable
HD5 format (Fig. 2.2) [8]. Genetic data for the UK Biobank cohort is stored in compressed
BGEN format, reading this dataset into memory in order to perform computation is not
feasible due to their large size. Therefore, I subsetted BGEN files into less compressed
and more accessible file formats. Firstly, a GEN file for each block containing the dosage
genotype data for all variants within that block, this was generated by subsetting the
BGEN files using QCTOOL [16], following this the GEN files are converted to HD5 format
[14]. GEN format is a less compressed alternative to BGEN which can be more easily read
by software. HD5 is a common file format for which packages and libraries exist in R for
the manipulation of this data. HD5 files were subsequently read by an R script using the
rhdf5 package. The R script fit linear regression models using the fastLm package iterating
through the steps previously described (Section 2.2.8.1) and identified a parsimonious set
of conditionally significant variants for each block. Once all blocks were analysed using
the conditional analysis procedure, conditionally significant variants identified from blocks
were combined to perform a genome-wide level conditional analysis. These variants were
again extracted from the BGEN files into a separate GEN file (one for each chromosome)
which was then converted to HD5 file and analysed by an R script which performed a final
round of conditional analysis.
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Figure 2.2: Flowchart of software pipeline for conditional analysis algorithm.
Initially univariate summary statistics for variants in each block were extracted, and the
genotype data for these variants were extracted from the BGEN file into a GEN file and
converted to HD5 format. The HD5 files were read by the multiple-stepwise conditional analysis
script which generated a list of independent variants for each block. The independent variants
for each block were collated chromosome wide and these variants were extracted again from the
BGEN file into a GEN file and converted to HD5 format. A chromosome wide conditional
analysis was executed generating a final list of conditionally significant variants.
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2.2.9 Linkage disequilibrium grouping to identify total number
of signals
Conditional analysis identifies the number of independently associated variants for each
phenotype. LD grouping can identify the number of independent signals identified across
multiple phenotypes. In order to assess the number of independent association signals
across the 28 phenotypes studied in the analysis, I used a LD clumping procedure with
a threshold of r2 > 0.8 to assign conditionally significant variants to independent sets.
Where the correlation between variants in the same set is high, but variants between sets
have a correlation or LD lower than the r2 > 0.8 threshold. The LD clumping protocol
begins with generation of a correlation matrix between all conditionally significant variants
using PLINK and execution of the following steps:
1. Iterate over conditionally significant variants in order of chromosome and position,
terminate once iterated over all conditionally significant variants.
2. Populate set F with the conditionally significant variant chosen in Step 1) and all
conditionally significant variants that are in LD r2 0.8 or higher with this variant.
3. If none of the variants in set F are in a pre-existing LD set then create a new LD
set with these variants, return to step 1).
4. If variants in set F exist in a single LD set which already exists, then assign all
variants in set F to that LD set, return to step 1).
5. If variants in set F exist in more than one pre-existing LD sets, then merge all
variants in those LD sets, and variants in set F , into a new larger LD set, return to
step 1).
6. Terminate once the algorithm has sequentially iterated over all conditionally signifi-
cant variants.
The result of this algorithm is assignment of all conditionally significant variants to LD
sets based on a threshold of r2 > 0.8 pairwise LD. It is important to distinguish between
LD sets as a measure of distinct genetic association signals and determination of genetic
signals based on locus or physical distance. Genetic loci are defined based on genomic
location, however LD sets are defined based on variant LD. This means that two LD sets
could be physically overlapping but distinct signals if the conditionally significant variants
which constitute the LD sets are in low LD. This is often the case with rare variants which
may be allocated to distinct LD set amongst a preexisting association signal of common
variants in a locus.
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Meta-analysis UK Biobank Only
BASO#, EO#, HCT, HGB,
LYMPH#, MCHC, MCH, MCV,
MONO#, MPV, NEUT#, PLT#,
RBC#, RDW
MRV, PDW, LYMPH%, RET#
EO%, PCT, HLSR#, HLSR%,
IRF, MSCV, NEUT%, RET%
MONO%, BASO%
Table 2.3: Traits studied in the meta-analysis (including UK Biobank) and
traits studied in UK Biobank only.
The meta-analysis (including the UK Biobank study) was restricted to fewer blood cell traits
compared to the UK Biobank study. Of 28 traits studied in UK Biobank, 14 were analysed in
the meta-analysis, this is due to the absence of traits within many studies consisting of the
meta-analysis. A description of traits is presented in Table 2.1.3.
2.2.10 Meta-analysis conditional analysis
Initial analysis was performed on 28 blood cell phenotypes from the UK Biobank cohort,
this was followed by a meta-analysis of 14 blood cell traits (Table 2.3) adding an additional
159,973 participants of European ancestry from 25 studies (Table 2.4). The purpose of
the meta-analysis was to achieve a large sample size to discover additional association
signals. Conditional analysis of the meta-analysis summary statistics data was performed
using the GCTA-COJO algorithm which approximates a variance-covariance matrix for
the genotype values due to the lack of individual level participant data in a meta-analysis
setting (Section 2.2.11.2). Furthermore, GCTA-COJO uses a protocol alternative to the
conditional analysis defined above (Section 2.3.1) which calculates joint models with subsets
of all variants in the dataset not just the genome-wide significant subset as utilised in the
multiple stepwise conditional analysis protocol. I hypothesised that many sub-threshold
variants which are not genome-wide significant may be conditionally significant when
placed in a joint model. To study this I performed analysis to test if variants identified
by GCTA-COJO were jointly significant when accounting for conditionally significant
variants already identified by conditional analysis of UK Biobank (Section 2.3.2). However,
the GCTA-COJO algorithm relies on a reference sample approximation in the absence
of exact genotype and phenotype data. If the approximation for the variance-covariance
matrix of the genotype values made by GCTA is not accurate, this analysis may lead to
false positive results (Section 2.2.11.1). Therefore, I tested the conditionally significant
variants from the meta-analysis identified by application of GCTA-COJO, in the UK
Biobank population using a joint model utilising individual level genotype and phenotype
data. Firstly, I calculated the LD between conditionally independent associations as
identified by GCTA-COJO to identify highly correlated variants which are proposed as
independent by GCTA-COJO. Secondly, I performed statistical tests to identify which
variants obtained from GCTA-COJO conditional analysis of the meta-analysis summary
statistics are independent from conditionally significant variants identified from the UK
Biobank cohort alone.
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Study Name Samples in analysis References (PMID)
Airwave 13,113 25194498
BioME 802 21573225
CaPS 1181
1999035
21043637
11395343
CHD 3249 1669507
Estonia (Chip) 22417 28031487
Estonia (WGS) 2242 28031487
Framingham Heart
Study
6451 14025561
FINCAVAS 924 16515696
GERA EA Chip 53822 26092716
GERA AFR Chip 1363 26092716
GERA LAT Chip 1504 26092716
Health2006 3177 23615486
Health2008 752 22587629
Health2010 1474 25113139
INTERVAL 39260 28941948
MESA (EA) 1172 12397006
MHIphase1 1991 24777453
MHIphase2 3436 24777453
RS-I 1455 29064009
RS-II 1269 29064009
RS-III 2378 29064009
SHIP 3159 20167617
SHIP-TREND 940 20167617
UKBB EA 456785 30305743
WHI (EA) 17682 24777453
YFS 1889 -
Table 2.4: Studies which contribute their summary statistics to the meta-
analysis of FBC haematological phenotypes
In total 26 studies contributed to the meta-analysis of haematological traits, the largest study
was UK Biobank which contributed 456,786 individuals with the smallest being BioME with 802
individuals. The primary prublication for the ‘YFS’ has not yet been published and a reference
is not present in the table.
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2.2.11 GCTA conditional and joint association
The GCTA-COJO package allows the construction of useful joint models using GWAS
summary data. This method is effective in meta-analyses where individual level genotype
and phenotype data cannot collated due to data sharing restrictions. Conditional and joint
analysis using summary-level statistics are estimated using LD from a reference sample
which is similar to the population cohort. The method for estimation of joint effects of
multiple SNPs using GWAS summary statistics and a reference population is described
by Yang et al [181], who then extend their derivation to perform step-wise conditional
analysis. Their methodology is implemented in the GCTA-COJO software package. There
are limitations associated with the GCTA-COJO approach due to the assumption that
allele frequencies and LD between variants in the reference sample population are the
same as the study sample population. Due to the much larger population size of our
meta-analysis compared to any available reference population we are able to model the
association of very rare variants which are not likely to be well represented in the reference
population. Therefore, a reference LD set using 100,000 individuals from the UK Biobank
dataset was generated.
In the next section, I explain the implications of meta-analysis in providing additional
insight beyond the GWAS of the UK Biobank cohort alone (Section 2.2.11.1). Following
this, I work through the approximation underlying the GCTA-COJO package (Section
2.2.11.2) and finally, describe the GCTA-COJO conditional analysis protocol (Section
2.2.11.3).
2.2.11.1 Implications for the meta-analysis of blood cell traits
The GCTA-COJO algorithm is very similar to the forward and backward stepwise regression
as defined previously in my analysis of Sysmex parameters (Section 2.2.8.1). The primary
difference being the ability to test all SNPs across the genome due to an approximation
which avoids direct use of the genotype and phenotype data (Eqn. 2.18). This is compared
to the previously described multiple-stepwise regression conditional analysis algorithm
which only tests genome-wide significant variants for conditional significance (Section
2.2.8.1). It can be hypothesised that the benefit of testing all variants, rather than
just the genome-wide significant subset of variants is that many sub-threshold signals
could reach conditional significance when analysed in a joint model. This is because, as
independent variants are added to the model, a greater proportion of variance in the
phenotype is explained, thus increasing the calculated statistical significance of variants in
the model. I attempt to identify such variants and present the results below in Section
2.3.2. Furthermore, GCTA-COJO allows conditional analysis on the meta-analysis results
providing an extra 159,973 samples to the conditional analysis which were not accessible
in the UK Biobank conditional analysis alone. However, the GCTA-COJO approximation
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(Eqn. 2.18) relies on the reference population providing a good estimate of LD between
variants in the sample population. The reference population must be large enough to
reliably calculate LD of tested rare variants and must also have close ancestry to the
sample population.
2.2.11.2 Estimation of joint effects by Yang et al., 2012
Yang et al, begin by considering a multi-SNP model as follows:
y = Xb+ e (2.8)
Where y = {yi}, a n × 1 vector of phenotype values. X = {xij}, a n × N genotype
matrix where each element of X is a function of the allele count of SNP or variant j in
individual i. The number of individuals and number of SNPs is n and N respectively,
e = {ej}, a N × 1 vector of residuals, and finally b = {bj}, a N × 1 vector of SNP effects.
Yang et al also centre phenotype values (y) to removing the requirement for an intercept
term. Given (Eqn. 2.8) joint effects can be estimated using the least-squared approach as
follows:
bˆ = (XTX)−1XTy, var(bˆ) = σ2J(X
TX)−1 (2.9)
Where σ2J represents the residual variance of the joint model (the capital J subscript
represents the joint model). However, in many cases individual level phenotype or genotype
data is not accessible, therefore the data y and X are unavailable. GCTA approximates bˆ
and var(bˆ) with a reference population and a set of univariate summary statistics defined
as follows where each variant (indexed by j) is tested for association with the phenotype:
y = xjβj + ej (2.10)
Where xj is the column j in X and βj is the effect of variant j on the phenotype, this
is the marginal effect of SNP or variant j on the phenotype, as before ej is the remaining
residual. As we are not taking into account covariances between the variants (because
Equation 2.10 is not a joint model), the diagonal of X ′X is represented by diagonal matrix
D, where Dj =
∑n
i x
2
ij, such that the marginal effects for multiple variants is represented
as follows:
βˆ = D−1XTy, var(βˆ) = σ2MD
−1 (2.11)
Here σ2M is the residual variance in the univariate model (Eqn. 2.10). Of course,
obtaining Dj requires individual level genotype data, which is unavailable in this context,
an approximation to obtain Dj is described later (Eqn 2.17). I have previously discussed
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the drawbacks of single-SNP or univariate analysis at length, namely LD between variants
resulting in proxies of a variant causally associated with a change in phenotype also
appearing significantly associated (Section 1.4), thus making it difficult to determine the
true number of associated signals in a locus. Joint models of SNPs can identify the total
number of independent signals in a locus. It is such joint models which are approximated
by GCTA-COJO.
It was previously shown by Yang et al., that XTy = Dβˆ (Eqn. 2.11). Therefore Yang
et al re-wrote the joint model (Eqn. 2.9) in terms of Dβˆ which includes βˆ obtainable in
the summary data shared from univariate GWAS analysis (Eqn. 2.11). An approximation
for D, the diagonal matrix of XTX using a reference population is described later (Eqn.
2.17).
bˆ = (XTX)−1Dβˆ, var(bˆ) = σ2J(X
TX)−1 (2.12)
The coefficient of determination of a multiple or joint regression model (represented by
subscript J) is a calculation of the total phenotypic variance explained by the covariates
(in this case the SNPs) is as follows:
R2J =
bˆTXTy
yTy
=
bˆTDβˆ
yTy
(2.13)
Which can be used to calculate residual variance of the joint model σˆ2J and residual
variance of the single-SNP analysis σˆ2M(j) as follows:
σˆ2J =
(1−R2J)yTy
n−N =
yTy − bˆTDβˆ
n−N (2.14)
σˆ2M(j) =
yTy −Djβˆ2j
n− 1 (2.15)
Where N is the number of variants and n the number of samples. Given the squared
standard error of the estimate of the effect size for each variant (indexed by j) is S2j =
σˆ2M(j)/Dj we deduce that: y
′y = DjS2j (n− 1) +Djβˆ2j , and this can be calculated for each
SNP from data readily available in GWAS summary data.
In order to perform the calculations listed above in the absence of individual level data,
the matrix D must be approximated. D is a diagonal matrix of the variance-covariance
matrix of variant genotypes X ′X. As shown by Yang et al., 2012 variances can be calculated
from allele frequencies and covariances from LD in a suitable reference population. The
genotype matrix of the reference sample is defined as W = {wij} where j is an index over
the SNPs in the reference sample of size m. Furthermore, Dw is the diagonal matrix of
W ′W with DW (j) =
∑m
i w
2
ij defined using the allele frequencies available from GWAS
summary data. Assuming the reference sample is drawn from the same population as
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the meta-analysis cohort, LD correlations between variants will be approximately similar.
This approximation is defined as follows, with the LD between two variants i and j in the
genotype matrix X defined on the left hand side:∑n
j xijxik√∑n
i x
2
ij
∑n
i x
2
ik
≈
∑n
j wijwik√∑n
i w
2
ij
∑n
i w
2
ik
(2.16)
Following, we can denote the variance-covariance matrix X ′X to be approximately
equal to B defined as such:
Bjk ≈
√
DjDk
DW (j)DW (k)
m∑
i
wijwik (2.17)
It was defined above that Dj =
∑n
i x
2
ij, as xij is not available allele frequencies
from the summary statistics are used: Dj ≈ 2pj(1 − pj)n. Therefore, Yang et al., 2012
can approximate the joint analysis of multiple SNPs as follows, with b˜ represents the
approximated joint effect sizes of SNPs in the model:
b˜ = B−1Dβˆ, var(b˜) = σ2JB
−1 (2.18)
Yang et al., make further adjustments to their estimates of the variance-covariance
matrix to account for changes in sample size between different SNPs within the meta-
analysis. Conditional analysis is performed as an extension of the joint model defined
above, using the same approximation to allow estimation in the absence of individual level
genotype and phenotype data, for more details see [181].
2.2.11.3 GCTA-COJO conditional analysis
Yang et al., apply the step-wise conditional analysis algorithm across the entire genome
using their approximate joint regression models as follows:
1. Begin the model including the most significant SNP across the entire genome.
2. Calculate the P-values of all remaining SNPs conditional on SNPs already in the
model. Do not test SNPs which are highly correlated with SNPs already in the
model. Highly correlated SNPs are defined as those with an r2 threshold usually set
to 0.9.
3. Select the SNP from Step 2 with the lowest conditional P-value, assuming this is
below the set significance threshold.
4. Fit all SNPs in the model in a single joint model to test for significance dropping
variants which are below the significance threshold.
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5. Repeat Steps 2, 3, and 4 until no SNPs are added or removed from the model.
6. Perform a final joint model test to ensure all are conditionally significantly associated
with the phenotype.
This algorithm results in sequential testing of all variants in the joint model. Similar
to the multiple stepwise regression procedure, this type of conditional analysis can only
identify sentinel or representative variants and cannot necessarily identify the variant
mechanistically causal for the signals of interest. However, determination of the number
of independent association signals in a locus could inform setting of priors in a fine-
mapping procedure which can determine credible sets of variants likely to be causal for
the association signal.
2.3 Results
2.3.1 Conditional analysis of UK Biobank identifies novel sig-
nals
A primary motivation for my work was to identify new genetic associations with full blood
count haematological measurements. Multiple-stepwise conditional analysis identified
16,900 associations across 7,122 LD sets representing independent association signals in 23
chromosomes (Section 2.2.9). This is almost three-fold greater than the 6,736 associations
across 2,706 LD sets identified in the previous largest GWAS of the same phenotypes in
173,480 individuals performed by Astle et al., 2016 [15]. I identified 7,122 novel sets, defined
as those which do not contain any variants which are in LD r2 > 0.8 with any variants
identified by Astle et al (Fig. 2.3). A full list of conditionally significant associations and
their comparison with Astle et al., can be found in Section A.2.
2.3.2 Distinct associations identified by GCTA-COJO
The meta-analysis includes 23 studies (including UK Biobank) with a total sample size of
563,085 individuals, versus 403,112 individuals in UK Biobank alone. The higher power
afforded by the meta-analysis allows discovery of additional association signals. Because a
large proportion of samples in the meta-analysis are from the UK Biobank cohort, I sought
to determine which of the association signals identified by the meta-analysis are distinct to
those already identified by analysis of the UK Biobank cohort alone (Section 2.3.1). To test
this I used genotype and phenotype data from the UK Biobank cohort to create exact joint
models instead of relying on conditional analysis that was performed on the meta-analysis
summary statistics using the GCTA-COJO module. From the phenotypes, I regressed
out the effect of all conditionally independent variants identified from analysis of the UK
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Figure 2.3: Bar plot showing number of novel signals identified per trait.
A plot of conditionally independent associations across the 28 studied haematological traits
assigned as ‘not-novel’ if they exist in an LD clump which contains conditionally significant
variants with higher than r2 > 0.8 pairwise LD with any trait identified by Astle et al., 2016 [15]
or assigned as ‘novel’ otherwise. Of all associations 52.0% as designated as novel compared to
Astle et al., 2016 [15]. This result shows that my conditional analysis of up to 403,112
individuals in UK Biobank makes new findings compared to the previous largest study of the
same haematological phenotypes [15].
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Figure 2.4: Flowchart showing meta-analysis conditional analysis pipeline.
Variants identified by GCTA-COJO following meta-analysis are put in a joint model to test if
they are significantly associated given residuals calculated by regressing out conditionally
significant variants identified by conditional analysis of the UK Biobank dataset. The threshold
of significance was made less stringent account for the smaller sample size in the UK Biobank
dataset compared to the meta-analysis.
Biobank cohort alone. Then, I created a joint model of conditionally independent variants
identified from the GCTA-COJO analysis to test for their significance of association beyond
what was already discovered from the UK Biobank cohort alone (Fig. 2.4).
This analysis identified 626 associations which are significantly associated with their
respective phenotypes distinct to the conditionally significant variants identified from
analysis of UK Biobank. Notably, most of these associations are near to previously defined
UK Biobank conditionally significant variants. Only 193 variants exist more than 1MB
from a UK Biobank conditionally significant variant (Fig. 2.5). Labelling each of the 626
distinct meta-analysis associations with its best LD proxy from the UK Biobank variants
shows that most are in very low LD with previously discovered UK Biobank variants.
From the total of 626 distinct meta-analysis associations, all but one association is in LD
r2 > 0.8 and 454 associations in LD r2 < 0.02 with the set of UK Biobank conditionally
independent associations for their respective traits (Fig. 2.6).
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Figure 2.5: Histogram showing the absolute distance of distinct meta-analysis
variants to the nearest UK Biobank association.
The 629 new associations identified by meta-analysis of 23 studies by GCTA-COJO are plotted
in a histogram (y axis log scaled) depending on their distance to the nearest variant associated
with the same trait identified by conditional analysis of up to 403,112 individuals in UK Biobank.
Only 13 identified significant associations exist more than 10MB (range x axis) and only 193 less
than 1 MB from the nearest UK Biobank conditionally significant variant. This plot shows that
discovery of new association signals is more likely to be near to already discovered signals.
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Figure 2.6: Histogram showing the highest pairwise LD meta-analysis variants
to UK Biobank associations.
The 629 new associations identified by meta-analysis of 23 studies by GCTA-COJO are plotted
in a histogram (y axis log scaled) depending on their highest LD to any variant associated with
the same trait identified by conditional analysis of up to 403,112 individuals in UK Biobank.
Only 1 identified significant association has an LD r2 > 0.8 (range X axis) and 454 have
r2 < 0.02. This result shows that almost all of the 629 new associations are in very low LD with
previously discovered signals.
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As previously explained the phenotype is adjusted by regressing out the effect of
conditionally significant variants identified by UK Biobank. Following this I classified
associations identified by GCTA-COJO of meta-analysis results into four categories:
• Not significant (9,834): The P-value for the test of genetic association with the
adjusted phenotype is not significant given a P-value threshold of -log10(P ) > 6.
• Threshold (507): This variant is below the UK Biobank significance threshold
-log10(P ) > 8.08, but above the meta-analysis threshold -log10(P ) > 8.30, and
loosened conditional meta-analysis significance threshold -log10(P ) > 6.
• Jumper (68): The tested variant is not associated at genome-wide significant threshold
in the meta-analysis summary statistics, but becomes significant in the joint model.
• Faller (47): This variant is associated with a lower effect size in the joint model than
it is in the univariate meta-analysis summary statistics.
• Other (7): Does not fit into any of the previous categories, these variants exist within
the loosened conditional meta-analysis significance threshold.
These results show that most distinct associations identified by the meta-analysis are
identified due to the larger sample size afforded in the meta-analysis GWAS. Intriguingly,
I identified a set of 1,227 associations identified by GCTA-COJO which are in LD r2 > 0.9
with associations with the same trait. Given the high LD between these associations it
is unlikely that they are truly distinct signals and could represent false positive signals
caused by the reference sample approximation used by GCTA-COJO.
2.4 Summary
In this chapter I discuss my contribution to the largest GWAS of complete blood count
(CBC) haematological phenotypes including 14 phenotypes in a meta-analysis of 563,085
individuals across 23 studies, and a single cohort analysis of 28 phenotypes in 403,112
individuals. My subsequent exact conditional analysis using a stepwise regression protocol
of the UK Biobank cohort identified 16,900 associations across 7,112 LD sets of which 5,106
are novel signals compared to the previously largest GWAS of haematological phenotypes
performed by Astle et al., [15]. I also present an additional set of 629 associations
identified from the meta-analysis study determined to be independent from signals in the
aforementioned 7,112 LD sets by exact meta-analysis conditional analysis.
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Chapter 3
Data collection and quality control
of cytometry parameters
3.1 Introduction
I previously discussed the ability of flow cytometry based methods to make measurements
from blood cells including SSC, SFL, and FSC (Section 1.2.2). In this chapter I show that
these additional parameters of blood cells can be clinically and functionally informative
and identify association signals distinct to the results of FBC GWAS which largely measure
blood count and volume phenotypes (Section 2.1.3). I show that GWAS of these novel
and functionally relevant phenotypes is able to identify distinct associations compared to
the largest previous GWAS of FBC phenotypes by Astle et al., with a roughly 3.8 times
larger sample size [15]. The results generated in this chapter will inform further work in
Chapter 4, to better understand the genetic architecture of the functional properties of
blood cells by performing the first ever GWAS and downstream analysis of SSC, SFL, and
FSC blood cell parameters.
I begin by discussing the INTERVAL study and the extraction of blood phenotypes
from the Sysmex XN-1000 analyser, following this I discuss genotyping of participants,
including quality control and variant imputation. Then I provide a review of the literature
regarding the clinical and functional relevance of Sysmex parameters. Finally, I describe
phenotype and genotype QC of data which is prepared for the GWAS and downstream
analyses in described Chapter 4.
3.1.1 INTERVAL study
INTERVAL is a randomised clinical trial of 45,263 healthy blood donors who have been
assigned to blood donation schedules of 8, 10, or 12-weeks for male participants and 12, 14,
or 16-weeks for female participants [11]. Donors were recruited from 25 National Health
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Service Blood and Transplant (NHSBT) static donor centres across England [121].
The purpose of the trial was to identify factors which influence the safe interval for blood
donation. In order to assess donor health, and identify factors which may predict the safe
optimum interval for blood donation a range of haematological and genetic measurements
have been performed. Participants also answer an extensive questionnaire to assess their
mental and physical health, lifestyle, and diet, prior to beginning the trial and finally
upon completion after two years of participation. Informed consent was obtained from all
participants, and the INTERVAL study was approved by Cambridge East Research Ethics
Committee. Participants who have subsequently withdrawn from the study were removed
at the time of analysis. I studied phenotype data collected at baseline of the trial from
participants prior to being randomised to a blood donation schedule. However in the case
of missing measurement data from the second time point measured upon completion of
the trial was used (Section 3.1.2).
3.1.2 Extraction of extended Sysmex cytometry traits
The INTERVAL study used two Sysmex XN-1000 haematological analysers, the hardware
and software for the analysers were provided by the company Sysmex. Following flow
cytometry of a sample, the Sysmex analyser internally computes thousands of variables
which are used to produce a haematological report. In my study, I was not only interested
in studying parameters which are output in the standard Sysmex haematological report,
but also accessing variables which the software calculates that are not directly accessible
to the user. In many cases these hidden variables have become accessible in later versions
of the Sysmex software, examples include RE-LYMP and AS-LYMP measures of the
reactive and antibody synthesising sub-population of lymphocytes respectively. For each
analysis performed, the Sysmex analyser also saves an encrypted binary file containing
data calculated internally by the software which contains the aforementioned hidden
variables and is used to produce the haematological report accessible to the user. Following
negotiation with Sysmex we were given a decryption key to access this encrypted binary
file, and I searched through the thousands of variables to identify relevant markers of
haematological function. I communicated directly with representatives of Sysmex (J.
Saker) to confirm the variables I had identified represented the parameters which I was
intending to analyse. Parameters which were extracted in this way include reactive
lymphocytes (RE-LYMP), and all SSC, SFL, FSC, and distribution width parameters
associated with eosinophil, basophil, red blood, or platelet cells. Unfortunately, for these
extracted parameters, the first 20% of binary files were overwritten during the course of
the original study, this meant that baseline time point measurements for some Sysmex
parameters were missing. In order to address this I replaced this measurements with final
time point measurement at two years whenever possible. This is reflected by the I(i)
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variable when adjusting for environmental factors (Section 3.2.8). A full description of all
the Sysmex parameters extracted and analysed in my study is available at Chapter 3.2.2.
3.1.3 Genotyping and quality control
Genotyping of participants and subsequent imputation and QC was performed in a previous
study [15]. I will give an overview of sample collection, genotyping, imputation, and QC
steps, for more detail please refer to Astle et al., 2016 [15].
3.1.3.1 Sample collection and genotyping
Blood samples were shipped in buffy coat aliquots to LGC Genomics (UK) where DNA was
extracted using a Kleargene method. Subsequently samples were shipped to Affymetrix
(Santa Clara, California, USA) in 96-well barcoded wells including two empty wells for
Affymetrix control samples. Genotyping was performed with an Affymetrix GeneTitan
Multi-Channel Instrument implementing the Affymetrix Axiom 2.0 Assay Automated
Workflow. A customised UK BIOBANK Affymetrix Axiom array with 820,967 probes
was employed to assay SNPs and short insertion deletion variations (Section 3.1.3.2).
Genotypes were called using Affymetrix Power Tools software which implements the
Axiom GT1 algorithm [15]. For more details please refer to the paper by Astle et al.,
2016 who performed and described this work in their study of the genetics of standard
haematological measurements.
3.1.3.2 Genotyping array
Genotyping for this study utilised a customised UK Biobank Affymetrix Axiom array
with 845,485 probesets assaying 820,967 single nucleotide variants (SNVs) and short
insertion/deletions. More probes exist than number of genotyped SNVs, this is because
some SNV exist in regions with high sequence homology making these variants difficult to
genotype. In such cases multiple probes are sometimes designed to target these variations.
Probesets were selected to target variants which meet the following criteria:
• A genome wide scaffold which provides good coverage of common (MAF<5%) or
low frequency variation (1%<MAF<5%) in the European population. This is the
basis of later imputation (Section 3.1.3.3).
• Rare variants which exist in exomic regions and are likely to have transcriptional
consequences (non-synonymous, splice altering, truncating).
• Rare variations known to increase the risk of cardiac disease, cancer, or listed on the
human gene mutation database (HGMD) database.
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The genome wide scaffold was designed using a custom algorithm based on the 1000
Genomes CEU population, European 1000 Genomes population, and a further tranche of
variants selected to boost imputation of low frequency variants [15].
3.1.3.3 Quality control and variant imputation
Imputation allows variants which have not been directly genotyped to be inferred from
genotyped variants. Imputation is fundamentally based on the principle of LD between
regions of the genotype (Section 1.4). To enable reliable imputation, it is important to
establish an initial set of high quality genotyped variants which serve as a scaffold. To
ensure this is the case genotyped variants were filtered based on the following criteria:
• HWE filter of P-value < 5× 10−6.
• Call rate filter of 99% in batches where the variant did not fail.
• Variant must have passed in atleast eight of the ten batches where it was genotyped.
• All monomorphic, non-autosomal, and multi-allelic variants were removed.
• Variants must have a MAF>0.04%.
Based on the following criteria QC was also performed on samples, excluding those
which met any one of the following criteria:
• Samples with more than 10% sample contamination [89].
• Samples with 3 - 10% sample contamination and ten or more first or second-degree
relatives in the study.
• Duplicate samples.
• Samples with heterozygosity three standard deviations from the mean.
• Samples who were missing or had mismatch sex information.
• Samples who are not of European ancestry.
• Samples with poor genotype signal intensity (<82%) and low call rate (<97%) based
on roughly 20,000 probes to be known of high quality.
Following genotype and sample based QC, genotyped data was phased using SHAPEIT3
with chunks of 5,000 variants and an overlap of 250 variants per chunk [126]. The genotype
data was used for imputation using IMPUTE3 [85] in chunks of 2mb with a 250kb buffer
region. A combined 1000 Genomes Phase 3-UK10K panel was used for both phasing and
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imputation. Imputation was implemented using the positional Burrows-Wheeler transform
(PBWT) imputation algorithm [58] on the Sanger imputation server. No imputation
quality or variant frequency filters were applied at this stage, in total 87,696,910 variants
were imputed or genotyped [15]. Following imputation of the INTERVAL genotype data,
Astle et al., 2016 used whole-exome sequencing (WES) data for 3,976 INTERVAL study
participants who were also included in the imputation dataset to confirm a very high
concordance between sequencing and genome imputation. Concordance ranged with a
median precision from 99.5% for common variants (MAF>5%) to 98.5% for rare variants
(MAF<1%). In addition IMPUTE3 will also calculate an info score representing the
certainty in the value of imputed variant. INFO score ranges from 0 to 1 representing
poorly to well imputed variants respectively. The INFO score metric represents a ratio
for calculation of effective sample size, at total sample size N , an imputed SNP will have
effective sample size dependent on it’s INFO score: INFO ∗N . GWAS studies tend to
use an INFO score filter of around 0.3 or 0.4 [38] [186] [15], with an INFO score of greater
than 0.4 being defined as well-imputed [118]. I utilised an INFO score filter of 0.4 leaving
26.8 million variants to be tested in my GWAS.
3.2 Methods
3.2.1 Blood sample collection
Participants in the INTERVAL study were assessed for a range of health and lifestyle factors
which included a questionnaire and a full blood haematological analysis at recruitment
and upon completion of the trial, this data is the subject of my analysis. Samples for
haematological analysis were collected from a pouch attached to the standard blood
collection unit during blood donation. Blood samples were collected in, 3 ml or 6 ml
ethylenediaminetetraacetic acid (EDTA), and 6 ml serum tubes. After collection the
tubes were inverted three times and transported at ambient temperature to NHSBT
sample holding sites at Manchester, Colindale (London), and Bristol. EDTA is not noted
to cause a difference in the mean of activation effects of white cells, although some
differences in cytokine production have been observed [103]. Following collection, samples
were transported to the UK Biocentre facility in Stockport, UK for analysis. Almost all
samples (98%) were processed within 48 hours of venipuncture, and 72% within 24 hours
[15]. Analysis of samples was performed with a Sysmex XN-1000 analyser from which
haematological indices utilised in my analysis were derived.
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3.2.2 Sysmex flow cytometry channels
The Sysmex XN blood cell analyser is a modular system for analysing blood samples
containing 4 flow cytometry, one electrical impedance channel, and a photometric channel
for haemoglobin measurements. Each sample is aliquoted into six channels responsible
for measuring different haematological cell types and properties. Reactants particular to
each channel lyse and stain aliquots to target cell types and to allow polymethine and
oxazine dyes to bind to nucleic acids in organelles and the nucleus. The composition of
the reagents is kept commercially confidential by Sysmex. The Sysmex haematological
analyser contains the following channels of measurement:
• The WNR (white count and nucleated red blood cells) channel detects nucleated red
blood cells (NRBC) and provide an accurate count of basophil cells.
• The WDF (white cell differential channel by fluorescence) channel is responsible
for analysis of white blood cells including counting lymphocytes, neutrophils, and
monocyte cells.
• The PLT-F channel performs platelet measurements, including counting mature and
immature platelets.
• The RET (reticulocyte) channel provides measures of erythropoiesis including retic-
ulocyte count and reticulocyte maturity.
• The Photometric channel analyses haemoglobin content in red blood cells using
sodium lauryl sulphate staining agent.
• The Impedance channel measures passing of blood cells through an aperture between
electrodes allows measurement of red cell phenotypes such as cell volume, cell count,
haematocrit, and platelet count.
Within each channel light from a stable red diode laser is incident on cells passing in
single file through the flow cytometer. This results in three bands of light being recorded
from each cell. Two light sources of different wavelength are separated by a dichroic
mirror to obtain SSC and SFL light intensity measurements. Light passing through
cells is recorded in a separate third direction FSC (Fig. 3.1). Sysmex parameters are
recorded from these three sources of light. I also assess distribution width of each of the
measurements (SSC, SFL, FSC) for each cell type in the sample. Distribution width is
determined as the width of each peak of light at 20% of the peak height. Each cell is
plotted on a three dimensional ‘scattergram’ based on its SSC, SFL, FSC values (Fig.
3.4). Cells are classified into cell types using thresholds based on the position of cells
on the three dimensional scattergram. The Sysmex parameters studied in my analysis
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Figure 3.1: Flow cytometry of haematological cells.
Cells flow single file through the Sysmex flow cytometry channel and are hit by a laser beam,
light is scattered or fluoresced by dyes in the cell and this is recorded resulting in three readings
(SSC, SFL, and FSC) per cell. * SFL is an index of nucleic acid content also influenced by
membrane composition of cells which affects the rate of absorption of nucleic acid staining dye
into the cell (Figure adapted from [45]).
involve the median position and distribution width of each cell type in the SSC, SFL, FSC
axis, and also counts of cells which are outliers from the primary clusters of cells in their
respective scattergram, examples of which are given below. These cellular properties have
been shown to be relevant for diagnosis of disease and to measure important physiological
properties (Section 3.2.3).
3.2.2.1 PLT-F Channel Parameters
The PLT-F channel provides a count of mature and immature platelets (Table 3.1). Cells
are lysed and stained using a fluorescent nucleic acid marker which also helps remove
interfering particles such as RBC fragments [165] (Fig. 3.2).
3.2.2.2 RET Channel Parameters
The RET channel is responsible for measuring circulating red blood cell maturity and
measures of reticulocyte and red blood cell haemoglobin content (Table 3.2). As retic-
ulocytes mature they lose their nucleus and their cellular nucleic acid content drops.
The SFL measurement is used to classify reticulocytes as high fluorescence reticulocytes
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Figure 3.2: PLT-F channel scattergram.
The PLT-F channel with SFL and FSC measurements plotted, the channel allows good
separation within the platelet population allowing identification of the immature platelet
fraction (IPF) and highly fluorescent immature platelet fraction (H-IPF) fraction. Furthermore,
the PLT-F channel provides good separation between platelet, white blood cell, and red blood
cell types.
(HFR), medium fluorescence reticulocytes (MFR) to low fluorescence reticulocytes (LFR),
representing increasing stages of maturity, eventually cells join the red blood cell (RBC)
population (Fig 3.3). Cells are perforated by a lysis reagent which allows a fluorescent
marker to pass into the cell staining nucleic acids [165].
3.2.2.3 WDF Channel Parameters
The WDF channel is responsible for counting of lymphocyte, neutrophil, and monocyte
cells. This channel also measures counts of cells which are outlying from their primary
cluster of cells, such as immature granulocytes (IG), RE-LYMP, and antibody synthesising
lymphocytes (AS-LYMP) (Table 3.3). In total 29 of the 63 Sysmex parameters studied in
my analysis originate from the WDF channel. Lysis reagents perforate the cell membrane
allowing a fluorescent dye to stain nucleic acids. Reagents are designed to keep the cells
largely intact and to ensure that the rate of fluorescent dye uptake is proportional to
nucleic acid content which is recorded by the SFL measurement [165]. Immature cells such
78
Sysmex Parameter Description
H-IPF
Highly Fluorescent Immature Platelet Fraction:
A measure of highly immature platelets
IPF & IPF#
Immature Platelet Fraction
Immature Platelet count
P-LCR
Platelet Large Cell
Ratio
PLT-F-SSC, SFL, FSC, -DW Platelet Scatter and distribution width
Table 3.1: PLT-F channel parameters.
Table of the 10 parameters studied from the PLT-F channel, DW represents the intra-individual
distribution width for each of the SSC, SFL, and FSC measurements.
Sysmex Parameter Description
IRF
Immature reticulocyte
fraction
Hyper-He Hyper haemoglobinised red cells
RBC-He Red blood cell haemoglobin
RET-SFL, FSC Reticulocyte scatter parameters
RET-He Reticulocyte haemoglobin
LFR, MFR, HFR Low, Medium, High fluorescent reticulocytes
IRF-FSC
Immature reticulocyte
fraction forward scatter
RET-RBC SSC, SFL and -DW
Red blood cell
RET scatter
Delta-He
Difference between RBC
and Reticulocyte haemoglobin
Table 3.2: RET channel parameters.
I analysed 14 parameters from the RET channel, where ‘-DW’ represents distribution width for
each of the SSC and SFL measurements. The measurements are derived from the red blood cell
and reticulocyte cell types.
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Figure 3.3: RET channel scattergram.
The RET scattergram, each cell is plotted with SFL and FSC on the x and y axes respectively,
the z axis (SSC) is hidden. Measurements are assigned per cell-type based on the median
position of the cell cloud in each axis of the scattergram. Cell types are highlighted in the three
axes, RBC: red blood cells, PLT-O: optical observation of platelet count (compared to
impedance), LFR: low fluorescence reticulocytes, MFR: medium fluorescence reticulocytes, HFR:
high fluorescence reticulocytes, RBC Fragments: fragments of red blood cells this cluster is not
analysed.
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Sysmex Parameter Description
NE-SSC, SFL, FSC, and -DW Neutrophil scatter parameters
EO-SSC, SFL, FSC, and -DW Eosinophil scatter parameters
MO-SSC, SFL, FSC, and -DW Monocyte scatter parameters
LY-SSC, SFL, FSC, and -DW Lymphocyte scatter parameters
RE-LYMP# (count)
RE-LYMP% (of white blood cells)
RE-LYMP(L)% (of lymphocytes)
Reactive
lymphocytes
IG# (count)
IG% (of granulocytes)
Immature Granulocytes
Table 3.3: WDF channel parameters
I analysed 29 parameters from the WDF scattergram, ‘-DW’ represent the intra-individual
distribution width for each of the SSC, SFL, and FSC measurements. Parameters are stratified
across the five primary white blood cell types and also immature granulocytes which largely
consist of immature neutrophils. Parameters are split across neutrophil, eosinophil, monocyte,
lymphocyte, and immature granulocyte (mostly consisting of immature neutrophils) cell types.
Sysmex Parameter Description
BASO-SFL, FSC, and -DW Basophil Scatter
Table 3.4: WNR channel parameters.
Four Basophil phenotypes were studied from the WNR channel, DW represents distribution
width parameters for SFL and FSC.
as immature granulocyte count (IG#) or highly activated cells such as (RE-LYMP or AS-
LYMP) tend to contain higher levels of nucleic acids and have higher SFL measurements
(Fig. 3.4). Cells are also separated according to their SSC and FSC measurements,
which are measures of cell structure which are indicative of cell granularity and cell size
respectively (Fig. 3.4).
3.2.2.4 WNR Channel Parameters
The WNR channel only measures SFL and FSC, and is responsible for counting nucleated
red blood cells, total white blood cell count, and basophil count (Table 3.4). The ‘ghost’
proportion of the scattergram is occupied by contaminants such as air bubbles and lipids.
Similar to the WDF channel, cells are processed in a two stage reaction, starting with
perforation of the white cell membranes keeping the cells largely intact, following this,
nucleic acids in the cells are stained with a fluorescent dye to allow detection by the
flow cytometer (Fig. 3.5) [165]. The cell membrane of NRBC is lysed and the nuclei are
stained [165]. NRBCs exist in circulation of newborn infants and can be diagnostic of
myelodysplastic syndromes when observed in adults [153], given that participants in the
INTERVAL study are healthy adults (18 years of age or older) these cells are not observed
in the scattergram (Fig. 3.5).
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Figure 3.4: WDF channel scattergram
A plot of the WDF scattergram from an individual in the INTERVAL study, each cell is plotted
with SSC and SFL on the x and y axis respectively, and the z axis (FSC) hidden. Measurements
are assigned per cell-type based on the median position of the cell cloud in each axis of the
scattergram. Cell types are highlighted in the three axes, LY: lymphocytes, RE-LYMP: reactive
lymphocytes, AS-LYMP: antibody synthesising lymphocytes, MONO: monocytes, IG: immature
granulocytes, NEUT: neutrophils, BASO: basophils, EO: eosinophils.
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Figure 3.5: WNR channel scattergram.
A plot of the WNR scattergram from an individual in the INTERVAL study, each cell is plotted
with SSC and SFL on the x and y axis respectively. Measurements are assigned per cell-type
based on the median position of the cell cloud in each axis of the scattergram. WNR separates
basophil cells from the white blood cell population. NRBC are not observed as this cell
population does not occur in healthy adults. Approximate cell types are highlighted based on
thresholds set in the two axes.
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Sysmex Parameter Description
MicroR / MacroR
Microcytic and Macrocytic
RBCs (as percentage of all RBCs)
RDW-SD Red cell size distribution width
Delta-HGB Cell free haemoglobin
RPI
Reticulocyte Production Index
Calculated: RET% ∗HCT/(2 ∗ 0.45)
Table 3.5: Other parameters.
I studied six parameters which were derived from electrical impedance, photometric analysis, or
calculated from flow cytometry measurements, or calculated from a combination of flow
cytometry and impedance measurements.
3.2.2.5 Other Parameters
In addition to flow cytometry the Sysmex analyser employs an electrical impedance
channel (Section 1.2) to measure RBC and platelet parameters, such as mean cell volume
in the blood or median size of individual blood cells, and a photometric channel which
measures red blood cell haemoglobin content. I utilised six of these parameters in my
analysis, including parameters which are derived from a combination of impedance and
flow cytometry (RPI) and parameters which are calculated from a combination of flow
cytometry measurements (Table 3.5).
3.2.3 Flow cytometry, immune cell function, and disease
I sought to understand the clinical and functional relevance of Sysmex measurements
of blood cells, SSC, SFL, and FSC (Section 3.2.2). Previous studies show that Sysmex
parameters of white cells correlate with changes in cell function, activation, morphology,
and disease status including: myelodysplastic syndromes, toxic granulation, sepsis, septic
shock, and Szary disease [13, 64, 188, 103, 131, 145]. The functional and clinical relevance of
Sysmex parameters makes these phenotypes important intermediate traits, the significance
of intermediate traits is discussed in Section 1.6.4. The ability to make automated high-
throughput measurements using Sysmex enables GWAS study of such phenotypes, where
the interpretation of GWAS results could provide important insights into human biology a
detailed in Section 1.6.
Comparison to manual assessment of blood smear images shows that Sysmex parameters
capture clinically important changes in white cell morphology [188]. Blood smear samples
from 158 patients were scored by neutrophil granularity on a scale of 1 to 4 by trained
haematological medical technicians [188]. The Sysmex parameter NE-SSC correlated
with manual measurements of granularity performed by smear test (Spearman’s rank
correlation coefficient: rs=0.839, P-value<1× 10−4) [188] (Fig. 3.6). Automated Sysmex
measurements provide an advantage as manual measurements of granularity are slower to
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Figure 3.6: Comparison of granularity assessed by manual microscopy and
Sysmex flow cytometer.
Assessments of toxic granulation neutrophils (TGN) granularity by GI-Index, a measure of SSC
performed by Sysmex and by manual microscopy. The granularity index assessed by flow
cytometry correlates with manual assessments of granularity (rs = 0.839, p <1× 10−4) (Figure
reproduced from [188]).
perform and depend on interpretation of the individual haematologist.
Automated Sysmex measurements can also assess monocyte, neutrophil, and leukocyte
activation following in vitro stimulation by activating compounds formyl-methionyl-leucyl-
phenylalanin (fMLP) and lipopolysaccharides (LPS) [103]. Sysmex parameters have been
compared to an automated image analysis pipeline of blood smear images to classify
neutrophils, monocytes, and the combined leukocyte population into hypo or hyper-
granulated categories [103]. In response to activation, neutrophils showed an initial hypo-
granularity reaction and long term hyper-granularity which persists until approximately
three hours after incubation with activating compounds. A statistically significant (P<1×
10−4) correlation was seen between all neutrophil Sysmex measurements (NE-SSC, NE-SFL,
NE-FSC) and automated measurements of neutrophil activation derived from microscope
image analysis, including when cells were activated with LPS (P-value<1 × 10−4, rs =
0.693) and fMLP (P-value<1× 10−4, rs: 0.641) [103].
An additional study to determine the utility of lymphocyte, monocyte, and neutrophil
Sysmex parameters to diagnose sepsis found clinically significant correlation between these
indices (except for NE-FSC, and LY-FSC) and occurrence of sepsis. MO-SSC and NE-SFL
had the best diagnostic performance (AUC 0.75, and 0.72 respectively) [35]. Statistically
significant relationships between Sysmex measurements (in particular neutrophil indices)
and sepsis have been reported by a number of other authors [131] [13], and also other
diseases including toxic granulation [188], and myelodysplastic syndromes [145] [64].
Se´zary disease is a form of cutaneous T-cell lymphoma. Malignant lymphocytes cause
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inflamed, itchy, lesions on the skin of patients which develop into tumours. Se´zary cells
are characterised with irregular nuclei and condensed chromatin versus smaller cells with
regular nuclei and clumped chromatin in chronic lymphocytic leukemia patients [31].
Automated analysis by Sysmex has been used to identify abnormal T cells typical of Se´zary
disease. LY-SSC was associated with the count of Se´zary cells (classification threshold
LY-SSC above 85, sensitivity 100%, specificity 94%) and LY-FSC (classification threshold
LY-FSC above 67, sensitivity 89%, specificity 94%) to the presence of larger cells, both of
which are diagnostic factors of Se´zary disease [31]. This is consistent with the definition
of these parameters and the known difference in morphology of neoplastic cells. Thus
these Sysmex haematological measurements are consistent with expected differences in
cell size, morphology, and nuclear structure. Brisou et al, suggested that these differences
as identified by Sysmex parameters could be used to diagnose Se´zary disease in a clinical
setting [31].
However, there are limitations to the interpretability of these parameters. For example
side-fluorescent light (SFL), a measure of DNA/RNA content cannot be used purely as a
surrogate for the quantity of nucleic acids in the cell, because the dye does not saturate the
cell due to short reaction time. SFL intensity depends on cell membrane composition and
also nucleic acid content. Sysmex reports monocyte measurements as having higher average
SFL values than lymphocytes, but a resting monocyte does not have a higher nucleic
acid content than a resting lymphocyte (personal communication J. Saker, Sysmex) [151].
However, within a single cell type, Sysmex parameters are consistent with physiological
changes within that cell type. It is this variation between individuals in the INTERVAL
study which I utilise to perform a GWAS analysis.
3.2.4 Adjusting variables for scale
Sysmex parameters occur in varied scales of measurement, including percentages, ratios,
and positively supported data for example cell counts which never hold negative values. In
order to adjust for technical (Section 3.2.7) and environmental (Section 3.2.8) covariates, the
parameters were transformed depending on their scale of measurement prior to adjustment.
The transformations were performed as follows, where x is a vector of phenotype values.
• Percentages 0 < x < 100, division by 100 and logit transformation: a(x) = logit( x
100
).
• Ratios 0 < x < 1, logit transformation: a(x) = logit(x).
• Positively supported x > 0, log transformation: a(x) = log(x).
The logit transformation logit(x) = log x
1−x maps probability values from [0, 1] to (−,+).
Logit transformed data with infinite bounds makes the distribution of the dependent
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variable more like a normal distribution thus enabling better specified linear regression
(Section 1.5) [92]. As described previously in Section 2.2.4 linear regression is the statistical
test utilised by GWAS to identify genetic associations.
3.2.5 Additive models and splines
Additive models (AMs) include both parametric and non-parametric predictors [76]. Non-
parametric predictors allow additional flexibility as they do not require a specific function
to be predefined. AMs can be used to model predictor variables which are cyclical (such
as seasonal effects) or have otherwise non-linear effects on the dependent variable. AMs
extend linear models where the linear elements
∑
βjXj are replaced by a sum of smoothing
functions
∑
βjmj(Xj). Where mj() is a unspecified function not required to be defined
by the user, thus the non-parametric form of AMs [76]. This is an extension of linear
regression, instead of optimising the fit of a linear line to a set of data points we optimise
the fit of an arbitrary function mj(Xj). However, in most cases it is prudent not just to
optimise the fit of a curve to data points, but also ensure ‘smoothness’ or simplicity of that
curve. This is called ‘smoothing’ and is discussed in more detail below. I utilise smoothing
splines in my analysis. I will begin with a brief description of smoothing followed by
splines including B-splines, P-splines, cyclic splines, and thin-plate splines.
Smoothing
As previously described AMs models optimise a curve to fit a set of data points (Section
3.2.5), however in a non-linear setting curve complexity can increase such that the resultant
model is not representative of the true relationship between dependent and independent
variables. This is called over-fitting and has been described by a number of authors [78]
[77, p. 398]. Therefore, smoothing is utilised to reduce model complexity avoiding highly
curved functions which contort to fit to every data point. Mathematically, curvature or
smoothness at any point can be defined as the second derivative of the function m(x)
represented by m′′(x). Smoothness of m(x) across its entire domain is defined by the
following integral
∫
(m′′(x))2dx, the squared operation is applied to avoid distinction
between negative or positive curvature. In order to generate a regression, an objective
function is created which states that a) we want a function m(x) which fits as closely as
possible to the data points and b) we want this function to be smooth [154, p. 177]:
L(m,λ) ≡ 1
n
n∑
i=1
(yi −m(xi))2 + λ
∫
(m′′(x))2dx (3.1)
Where x and y are the independent and dependent variables respectively, and λ is a
hyper parameter which modulates the smoothness, a higher λ will prioritise smoothness
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over the fit of curve. The first term simply models the fit of the curve to the real values
and the second term quantifies smoothness of the curve. A solution to this objective
function will generate a function with a trade-off between maximising fit to the data while
also maximising smoothness of the curve. The precise value of λ is set by cross validation
over the dataset, for more details see [154, p. 179].
Piece-wise polynomials and splines
In the previous section I left ambiguity regarding the definition of m(x) (Eqn. 3.1) which
depends on the context of implementation. One such implementation is that of smoothing
splines, this is where spline functions are used to define m(x). To begin I will describe
piecewise polynomial functions and extend that definition to that of splines. Piecewise
polynomial functions are best described visually (Fig. 3.7), in essence they split the domain
of the input variable at into pieces, in each piece a function with differing constants is
defined (Fig. 3.7) [77]. The points at which distinct pieces are bounded is termed ‘knot
points’. Please note the distinction between smoothness of each function within each piece
and between pieces. Each piece in the displayed figure is maximally smooth (as they are
linear or straight lines), however there is discontinuity between pieces. Discontinuity and
smoothness at the knots points cannot be addressed by smoothing which is only applied
to functions between knot points (Eqn. 3.1) and is instead addressed by enforcing that
functions which meet at a knot point have equivalent values and also equivalent first and
second order (or more) derivatives depending on the order of the piecewise functions (Fig.
3.8). Application of piecewise polynomials is limited due to the mathematical properties
of the piecewise curve, an adaptation of this method is B-splines (basis splines), here
a series of polynomials spanning the feature space is fit to the data (Fig. 3.9). This is
explained further in the Appendix of Hastie and Tibshirani [77, p. 186]. P-splines are the
application of smoothing to the fitting of B-splines to ensure that the spline is smooth as
well as continuous (Section 3.2.5). An additional constraint would be to ensure that the
spline takes the same value at the lower and upper limit of the domain, this is termed a
cyclic spline and is effective in modelling cyclic data predictor variables such as day of
year or day of the week. In contrast to B-splines which are generated on a single variable,
thin plate splines allow fitting of splines to multiple dimensions of data. This involves
multidimensional generalisation of the B-splines described above, for more detail see [77,
p. 162].
3.2.6 Exclusion of outliers and erroneous measurements
Each Sysmex measurement is associated with an interpretive program (IP) message
labelling the measurement as potentially ‘abnormal’, this could occur in participants with
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Figure 3.7: Examples of piecewise constant linear functions.
A plot of data points for which the piecewise functions have been fitted with independent and
dependent variables on the x and y axes respectively. Three pieces are defined based on two
knots indicated by ξ1 and ξ2, within each piece a different function is defined to best fit the data
in that piece. Piece-wise functions are not enforced to meet at the knot points hence the
discontinuity at knot points (Figure source [77]).
unusually low or high counts of cells, such as lymphopenia or lymphocytosis or containing
unusual blood cell morphology, for example the presence of nucleated red blood cells or
immature granulocytes. IP messages are generated by the haematological analyser and are
classed into three categories, abnormal, suspect, or negative. I excluded all measurements
associated with an abnormal or suspect IP flag. Following exclusion of measurements
based on IP flags, I performed technical (Section 3.2.7) and environmental (Section 3.2.8)
adjustment and utilised a PCA to identify outlying measurements which I removed from
further analysis. Phenotypes were categorised into seven non-mutually exclusive classes,
those related to platelets, red cells, reticulocytes, white cells, granulocytes, myeloid cells,
and all phenotypes. For each of these categories the PCs were calculated and scaled
by variance explained, squared, and summed to calculate the total deviation of each
measurement from the population centre. An equal number of PCs were selected to the
number of directly measured phenotypes in each class. Measurements which sufficiently
deviated from the population centre were excluded, this was assessed with a χ2 distribution
(P-value< 1× 10−7) (Fig. 3.10). If a measurement was an outlier within one category, the
data for that sample was excluded across all phenotypes in further analyses.
3.2.7 Technical variation of Sysmex parameters
Technical factors which influence Sysmex parameters add noise to measurements which
increases false negative findings in GWAS analyses and also reduces power to identify
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Figure 3.8: Examples of cubic polynomial piecewise functions.
A plot of data points for which cubic piecewise functions have been fitted with independent and
dependent variables on the x and y axes respectively. Three pieces are defined based on two
knots indicated by ξ1 and ξ2, A discontinuous function can be made continuous and smooth at
the knot points by enforcing equal values for the function and first or second derivatives of the
function at the knots (Figure source [77]).
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Figure 3.9: Fitting of cubic B-splines.
Data points are plotted with independent and dependent variables on the x and y axes
respectively. a) A series of B-spline basis functions of third polynomial degree. b) Weighting of
B-splines to enable the summation of B-splines to generate a function f(x) to fit a dataset
(Figure source [55]).
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Figure 3.10: First two principal components of measurements in the platelet
category.
Each data point represents an individual for which platelet measurements were recorded and the
first two PCs for measurements in the platelet category are plotted, subsequent principal
components are not visualised although they do contribute to the detection of outliers. Outlying
data points are highlighted in red and defined by those in the upper tail of a null χ2 distribution
with P-value< 1× 10−7. Platelet measurements for outlying individuals are excluded from
further analysis.
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influential genetic associations. Technical variation is not likely to increase false positive
rates because there is no correlation between the technical variables and the genotype of
the study participants. I modelled the effect of technical covariates on each blood trait
using a AM and adjusted haematological indices to remove the effect of technical factors.
Measured traits were technically adjusted independently, the technical correction
procedure began by excluding measurements from outlying days, defined as those with a
Z score more than 8 from the daily mean. Following this, a generalised additive model
(GAM) model was used to adjust measured indices for technical and seasonal variation,
finally derived parameters were re-calculated accordingly from the measured parameters
(Supp Table A.7). Defined parameters are blood traits which are calculated from ratios,
percentages or other combinations of directly measured traits were re-calculated following
technical adjustment of the measured traits. I corrected for a range of factors including
time passed from start of the study, day of the year (ordinal from 1 to 365), time between
venipuncture and sample analysis, day of the week, and instrument id. The adjustment
was made across all measurements indexed by i using a GAM (R package mgcv) and
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smoothing terms with P-spline, cycling smoothing or thin plate splines:
E(a(yi)) = s[t(i)⊗m(i)] + c[tyear(i)] + tp[(tday(i), tven(i)⊗ (m(i), I(i))]+∑
D∈{mon .. sun}
1D(i)=D +
∑
m
1m(i)=m
(3.2)
In equation 3.2:
• a(xi) represents the trait values xi transformed as described in Section 3.2.4.
• t(i) denotes the number of seconds between the first day of the study and measurement
i.
• m(i) is a categorical variable with two levels for each of the two machines used to
record measurements.
• D(i) is a categorical variable with 7 levels representing the day of the week on which
the measurement was made.
• tyear(i) is the number of seconds between January 1st and the time at which the
observation was made.
• tday(i) is the number of seconds between measurement of observation i and midnight
(am) on the day of observation.
• tven(i) represents the number of seconds between midnight (am) on the day of
observation and venipuncture.
• I(i) is a binary variable which indicates whether the delay between measurement and
observation was imputed tven(i). Imputation was performed by a median calculation
of real values for the tvenn(i) variable.
• s[] a P-spline smoothing term for univariate terms.
• c[] cyclic smoothing term for seasonal data such as time of year, tyear(i).
• tp[] a thin plate spline smoothing term for bivariate data.
• ⊗ represents an interaction between variables.
The first term s[t(i) ⊗m(i)] in the equation (Eqn. 3.2) models long term drift and
calibration of the Sysmex analysers using a smooth P-spline with 50 knots. Drift is defined
as systematic changes in recordings of the Sysmex analyser over the three year time period
of analysis (Fig. 3.11). In contrast, calibration effects result in immediate and large change
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in the mean recordings of the Sysmex analyser as a result of periodic calibration of the
analyser (Fig. 3.11). These effects are modelled independently by haematological analyser
represented with categorical variable m(i). The second term c[] models seasonal effects
using a cyclic smoothing term with 30 knots. To avoid an increasingly complex model,
the second term assumes that the Sysmex instruments are influenced in the same way by
seasonality effects. Thus seasonality is not modelled independently between the analysers.
The third term jointly effectively models the effect of time delay between venepuncture
and analysis, this effect is allowed to vary depending on the analyser and whether the
tvenn(i) variable was recorded or impute from the median of measured values (Section
3.1.2). The third term is modelled with a thin plate spline with 30 knots. Finally, I include
dummy variables to model day of the week and the effect of instrument on the parameter
measurements. Knots were chosen to be consistent with the similar data correction
procedure performed by Astle et al [15]. The adjustment described was implemented in R
code and is available on github [7].
Following application of the adjustment procedure on all 63 parameters I performed
a manual inspection to assess the performance of the adjustment of all covariates. Each
parameter was plotted against each covariate separately before and after correction (an
example is Figure 3.11). It will be expected that these results will show less variation in
the parameter values along the covariate x axis following correction compared to prior to
correction. Inspecting all aforementioned plots indeed showed that this is the case and
adds confidence to correction procedure which relies on the generation of splines.
3.2.8 Environmental variation of Sysmex Parameters
Following technical adjustment, Sysmex parameters were also adjusted for environmental
covariates which are known to influence the values of blood measurements:
E(env(yi)) = s[age(i)⊗meno(i)] + tp[(log(weight(i)), log(height(i))⊗meno(i)]+∑
drink(i)
1drink(i)=drink +
∑
alc(i)
1alc(i)=alc+
s[pack yrs(i)] +
∑
smokes
1smokes(i)=smokes +
∑
smokea
1smokea(i)=smokea+∑
int
1int(i)=int +
∑
weight na
1weight na(i)=weight na +
∑
height na
1height na(i)=height na+
∑
pack yrs na
1pack yrs na(i)=pack yrs na
(3.3)
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Figure 3.11: Variation in recorded mean daily value of the NE-SSC parameter
over time before and after adjustment.
Each data point is the mean daily recorded value for the NE-SSC parameter over time course of
the study, adjustment is performed by fitting the model described in Equation 3.2 and plotting
the residuals. a) Raw mean daily recorded values from analyser for parameter NE-SSC shows
considerable systematic drift and changes due to calibration effects. b) Mean daily recorded
values post adjustment of data for technical covariates. This plot shows significant systematic
drift of NE-SSC values and correction of a large proportion of this drift following adjustment.
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In equation 3.3:
• ei are the residuals for measurement i obtained from the technical adjustment model
described in Equation 3.2.
• s[] a P-spline smoothing term for univariate terms.
• c[] cyclic smoothing term for seasonal data used here, time of year (tyear(i)).
• tp[] a thin plate spline smoothing term for bivariate data.
• age(i) is the age of the participant.
• meno(i) is the menopausal status of the participant:
meno(i) ∈ {post, pre, hyst, male, NA}.
• weight(i) is the weight of the participant.
• height(i) is the height of the participant.
• drink(i) is the drinking status of the participant:
drink(i) ∈ {never, previous, current, NA}.
• alc(i) is the alcohol consumption of the participant:
alc(i) ∈ {rarely, 1 to 3 month, 1 to 2 weeks, 3 to 5 weeks, most days, never}
• pack yrs(i) a calculation of the pack years a participant has smoked.
• smokes(i) is the smoking status of the participant: smokes(i) ∈ {never, previous, current, NA}
• smokea(i) is the participants frequency of smoking:
smokea(i) ∈ {special occasions, rarely, occasional, most days, every day, never}
• int(i) sex and assigned donation arm of the participant where the measurement was
taken upon completion of the study:
int(i) ∈ {baseline, M8, M10, M12, F12, F14, F16}
• weight na(i), height na(i), pack yrs na(i) binary variables set to true if the partici-
pant has missing values for weight, height, or pack years smoked variables.
The first term in Equation 3.3 models the effect of age and menopause status on
Sysmex parameters using a P-spline with 30 knots. The effect of log transformed height
and weight and interaction with menopause status is modelled with a thin plate spline
with 30 knots. Menopause status has been shown to influence blood cell measurements
including red blood cell and platelet count [115, 41]. Dummy variables are used to model,
drinking status, drinking frequency, smoking status, and smoking frequency and a P-spline
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(19 knots) is used to model the effect of pack years smoked per participant on the Sysmex
parameter. Pack years smoked is calculated based on participant responses to the health
questionnaire at baseline of the study. Both smoking and drinking have been shown to
influence blood cell measurements [160, 132]. Dummy variables are also used to model
missing values for height, weight, and pack years smoked. The described adjustment was
implemented in R code and is available on github [7]. Following adjustment for technical
and environmental factors, PCs were constructed to identify and exclude outlying Sysmex
parameter measurements as described in Section 3.2.6.
3.3 Summary
In this chapter I describe blood sample collection and genotyping in the INTERVAL study
and provide a detailed description of steps for collection and QC of the Sysmex parameters
and genotype data. I adjusted Sysmex parameters to remove technical and environmental
factors which add variation to the phenotypes studied in my analysis. Removing such
influencing factors reduces variability in the phenotypes and increases power to detect
association signals. Following extraction and QC of SSC, SFL, FSC from Sysmex analysers
in the INTERVAL study I performed the first ever GWAS analysis of these parameters
which is discussed in Chapter 4.
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Chapter 4
The genetic architecture of
cytometry parameters
4.1 Introduction
GWAS of blood cell traits measured by automated FBC such as cell counts and cell
volumes are a powerful approach to link disease-associated risk variants to the distinct
types of blood cells and their molecular pathways [15]. However, these traits mostly
provide information about genes and pathways regulating processes such as stem cell
lineage-fating choices and blood cell survival. In particular for white blood cells, analytical
methods to infer which variants identified by GWAS of CBC parameters influence cell
function do not exist. To uncover this class of variants requires measurement of white cell
function in thousands of individuals. This is not feasible because functional assays are
laborious, often have poor reproducibility, and cannot be parallelised [110].
I report an alternative approach to obtain, in a large number of individuals, parameters
which are proxies for immune cell function, particularly of granulocytes (neutrophils,
eosinophils and basophils) and monocytes. As previously explained in Chapter 3, these
parameters are obtained by exploiting flow cytometry measurements underlying the routine
FBC by the Sysmex instrument. In this chapter, I present the first ever GWAS of SSC,
SFL, FSC blood cell phenotypes where I identified novel association signals compared to
the previous largest GWAS of haematological phenotypes performed by Astle et al. [15].
The comparison was performed with Astle et al., 2016 as this was the largest published
GWAS of blood cells available at the time of this analysis. My analysis identified 2,172
genetic associations annotated to genes by VEP known to be relevant in chemotaxis,
adhesion, activation, degranulation and many types of immune responses. The results of
this analysis was the basis of downstream analysis to further understanding of haematology
and disease biology presented in Chapter 5.
99
4.2 Methods
4.2.1 Population stratification and relatedness
As previously described (Section 2.2.6), population stratification and relatedness within the
population of a GWAS study can lead to inflation in false positive or negative associations.
Multiple methods were utilised to account for broad population stratification within the
population cohort and relatedness between individuals in the cohort:
• Filter all samples to only include those of European ancestry (Section 3.1.3.3).
• Remove samples with a high degree of relatedness, as determined by IBD analysis.
• Include PCs and clinic, a variable recording the location of blood donation as
covariates in the GWAS model.
• Use a LMM model which allows potentially confounding polygenic effects to be
modelled by a random effect in the GWAS regression (Section 2.2.7).
• Filter tested variants by MAF>0.04%.
PCs were generated from approximately 100,000 high quality variants which were
selected by a number of factors including: the variant must be genotyped, MAF ≥ 2.5%,
missingness ≤ 1.5%, variants which aren’t insertions or deletions, and pruned to ensure low
LD [15]. PCs were used to remove individuals who are outlying from the general population
and therefore not likely to be of European ancestry. The purpose of excluding individuals
with non-European ancestry is to create a more homogeneous sampling population and
reduce the risk of false positive or false negative associations due to confounding population
structure. Following this, PCs were calculated from the European ancestry genotype data
and included as a covariate in the LMM enabling the model to account for population
stratification effects. In this model the top 10 PCs were used consistent with other
published GWAS studies of the INTERVAL dataset [15]. IBD analysis determines common
stretches of nucleotide sequence between two individuals which indicate they share a
common ancestor. If a large proportion of alleles between two individuals are identical by
descent, this suggests those individuals are closely related. Of each pair of individuals who
has higher than 98% of alleles IBD, one individual was removed from the study. Groups
of individuals who were related (IBD>20%) were iteratively trimmed by removing the
individual with the highest number of pairwise relationships and then the lowest call rate.
This analysis was performed on the INTERVAL dataset by Astle et al., [15].
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4.2.2 GWAS of haematological phenotypes
GWAS was performed on phenotype values which were adjusted for technical and environ-
mental factors, outlying measurements excluded, and residuals inverse quantile normalised
(Section 3.2). Following QC, genotype data was imputed from a genome-wide scaffold of
variants assayed by direct genotyping. Firstly the dataset was phased using SHAPEIT3
and then imputed using a combined 1000 Genomes and UK10K panel [15]. I filtered
imputed variants by INFO score 0.4 and MAF>0.04% (Section 2.2.5). A LMM was used
to test each imputed variant independently for marginal association with the phenotype.
The following covariates were included in the LMM: the first ten principal components
representing population structure, and the categorical ‘clinic’ variable which represents the
centre at which the participant donated their blood sample (Section 4.2.1). The LMM was
implemented using BOLT-LMM [106] which allows for computationally tractable LMM
GWAS analyses of large datasets (Section 2.2.7). The analysis was performed on the
Sanger high performance compute (HPC) cluster.
4.2.3 Comparison with GWAS of FBC phenotypes by Astle
2016
I compared the results of my GWAS and conditional analysis with the results obtained
Astle et al., in their GWAS of standard haematological traits [15]. The traits studied by
Astle et al., are measured in the same cell types from which the Sysmex parameters in my
study are derived. In order to assess whether findings made by my analysis identifies signals
unreported by Astle et al., I extended the previously described LD clumping procedure
(Section 2.2.9). Firstly, I performed LD clumping as previously described in Section 2.2.9.
The LD clumping procedure assigns conditionally significant variants to sets of variants
which exist in LD r2 > 0.8 with each other. Following this, I generated a LD matrix
between all the conditionally significant variants identified by my study or by Astle et al.
I then used this matrix to sequentially label LD sets as already ‘not novel’ if that LD set
contains any variants which are in LD r2 > 0.8 with any conditionally significant variants
identified by Astle et al.. Thus I annotated conditionally significant variants identified by
my analysis as novel or not-novel in comparison to association signals identified by GWAS
of FBC haematological phenotypes by Astle et al. [15]. This annotation was implemented
in R code and is available in a github repository [6].
101
4.2.4 Genetic correlation between inherited components of vari-
ance by Bulik Sullivan et al., 2015
The genetic correlation is the correlation in inherited components of variance between
two phenotypes. I estimated genetic correlation using the summary statistics generated
from a GWAS study [33]. LD score regression uses a pre-defined subset of common SNPs
and assumes a polygenic model of association. The polygenic model assumes the genetic
component of variation of a quantitative trait is determined by a set of genetic variants
that have independent additive effects. For SNP j the expected value of the product z
score of association with both traits is determined as follows [33]:
E[z1jz2j] =
√
N1N2ρg
M
`j +
ρNs√
N1N2
(4.1)
Where ρ is the phenotypic correlation amongst the Ns overlapping samples, the purpose
of this term is to adjust for correlation induced by a common sample population and
avoid biasing the calculated genetic correlation. ρg is the genetic correlation, N1N2 is the
product of the number of samples in each study, M is the number of variants used in the
estimation, and ` is the ‘LD Score’, a measure of the amount of genetic variation linked to
SNP j, calculated where k is an index over all other variants [33]:
`j =
∑
k
r2jk (4.2)
To calculate the genetic correlation defined by %g, we perform a regression of E[z1jz2j]
against `j for each SNP. The slope of this regression line will be
√
N1N2%g
M
from which the
genetic correlation %g is calculated. My implementation of LD score regression is available
in the following github repository [6]
Variant effect predictor
VEP is a software package which annotates genomic variants in coding and non-coding
regions to genes by searching for variants which overlap or are close to (threshold of 5000
base pairs) known transcripts and regulatory regions [114]. The impact of a variant is
classified into one of 48 sequence ontology (SO) terms which are then assigned into ‘HIGH’,
‘MODERATE’, ‘LOW’, or ‘MODIFIER’ terms in order of decreasing severity on the gene.
For example, ‘stop lost’ variants are classified as a HIGH impact modification due to the
disruption of a stop site, but ‘synonymous’ variants are classified as LOW impact as they
do not lead to change in amino-acid structure of the protein [114]. MODIFIER terms are
those where variants effect non-coding regions such as intergenic or intronic regions [114].
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4.3 Results
4.3.1 Genetic architecture of Sysmex parameters
GWAS and conditional analyses of 63 Sysmex parameters identified 2,172 conditionally
independent associations which clustered into 849 LD sets (Section 2.2.9). LD sets are
assigned to cell types depending on which phenotypes the conditionally significant variants
constituting the LD set are associated with.
Although associations with red blood cell or platelet phenotypes form a larger proportion
of the total findings, associations with these cell types are less likely to be distinct in
comparison to previous haematological GWAS results. I performed a comparison between
my study of Sysmex parameters and the study of FBC parameters by Astle et al. (Section
4.2.3) [15]. The study by Astle et al. is the largest GWAS of FBC traits and benefits
from a roughly four fold larger sample size (173,480 versus 39,656 individuals). Despite
this, of the 849 high LD (r2 > 0.8) sets identified by my study of Sysmex parameters,
423 are novel in comparison to Astle et al. [15]. I find a far greater degree of overlap
with LD sets containing variants associated with platelet and red cell traits than LD
sets assigned to white cells (Fig. 4.1, 4.2). A total of 375 LD sets were associated solely
with white cell Sysmex parameters of which 73.3% (275 sets) are not reported by Astle
et al.. This is compared to a total of 410 LD sets assigned solely to platelet or red cell
Sysmex parameters of which 30.5% are not reported by Astle et al. (Fig. 4.1, 4.2). This
finding is consistent with low genetic correlation observed between white cell Sysmex
parameters and traits studied by Astle et al. (Fig. 4.5) [15]. The striking difference
in novel associations comparing white cell and red cell or platelet phenotypes can be
explained by the intra-cellular complexity and heterogenity of white cells. Neutrophils,
eosinophils, basophils can be highly granulated cells and associations with side scatter of
these cells are often located in known granule genes. A full list of conditionally significant
associations, their comparison with Astle et al.,, colocalisation with eQTL, pQTL, and
disease GWAS can be found in Table A.1. Furthermore, white cells exhibit greater cellular
heterogenity, especially the lymphocyte cell population which is an amalgamation of many
lymphocyte sub-types, in particular reactive and antibody synthesising lymphocytes are
known to vary in SFL, and FSC measurements (Section 3.2.2.3).
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Figure 4.1: Assignment of LD sets to cell types and examples of sets labelled
as ‘not reported’ by Astle et al., 2016.
a) Conditionally significant variants were clustered into 849 high linkage disequilibrium sets
which are in linkage disequilibrium r2 > 0.8 representing distinct association signals. Sets were
assigned to cell types depending on their association with Sysmex parameters. Sets were labelled
as not reported if none of their constituent conditionally significant variants are in LD r2 > 0.8
with any variants identified by Astle et al., 2016 [15]. Most sets are specific to individual
haematological cell types (not-pleiotropic), this demonstrates the specificity of Sysmex
parameters. LD sets of white cell associations are more likely to be distinct in comparison to
Astle et al.. b) Association plots showing the P-value (-log1 0(P )) for association of each genetic
variant along the genome (x axis) with the phenotype (y axis). This plot shows statistically
significant associations at genes with known roles contributing to white cell function: DEFA1B,
HYAL3, RNASE6 and EXT1 with neutrophil, eosinophil, monocyte, and basophil cell type
Sysmex parameters, and lack of genome wide significant association with respective count
parameters as studied by Astle et al.., 2016.
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An informal literature review finds association signals identified by my analysis of
Sysmex parameters, but not from GWAS of FBC by Astle et al, are often annotated to
genes by VEP which play fundamental roles in immune cell function. GWAS of white
blood cell Sysmex parameters identified 767 associations mapped to 270 genes by VEP, of
these genes, 185 were not identified by GWAS of FBC blood phenotypes by Astle et al
[15]. Of these 185 newly identified genes 72 seem to have a plausible role in the immune
system, as shown in Figure 4.7. An example includes the DEFA locus encoding α-defensin
genes associated with NE-SSC. α-defensin genes at this locus have an established role
in neutrophil immune function accumulating in the granules of neutrophil cells [60]. In
response to pathogenic cells, the cysteine-rich cationic α-defensin peptides are released
from granules of neutrophil cells and create perforations in the pathogen cell membrane
[60]. Despite the established role of DEFA proteins in neutrophil function and physiology
this locus has not been identified by GWAS of traditional neutrophil parameters. Other
examples of new association signals compared to the findings of Astle et al., identified by
my analysis include:
• The PRG2 gene encoding the MBP protein is a major component of eosinophil
granules [136]. Similar to the α-defensin peptides discussed above, MBP is also
a cationic protein which once released from eosinophil granules carries out anti-
pathogenic function by perforating the cell membranes of pathogen cells [98].
• RNASE6, a known component of monocyte granules and a cationic ribonuclease
antimicrobial protein contributing to urinary tract sterility [18].
• EXT1, encodes a glycosyltransferase protein contributing in heparin biosynthesis
[102], heparin is known to be packaged in basophil granules [166] and has been
proposed as an anticoagulant increasing blood flow to infected tissues [27].
• HYAL3 encoding Hyaluronidase 3, a protease which degrades hyaluronan a major
component of the extracellular matrix. The role of HYAL3 in eosinophil function
has not been fully elucidated. However hyaluronidases have been implicated in
remodelling of the extracellular matrix and hyaluronan deposition has been shown
to correlate with eosinophil infiltration of tissues [44].
As previously mentioned, assignment of LD sets to cell types shows there is little
overlap between association signals across cell types (Fig. 4.1). This result indicates that
the genetic determinants of Sysmex parameters are largely cell type specific. Furthermore,
limited overlap is observed between Sysmex parameters of the same cell type - thus
suggesting that Sysmex parameters assay genetically distinct phenomena within a given
cell type (Fig. 4.2). This finding is supported by low phenotype and genetic correlation
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Figure 4.2: Overlap of LD sets of Sysmex parameters by cell type.
a-e) LD sets associated with Sysmex parameters and those assigned to count traits studied by
Astle et al., ‘DW’ represents the three distribution width parameters, in the case of NE-DW:
NE-SSC-DW, NE-SFL-DW, and NE-FSC-DW. Results show limited overlap between Sysmex
parameters, in particular for neutrophil and lymphocyte cell types.
between Sysmex parameters across cell types and to a lesser extent within a cell type (Fig.
4.3 and 4.4).
4.3.1.1 Allelic spectra
Plotting conditionally significant variants in an allelic spectra with effect size on the y axis
and MAF on the x axis shows general concordance with the expected trend: variants with
high effect size having lower MAF, and variants with low effect size having higher MAF
(Fig. 4.6). This trend is driven by natural selection, which eliminates variants with large
effect sizes, as such the effect alleles of genetic variants with large effect sizes are generally
deleterious to fitness [157]. In rare cases where arising genetic variation improves organism
fitness, the mutant allele is driven to become more common in the population and is
thus no longer the ‘minor’ allele the frequency of which is plotted in an allelic spectrum.
However, there are notable exceptions to this trend in the data - these are variants which
have a higher than expected effect size compared to their MAF. This phenomenon could
arise due to balancing selection [157], for example, this could occur of a genetic variant
is deleterious to fitness in some circumstances, but enhances the fitness of the organism
in other circumstances. As an example, conditionally significant variants located in the
α-defensin locus (chromosome 8, 6.78MB - 6.95MB) appear shifted from the expected
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Figure 4.3: Pearson Correlation r2 between Sysmex Parameter Phenotype
Values
Pearson correlation r2 between Sysmex parameters where the colour of each box indicates the
magnitude of the correlation with red indicating positive, and blue negative correlation.
Phenotypes are grouped by cell type, basophils, eosinophils, lymphocytes, monocytes,
neutrophils, platelets, and red blood cells. High correlation is observed between red cell and
platelet Sysmex parameters, limited correlation observed between Sysmex parameters of other
cell types and very little correlation across Sysmex parameters of different cell types. Phenotype
abbreviations are discussed in more detail in Chapter 3.2.2.
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Figure 4.4: Pearson Correlation r2 between Sysmex Parameter Phenotype
Values
Genetic correlation between Sysmex parameters calculated by LD score regression where the
colour of each box indicates the magnitude of the correlation with red indicating positive, and
blue negative correlation. Phenotypes are grouped by cell type, basophils, eosinophils,
lymphocytes, monocytes, neutrophils, platelets, and red blood cells. High correlation is observed
between red cell and platelet Sysmex parameters, limited correlation observed between Sysmex
parameters of other cell types and very little correlation across Sysmex parameters of different
cell types. Phenotype abbreviations are discussed in more detail in Chapter 3.2.2.
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Figure 4.5: Overview of novel signals identified across Sysmex parameters and
their correlation with traditional phenotypes.
The phenotypic and genetic correlation between each Sysmex parameter and a corresponding
FBC measurement is represented in a heatmap and labelled by P and G respectively. For each
phenotype a corresponding FBC measurement was selected for which there is the highest median
correlation across all Sysmex parameters for that cell type. In addition, the number of clumps
identified per parameter stratified by those novel, or not novel in comparison to Astle et al. are
displayed. Sysmex parameters of white cells have lower correlation with related FBC blood cell
measurements, red cell and platelet parameters have a higher correlation. This difference is
reflected in the number of novel independent signals identified for each trait. Reticulocyte count
(RET#), Mean cell haemoglobin (MCH), and Mean platelet volume (MPV). ‘Cell count’
represents the corresponding FBC cell count for that cell type. Phenotype abbreviations are
discussed in more detail in Section 3.2.2.
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relationship between effect size and MAF in an allelic spectrum (Fig. 4.6). α-defensin
proteins are a component of the innate immune system encoding antimicrobial peptides
released from granules to destroy pathogenic cells. Balancing selection to maintain a
heterogeneous population of proteins has been long hypothesised [82, 52]. Phylogenic
analysis of the α-defensin locus by comparison between primates (human, chimpanzee,
orangutan, macaque, marmoset) shows divergence in the encoding of α-defensin genes, but
also conservation of certain amino acid residues [52]. Evolution of the α-defensin locus
seems to be influenced firstly by a need to conserve functionally important properties, but
also the evolutionary advantage associated with encoding a diverse functionally diverse
range of antimicrobial peptides [52]. The functional diversity of antimicrobial peptides is
important as this allows activity against a range of pathogens and reduces the ability of
pathogenic strains to overcome immune action [52]
My work adds further evidence to the hypothesis of balancing selection of α-defensin
proteins. However, it must be noted that the α-defensin locus contains a high number
of repeated genetic elements, repeated genetic elements can make the assignment of a
genotyped variant to a location in the genome unreliable. This may be better addressed by
genome sequencing of this locus, which may help to identify repeated elements by genome
sequencing could also be an important genetic factor which modulates changes in neutrophil
granularity and the NE-SSC parameter. However, in many scenarios classical genome
sequencing technology can struggle to resolve regions where repeated elements constitute
longer stretches of DNA [139]. In the future, next generation sequencing technology such
as that provided by Oxford Nanopore may be provide a solution to better resolve repeat
regions [87].
4.3.1.2 Identification of functionally relevant genes
GWAS analysis of Sysmex parameters identifies genetic signals which are annotated by
VEP to be located in genes relevant to white cell function. I performed a literature review
of genes identified by VEP annotation of conditionally significant variants associated with
Sysmex parameters. My literature review found functional relevance of these genes in
a number of blood cell functions such as haematopoiesis, cell adhesion and chemotaxis,
cell activation, and others. The results of my literature review across the seven primary
blood cell types (platelets, red blood cells, neutrophils, eosinophils, basophils, monocytes,
and lymphocytes) are summarised in Figure 4.7 and corresponding references can be
seen in Table A.1. These results show that conditionally significant variants often appear
annotated to genes which perform known and functionally important roles in blood cells
4.7. Genes are further annotated by their colocalisation with eQTL, pQTL, or disease
GWAS association signals which is labelled in Figure 4.7 and discussed further in Chapter
5.
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Figure 4.6: Allelic spectra of conditionally significant variants.
Each conditionally significant association plotted with MAF on the x axis and effect size on the
y axis. Since a conditionally significant variant may appear associated with multiple Sysmex
parameters the same variant may appear more than once on the plot. Associations are coloured
by their VEP annotation to CDK6, α-defensin, HYAL3, or NLRP12 genes.
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4.4 Summary
GWAS analyses can identify variants which are significantly associated with a phenotype
of interest, however due to LD between variants in the genome the number of true genetic
signals is not apparent from this analysis alone. I performed a conditional analysis to
identify a parsimonious set of variants which represent the underlying genetic association
signals. I show that the genetic determinants of Sysmex parameters are largely cell type
specific, furthermore there is limited overlap between parameters for the same cell type.
Finally using an LD clumping approach, I compared the total number of signals identified
across all 63 Sysmex parameters in my study, with the genetic signals identified by Astle
et al. [15]. VEP annotation of my conditionally significant variants to nearby genes
and subsequent literature review shows identification of genes contributing to blood cell
function including cell chemotaxis and adhesion, cell activation and immune response, and
cell survival. The results of this work inform further downstream analysis to annotate
genetic signals using corollary datasets from eQTL, pQTL, and disease risk GWAS studies
(Section 5).
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Chapter 5
Downstream analysis and biological
inference
5.1 Introduction
In previous chapters I presented my GWAS analysis which has identified genetic variants
associated with changes in blood cell phenotypes. However, I began this thesis by outlining
my aims not only to identify new genetic associations with haematological phenotypes,
but also the interpretation of GWAS results and the potential for this interpretation to
inform biological and clinical experimentation. As previously explained in Section 1.6, the
primary challenges in interpretation of GWAS are as follows:
• Confident identification of the genes mediating each genetic association, a starting
point for further inference.
• Understanding the mechanisms of biology which lead to the emergence of a genetic
association and understanding the tissue specificity of those mechanisms.
• Inferring a causal relationship between two measurements, for example a risk factor
and disease risk, and the implications of this for the consideration of the risk factor
as a target for therapeutic modulation.
I explored these questions by performing a number of analyses detailed in this chapter,
including colocalisation and MR. In Section 1.6.2 I introduced genetic colocalisation
analysis, a tool for interpretation of GWAS results which can determine the same variant
is the common cause of associations with multiple phenotypes. With colocalisation I
have identified genetic determinants of blood cell phenotypes which have concomitant
effects on blood cell transcripts (Section 5.1.2), blood plasma proteins (Section 5.1.3), and
disease risk (Section 5.1.4). I focused my analysis on cardiovascular and immune related
disease outcomes due to the known role of blood cells in mediating these disease types
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[83, 15, 97, 49, 150]. A broad discussion of the implications of colocalisation analysis in
interpretation of GWAS results is given in Section 1.6.2.
However, colocalisation analysis is limited because it can only show that a genetic
association is simultaneously influencing a set of phenotypes. Colocalisation cannot
prove causal relationships between the associated phenotypes. MR can determine causal
relationships between two phenotypes, often termed ‘exposure’ and ‘outcome’ (Section
1.6.3). I utilise MR to explore potential causal relationships between blood cell phenotypes
and cardiovascular and immune disorders (Section 5.3.4).
I performed colocalisation between genetic associations from GWAS of 63 Sysmex
parameters and GWAS of 5,995 blood cell type specific transcripts, 1,478 blood plasma
proteins, and risk of 22 cardiovascular and autoimmune disorders. Blood cell type
specific transcripts where chosen in order to assess the influence of associations not only
on haematological parameters but expression of genes in the relevant blood cell-types.
The dataset of 1,478 blood plasma proteins was chosen to study the influence of Sysmex
parameters on the composition of the plasma proteome, because many clinically therapeutic
drugs or candidate drugs target proteins in the plasma. We hypothesised that associations
with blood cell properties (particularly granulation) as measured by Sysmex parameters
would also influence composition of the blood plasma proteome. Furthermore, selection
of the blood plasma proteome dataset was practically convenient due to the size of this
dataset in terms of the number of proteins assayed and the sample size, furthermore this
data was readily available to me as the results were generated by colleagues analysing
samples from participants in the INTERVAL study. Finally, I performed colocalisation
with risk of cardiovascular and autoimmune disorders as these disease outcomes are those
which are known to be influenced by blood cell function.
My analysis has annotated genetic determinants of Sysmex parameters to a range of
autoimmune disorders such as atopic dermatitis, multiple sclerosis, and celiac disease.
My results are informative for drug design and target selection, demonstrated by two
examples: replicating the known mechanism of action of Daclizumab by it’s influence of
lymphocyte cell properties via IL2RA (Section 5.3.2.1) a treatment for Multiple Sclerosis
(MS), and evidence for a common genetic determinant influencing IL-18R1 plasma protein
concentration, NE-FSC, and risk for celiac disease (Section 5.3.2.4). I have identified many
common genetic determinants between white cell granulation as measured by Sysmex
parameters and the blood plasma proteome (Section 5.3.3). Furthermore, I perform MR
analysis to assess causal association between white cell parameters and disease, and identify
causal relationships between NE-SSC and coronary artery disease (CAD) or lung cancer
and EO-FSC and asthma (Section 5.3.4).
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Cell Type CD Marker Cardiogenics CEDAR WTCHG BP Total
Monocyte CD14 758 300 432 1,490
Granulocyte
Neutrophil
CD15 300 300
T-Lymphocyte CD4 300 300
T-Lymphocyte CD8 300 300
B-lymphocyte CD19 300 300
Platelet PLA 268 156 424
Table 5.1: Contribution of studies to the eQTL analysis of blood cell types.
Number of individuals for which genotype and expression data was available is presented, all
individuals are healthy participants except for 363 individuals in the Cardiogenics dataset whom
have a previous history of coronary artery disease, BLUEPRINT (BP).
5.1.1 Quantitative trait loci
Quantitative trait loci (QTL) are genetic loci associated with variation in a quantitative
trait. Examples include eQTL or pQTL, representing transcript abundance (expression)
and protein concentration respectively. However, we must always enquire about the specific
nature of these phenotypes, for example, eQTL analysis can use blood cell type specific
RNA or RNA extracted from whole blood. The eQTL and pQTL results utilised in my
work are quantitative GWAS studies of transcripts expressed by specific blood cell types
and proteins in the blood plasma respectively.
5.1.2 Expression quantitative trait loci
I used eQTL data generated from a number of specific blood cell types separated using
immunophenotyping cluster of differentiation (CD) markers [94]. The CD method utilises
markers such as cell surface carbohydrates or proteins which can be signalling molecules or
cell adhesion proteins to identify cell types [59]. In total, I obtained eQTL data for platelets,
monocytes, lymphocytes, and neutrophils [94]. This eQTL analysis was performed by
Kreuzhuber et al., who combined individual level genotype and phenotype data collected
from a number of studies: Cardiogenics, CEDAR, Wellcome Trust Centre for Human
Genetics (WTCHG), and BLUEPRINT [94]. Sample sizes for each cell type ranged from
between 300 to 1,490 individuals (Table 5.1). Individuals participating in the Cardiogenics,
WTCHG and BLUEPRINT studies were healthy, in CEDAR of 758 participants, 395 were
healthy individuals and 363 had a history of coronary artery disease [94].
5.1.3 Protein Quantitative Trait Loci (pQTL)
Sun et al., performed an aptamer based assay (SOMAscan) which allowed the quantification
of 3,622 plasma proteins in 3,301 participants from the INTERVAL study, of which 2,994
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were studied in a GWAS of 10.4 million imputed variants. This analysis identified 1,927
significant associations (P < 1.5× 1011) with 1,478 plasma proteins [164]. Protein levels
were quantified with binding of aptamers to circulating proteins, in some cases it is possible
that associations could result from genetic variations which influence the affinity of aptamer
binding rather than changes in protein levels [164]. Sun et al. addressed this by comparing
the GWAS results for a subset of the proteins studied by SOMAscan with a complementary
antibody based Olink assay and found strong concordance between the predicted effect
size of associations (r = 0.83) [164].
5.1.4 Disease risk GWAS
Many case-control based GWAS of disease outcomes have been performed and many
associations with disease risk have been identified. However, a GWAS study in isolation does
not provide a full picture on which cell types, cell functions, proteins, and transcripts are
causally mediating a particular association. I have colocalised associations of haematological
phenotypes with associations with disease risk and identified genetic associations with
biological mechanisms involving both blood cell biology and disease aetiology. My dataset
of GWAS summary statistics for 28 disease outcomes is largely focused on cardiovascular
and immune disorders (Appendix 5.4), due to the known role of blood cells in mediating
such disorders [83, 15, 97, 49, 150].
5.2 Methods
5.2.1 Colocalisation
Methods for colocalisation analysis (Section 1.6.2) have been implemented in software
packages by a number of authors. In my analysis I utilise two implementations: coloc by
Giambartolomei et al. [70] and gwas-pw by Pickrell et al. [137].
coloc uses a user-set prior for the chance of association between a SNP and the
phenotype and the variance for this effect size. gwas-pw estimates prior parameters for
association of SNPs to the phenotype using a genome-wide optimisation procedure, and
averages over a set of priors for the variance of SNP effect sizes. The gwas-pw approach is
more computationally burdensome and also requires full genome-wide association summary
statistics. This is not available in the case of eQTL colocalisation as variants only 1 MB
on either side of each gene were tested for association. The genome-wide approach for
estimating priors is also inappropriate for pQTL colocalisation due to the very small
number of signals identified genome-wide per protein (1,927 associations for 1,478 proteins
tested).
In contrast, the coloc approach uses predefined priors, this is my preferred approach
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eQTL Celltype Sysmex Parameter
PLA
H-IPF, P-LCR, PLT-FSC,
PLT-FSC-DW, PLT-SFL, PLT-SFL-DW,
PLT-SSC, PLT-SSC-DW
CD19
LY-FSC, LY-FSC-DW, LY-SFL,
LY-SFL-DW, LY-SSC, LY-SSC-DW,
RE-LYMP(L)%, RE-LYMP#,
RE-LYMP%
CD15
NE-FSC, NE-FSC-DW, NE-SFL,
NE-SFL-DW, NE-SSC, NE-SSC-DW
CD14
MO-FSC, MO-FSC-DW, MO-SFL,
MO-SFL-DW, MO-SSC, MO-SSC-DW
CD8
LY-FSC, LY-FSC-DW, LY-SFL,
LY-SFL-DW, LY-SSC, LY-SSC-DW,
RE-LYMP(L)%, RE-LYMP#,
RE-LYMP%
CD4
LY-FSC, LY-FSC-DW, LY-SFL,
LY-SFL-DW, LY-SSC, LY-SSC-DW,
RE-LYMP(L)%, RE-LYMP#,
RE-LYMP%
Table 5.2: Colocalisation between haematological parameters and cell type
matched between eQTL.
A table of cell types for which eQTL data was collected by Kreuzhuber [94] and the cell type
matched Sysmex parameters for which colocalisation was performed. In total colocalisation was
performed for 47 eQTL and Sysmex parameter pairs.
for colocalisation with eQTL and pQTL data. Furthermore, the coloc was used by the
authors of the blood plasma proteome pQTL study to colocalise their results with a series
of eQTL and disease datasets [164]. Alternatively, for disease risk colocalisation I utilise
the gwas-pw method. Here there are a larger number of signals across the genome, but
fewer sets of GWAS summary statistics to be colocalised making the gwas-pw method
computationally tractable. I further discuss my reasoning for implementation of two
colocalisation methods in Section 5.3.1.
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Figure 5.1: Schematic of the models considered by gwas-pw.
Posterior probabilities are calculated for each of the described models. The first and second
model defines a single causal variant with phenotypes 1 and 2 respectively, the third model
describes a single causal variant with both phenotypes, and model 4 shows two distinct causal
variants for phenotypes 1 and 2. The null model with no association in either phenotype is not
shown (Figure source: [137]).
5.2.1.1 Colocalisation with gwas-pw by Pickrell et al., 2016
Using a Bayesian approach, posterior probabilities are computed for following models
which represent the underlying genetic architecture assuming at most one causal signal
for each phenotype in the locus. The total posterior probability will sum to 100%, thus
Pickrell et al. assume that all possible outcomes are captured in the following scenarios
(Fig. 5.1):
• Null Hypothesis: No associated genetic variants with either trait.
• Model 1: The locus contains one genetic variant which influences the first phenotype.
• Model 2: The locus contains one genetic variant which influences the second pheno-
type.
• Model 3: The locus contains one genetic variant which influences both phenotypes.
• Model 4: The locus contains two separate genetic variants which influence the first
and second phenotype respectively.
Calculation of posterior probabilities for the models (Fig. 5.1) begins with calculation
of Bayes factors which represent the evidence for a variant being associated with the first
122
or second phenotype: BF (p), where p ∈ {1, 2} is an index over the two phenotypes. Bayes
factors are the ratio between the likelihood ratio of a null (the variant is not associated)
and alternate hypotheses (the variant is associated). Bayes factors for SNPs in a chosen
locus are summed to calculate Regional Bayes Factors, RBFp for each model in the locus,
and RBF s are then used to calculate the posterior probability for each of the four models
in the locus.
Bayes factors are calculated using the Wakefield approximation, the Wakefield approxi-
mation allows computation of Bayes factors from frequentist p-values [174]. A Bayes factor
is calculated for the association of each SNP with phenotype 1 or 2 indexed by p ∈ {1, 2}:
WABFp =
√
1− rpexp[
Z2p
2
rp] (5.1)
Where Zp =
βˆp√
Vp
and rp =
Wp
Vp+Wp
, βˆp is the estimated effect size for association of
the SNP with phenotype p, and
√
Vp is the standard error of the effect size estimate.
rp is a shrinkage factor computing the ratio between variance of the prior W and total
variance. Thus, effect sizes are distributed as follows βp ∼ N (0,Wp) with Wp set to 0.01,
0.1, or 0.5 and the Bayes factors are averaged over those values. Not much reasoning is
given by Pickrell et al., to justify this choice for their prior on the variance of the effect
size. However, it could be argued that the degree of justification for the assignment of a
prior should be proportional to the degree of influence that prior will have on the final
estimated outcome. Most priors are assigned on the mean of an estimate (such as in
the coloc method), here Pickrell et al., assign a very broad set of priors on the variance.
Therefore, I do not find their lack of justification for their choice problematic. Since the
publication of gwas-pw in 2016 a better alternative has not been proposed (at the time of
writing). As mentioned, Bayes factors are averaged over the three prior values and are
defined as follows for the first three models:
BF (1) = WABF1 (5.2)
BF (2) = WABF2 (5.3)
BF (3) = WABF1WABF2 (5.4)
Broadly speaking, the calculation of the Bayes factors with the Wakefield approximation
relies on the asymptotic assumption that the sample size is “large” which is generally
satisfied in the context of a GWAS study. For a formal proof of Eqn. 5.1 see the Appendix
of Wakefield 2009 [174]. Regional bayes factors are defined across an entire locus to
represent the models defined above (Fig. 5.1), Regional Bayes Factors are computed as
123
follows for models (m) 1, 2 and 3, where K is the total number of SNPs in the locus
indexed by i:
RBFm =
K∑
i=1
pi
(m)
i BF
(m)
i (5.5)
The Regional Bayes Factor for model 4 is defined as follows:
RBF 4 =
K∑
i=1
K∑
j=1
pi
(1)
i BF
(1)
i pi
(2)
j BF
(2)
j I[i 6= j] (5.6)
The purpose of the I[i 6= j] term is to restrict the sum to pairs of Bayes factors for which
the corresponding causal variants are distinct for the two phenotypes. pi
(m)
i represents
the prior probability of association of SNP i with the phenotype. The SNP priors for all
models (m) are set as follows: pi
(m)
i =
1
K
, where K is the total number of SNPs in the
locus.
Finally, using the regional Bayes factors, the following likelihood function is constructed
indexing over all loci in the genome by I. Prior probabilities for each of the four models
are identified by optimisation of the following likelihood function:
l(θ|D) =
I∑
k=1
log(Π0 +
4∑
m=1
ΠmRBF
(m)
k ) (5.7)
Where Π0 is the prior probability that a region has no associated genetic variants, and
Π(m) is the prior probability of each of the four models (m) described above. RBF
(m)
i
is the Regional Bayes Factor of each of the four models indexed by m. The summation
indexed by m is over each of the four models or hypotheses. l(θ|D) is the definition of
posterior probability for all four models where θ represents parameters for all four models
and null hypothesis. We identify the prior probabilities (Π) by maximising the likelihood
function l(θ|D), thus identifying the prior probabilities for each model from the data
itself. From here, posterior probabilities (PP) for each locus can be constructed using the
Regional Bayes Factors RBFmi and prior probabilities Πm, where m is an index over all
possible models:
PP
(m)
i =
RBF
(m)
i Π(m)∑4
m=0RBF
(m)
i Π(m)
(5.8)
The method assumes at most one causal signal per phenotype in the locus of interest.
Furthermore, it is not possible to differentiate between models 3 and 4 if the causal variants
for each of the traits are in high LD. Note that calculation of the prior for model three
(Π3) is defined as the prior for the proportion of genomic regions containing a common
variant that detectably influences both phenotypes. If there is indeed a common causal
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variant which effects both phenotypes but this association signal is very weak, this locus
will not have a high posterior probability (PP) for colocalisation [137].
5.2.1.2 Colocalisation with coloc by Giambartolomei et al., 2014
Giambartolomei et al. begin by defining a null hypothesis and four alternative hypotheses
as described above, however the definitions of models 3 and 4 are switched when compared
to the colocalisation implementation by Pickrell et al. The posterior probability for each
of the four hypotheses h is defined as follows:
P (Hh|D) ∝
∑
S∈Sh
P (D|S)P (S) (5.9)
Where h is one of four hypotheses, and Sh represents a complete set of all possible
SNP ‘configurations’ which are true under each hypothesis. A configuration is a pair of
lists, where each list contains a binary element for each variant in the locus (Fig. 5.2).
Every configuration has two lists and each list has up to one binary element set to true
to represent the variant which is the causal mediator of the association signal. Each
hypothesis, for example, the hypothesis for a colocalisation occurring, has multiple possible
configurations. This is because it could be any one (or none) of all the variants in the
locus (represented by elements in the list) which could be associated with the phenotype.
The hypothesis for a colocalisation occurring, has n total possible configurations, where n
is the number of variants in the locus. An example of three configurations is presented in
Figure 5.2.
coloc makes the assumption that the prior for association is consistent across SNPs
and therefore we can simplify to the following:
P (Hh|D) ∝
∑
S∈Sh
P (D|S)P (S) = P (S|S ∈ Sh)×
∑
S∈Sh
P (D|S) (5.10)
Where the summation is summing over every SNP in the configuration set for that
model represented by Sh. To avoid calculating the proportionality constant which is
the Bayesian normalising constant (Eqn 5.9), Giambartolomei et al. divide by P (H0|D)
changing the calculation of posterior probability to that of posterior odds:
P (Hh|D)
P (H0|D) =
∑
S∈Sh
P (D|S)
P (D|S0) ×
P (S)
P (S0)
(5.11)
The first term in the equation
∑
S∈Sh
P (D|S)
P (D|S0) is summation of Bayes factors for SNPs
in each configuration within each hypotheses (indexed by S). This is the definition of
Regional Bayes Factors made above (Eqn. 5.5). The calculation of such is performed in
the same way from summary statistics using the Wakefield approximation (Eqn. 5.1). The
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Figure 5.2: Example of one configuration for each of the four hypotheses.
Configurations are represented by binary vectors, where each element in the vector is a SNP. A
value of 1 indicates the SNP is causally associated with the phenotype, and 0 indicates that the
SNP is not associated with the phenotype. One configuration per hypothesis (model) is
displayed, each model will have a large number of configurations and only one of which is shown
in the figure. The first plot shows the a single causal variant associated with the first or second
phenotype, the second plot shows two causal variants associated with phenotypes 1 and 2
respectively, and the final plot shows a single causal variant associated with both phenotypes
(Figure source: [70]).
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second term P (S)
P (S0
) represents the prior odds of the model under consideration and the
null hypothesis. Prior probabilities are defined by Giambartolomei as the following, p1, p2
representing the prior for association of a SNP with the first or second trait respectively,
and p12 representing the prior for association of the SNP with both the first and second
trait. Given that a SNP must exist in one of the four models defined above (Fig. 5.2),
p0 + p1 + p2 + p12 = 1 where p0 is the prior for association with no trait.
In my analysis to perform colocalisation between association signals with the Sys-
mex parameter traits and pQTL or eQTL association signals I used the following prior
probabilities:
• The prior for association of the SNP with trait 1 or 2: p1 = p2 = 1× 10−4.
• The prior for the SNP being associated with both traits p12 = 1× 10−6.
• The prior for the SNP being associated with neither trait: p0 = 0.999799.
The choice of priors represents an assumption of my approach, my confidence in this
assumption is based on the following factors:
• The successful implementation of coloc with the same prior probabilities by peer
reviewed publications which colocalise association signals with eQTL [70] and pQTL
[164] data, and sensitivity analysis performed by Giambartolomei et al. [70].
• The set priors are conservative given the design of my colocalisation experiment.
I only ever perform colocalisation in a locus if the following two conditions are
met: 1) There is a significant association in that region with both phenotypes. 2)
The conditionally significant variant associated with the Sysmex parameter has
a significantly associated proxy of LD r2 > 0.8 in the partner phenotype. The
significance threshold in the partner phenotype is defined separately based on that
specific GWAS study.
• A thorough and manual search through all the purported colocalising loci generated
from this prior inspecting colocalising loci and the LD structure within those loci to
check the purported colocalisations.
Finally, it must be stressed that no statistical procedure can prove an outcome with
full certainty. In the colocalisation approach a posterior probability for each of the four
aforementioned models including that of a colocalising loci is generated. When discussing
results I always resolve to communicate to the reader the posterior probability for the
discussed colocalisation being ‘true’ rather than presenting a binary true / false outcome
which simplifies the inherent uncertainty in the statistical procedure.
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5.2.2 Mendelian randomisation
A MR analysis uses genetic variants as instrumental variables to assess a causal relationship
between an exposure and outcome (Fig. 1.21). MR assesses causality utilising ‘instrumental
variables’ derived from the results of a GWAS study (Section 1.6.3). Instrumental variables
are independent genetic variants associated with the exposure of interest. A causal
association between the exposure and outcome of interest can be tested using the inverse
variance weighted (IVW) MR model. The following three assumptions must hold for a
genetic variant to be a valid instrumental variable [30]:
1. The variant must be predictive of the exposure, thus have a significant association
with the exposure.
2. The variant must be independent of any measured or unmeasured confounding
factors which influence both the exposure and outcome.
3. The variant must not influence the outcome through any pathway other than the
chosen exposure, often termed the ‘exclusion restriction criterion’.
Assumption 1) can be tested with a standard GWAS analysis which determines
significance of association between a genetic variant and phenotype. However, assumptions
2) and 3) are more difficult to test as they depend on factors which may not be measured.
For example, if a genetic variant influences an alternative unknown factor which also effects
the outcome, assumption 2) will be broken. Similarly, if the genetic variant is associated
with changes in an unmeasured confounding factor which influences both the outcome
and exposure, this could induce a seemingly causal relationship between the exposure
and outcome. As we are modelling complex biological systems, assumption 3) is rarely
ever true, variants are generally pleiotropic, meaning they influence multiple traits and
phenotypes. In the context of IVW analysis assumption 3) is relaxed to assume ‘balanced
pleiotropy’ between all instrumental variables. Balanced pleiotropy suggests that the
overall sum of pleiotropy across all instrumental variables should sum to zero. This can be
tested qualitatively with a funnel plot, or quantitatively using MR-Egger an extension of
the IVW model which allows the intercept of the regression line to vary. The assumptions
for valid instrumental variables rarely holds true for complex phenotypes such as the
Sysmex parameters studied in my analysis. Therefore, I utilise a number of alternative MR
models which relax the assumptions listed above and applied these methods as sensitivity
analyses to determine if estimated causal effects are consistent across the multiple MR
models with differing assumptions, this is discussed further in Section 5.2.2.2.
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5.2.2.1 Mendelian Randomisation Software Analysis Protocol
My MR analysis began with a set of conditionally independent variants which are associated
with the exposure and were intended to be instrumental variables for this exposure of
interest. Following this, my mendelian randomisation protocol proceeded with the following
steps which were implemented in a custom R pipeline utilising the TwoSampleMR package
by Hemani et al [80]:
1. The instrumental variables must be independent with each other, not only being
conditionally independent but also filtered to ensure none are pairwise LD higher
than 0.6 r2.
2. I collected the univariate summary statistics (estimated effect size and standard error
of this estimate) for association of the instrumental variables with the exposure.
3. I collected the univariate summary statistics for association of each instrumental
variable with the outcome.
4. In the case where the instrumental variable in question does not exist in the GWAS
of the outcome, a close proxy with LD greater than 0.8 r2 is used instead.
5. The effect size directionality between the exposure and outcome are ‘harmonised’,
as in many cases the definition of reference and alternative allele for a variant differs
between GWAS studies. At this stage, insertion or deletion variants are removed
due to potential inconsistencies in the way the alleles of such variants can be coded
and assigned to a specific base-pair in the genome.
6. I performed, not only the standard IVW and egger MR analysis, but also nine other
MR tests to test for robustness of a purported causal association. These sensitivity
tests are in Table 5.2.2.2 and discussed further in Section 5.2.2.2.
My usage of an LD threshold of 0.8 r2 is based on similar analysis by other authors
[80] [15], a correlation of 0.8 r2 (given a maximum possible r2 of 1.0) between two variants
is strong evidence that those variants are largely tagging the same underlying genetic
changes in most individuals. In step 4) of my protocol I removed insertion or deletion
variants simplifying the analysis, but also removing potentially informative instrumental
variables. This simplifying step also allowed me to utilise the TwoSampleMR R package
and MRBase platform by Hemani et al., to collect and harmonise instrumental variables
[80].
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5.2.2.2 Mendelian randomisation models
In total my MR analysis utilised 12 MR models, each of which varies slightly in the
estimation of causal effect between exposure and outcome. The 12 methods can be
assigned to the following categories: IVW, median based, and MR egger regression. MR
methods may be further modified by: weighting, penalisation, robust regression, and both
penalisation and robust regression together (Table 5.2.2.2).
Inverse variance weighted
IVW MR begins by calculating a ratio of association estimates between exposure and
outcome for each instrumental variable:
θˆj =
βˆY j
βˆXj
(5.12)
Where j is an index over all instrumental variables, βˆY j is the estimated effect size
of variant j on the outcome, and βˆXj is the estimated effect size of that variant on the
exposure. The estimation of variant effect sizes on a phenotype (exposure or outcome) is
performed as part of a GWAS analysis and this was presented in Section 1.5. These ratio
of association estimates are combined [36] to estimate the causal association (θˆIV W ) as
follows:
θˆIV W =
∑
j βˆ
2
Xjse(βˆY j)
−2θˆj∑
j βˆ
2
Xjse(βˆY j)
−2 (5.13)
The IVW estimator has the effect of weighting each instrumental variable by βˆ2Xjse(βˆY j)
−2,
or conceptually the ratio between the influence of the instrumental variable on the ex-
posure and uncertainty in the estimated effect of the variant on the outcome. A variant
with a small effect on the exposure and highly uncertain influence on the outcome has a
down-weighted influence on the final causal estimate θˆIV W .
Median based
The IVW method for estimating the causal effect becomes biased if even a single instru-
mental variable breaks the aforementioned assumptions (Section 5.2.2). This was described
by Bowden et al., as the IVW method having a 0% ‘breakdown level’ [30]. Bowden et al.,
proposed the median based MR approach where the causal estimate is simply calculated as
the median of all the calculated ratios between estimated effect on outcome and exposure
(Eqn. 5.12) [30]. This median based method has a 50% ‘breakdown level’, meaning that
up to 50% of the instrumental variables can be invalid without resulting in a biased causal
estimate [30].
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However, this median based approach is inefficient, particularly when the estimate
of effect sizes of the instrumental variables is uncertain. Furthermore, the certainty of
the causal estimate will not improve with an increasing number of instrumental variables.
Therefore, Bowden et al., also proposed the weighted median estimator. Here each
instrumental variable j is given a weight wj where weights are computed similar to the
IVW approach above: βˆ2Xjse(βˆY j)
−2. Weights are then standardised in order to sum to 1
the weighting of each variant then informs identification of the ‘median’ point. Given an
ordered list of effect size ratios θˆj, a cumulative weight sj =
∑j
k=1wk is computed and a
distribution is created which has an estimate θˆj at it’s pj = 100(sj − wj2 ) percentile [30].
We can see from this equation that the median (50% percentile) point will be shifted to
be ‘earlier’ compared to the classical paradigm if the instrumental variants with lower
estimated ratios are up-weighted, and the opposite in the converse scenario [30].
MR Egger regression
The IVW approach assumes that instrumental variants with no effect on the exposure
also have no effect on the outcome. This assumption mandates that the instrumental
variable should not effect the outcome except through the exposure of interest. However,
this assumption is often broken due to the pleiotropic nature of genetic variants which
often effect multiple phenotypes. The MR egger approach replaces the aforementioned
assumption with a weaker assumption which states that pleiotropic effects of the variants
on the outcome may exist, but must be independent and should not correlate with the
magnitude of association with the outcome [29].
MR egger introduces an intercept term which represents the overall pleiotropic effect
of the instrumental variables on the outcome [29]. As before, βˆXj is the estimated effect
on the exposure, and βˆY j estimated effect on the outcome:
βˆY j = γ0 + γEβˆXj (5.14)
Here γE is be computed as the estimated causal effect of the exposure on the outcome
and offers a more flexible approach compared to the IVW method. However the additional
degree of freedom introduced by estimating the intercept parameter γ0 will decrease power
to detect causal relationships compared to the IVW approach [29].
It should be noted that before an MR egger analysis, instrumental variables must be
re-orientated so that all genetic variants are in the ‘positive’ quadrant [29]. This means
that for all variants where βˆXj < 0, both estimated effect sizes on the exposure and
outcome are multiplied by -1 to ensure that estimated effect size on the exposure is not
less than zero. Orientation of genetic variants is arbitrary and depends on which allele is
considered to be the ‘effect’ allele. Consistent orientation of instrumental variables allows
proper estimation of the intercept term (Eqn. 5.14).
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Penalised regression
One implicit assumption made by the IVW approach is that the influence of the exposure
on the outcome is consistent regardless of the ‘pathway’ by which the exposure is influenced.
More specifically, sub-sets of genetic variants may influence the exposure by differing
biological pathways that then have a causal effect on the outcome of a different magnitude.
This assumption is unlikely to be true in practice especially when working with complex
intermediate traits such as the Sysmex parameters in question. Both ‘penalised’ or
‘robust’ regression techniques address this heterogenity by reducing the impact of outlying
instrumental variables (or variants) on the causal estimate.
Penalised regression will down-weight instrumental variables with a heterogeneous
(outlying) θˆj ratio (Eqn. 5.12) [30], where heterogenity calculated by the Cochrans Q
statistic [30]. The Q statistic is calculated as follows:
Qj = βˆ
2
Xjse(βˆY j)
−2(βˆj − θˆ) (5.15)
Here θˆ is the causal estimate of the IVW or egger regression, depending on which
method the penalised modifier is applied to. Following this, the weights of the variants
are calculated as follows:
w∗j = βˆ
2
Xjse(βˆY j)
−2min(1, 20qj) (5.16)
Where qj is the one sided upper P-value of Q statistic Qj on a chi-squared distribution
of degree freedom 1 [30]. The effect of this approach is that most variants are not influenced
by the penalisation, but the influence of outlying variants on the final causal estimate will
be severely down-weighted.
Robust regression
Robust regression is designed to allow greater tolerance to outlying instrumental variables
by down-weighting the influence of these data-points on the final estimate [142]. In this
example the MM-regression procedure is used [9]. In essence, Tukey’s bisquare objective
function is used to down-weight outlying instrumental variables in the estimation procedure:
w(rj) =
{
[1− rj
c
2
]2 |rj| < c
0 |rj| ≥ c
(5.17)
Where rj is the residual of data-point or instrumental variable j, w(rj) is the calculated
weight, and c is a tuning parameter. In the MM-estimation robust regression protocol the
tuning parameter c is initially set to 1.548 then 4.685 in a two step procedure [9] [142].
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5.3 Results
In this section, I present my results of colocalisation and MR analysis of the genetic
determinants of Sysmex parameters identified in Chapter 4. The purpose of MR is to
identify a causal association between tested Sysmex parameters (purported risk factors)
and disease outcomes (Section 1.6.3). Colocalisation can determine if two phenotypes
share a common genetic determinant in a locus of association. I discussed my motivations
for colocalisation regarding biological and aetiological inference in Section 1.6.2.
5.3.1 Colocalisation of genetic determinants of Sysmex parame-
ters with disease risk
The total set of GWAS summary statistics utilised for disease colocalisation is listed in
Tables 5.4, 5.5, and 5.6, and summary statistics utilised for eQTL colocalisation are listed in
Table 5.1. Furthermore, Sun et al., performed GWAS analysis for 1,478 plasma proteins as
measured by SOMAscan (Section 5.1.3) which I also studied in my colocalisation analysis,
a full list of plasma proteins can be seen in the relevant publication [164]. As previously
discussed in Section 5.2.1, the gwas-pw procedure utilised for disease colocalisation assigns
prior probabilities based on a genome-wide optimisation procedure. This genome-wide
calculation is not possible in the case of eQTL colocalisation as the association study
was limited to a 1 MB range around each gene, and inappropriate in the case of pQTL
colocalisation due to the small number of signals identified per protein phenotype (1,927
associations identified across 1,478 proteins tested). Therefore, for eQTL and pQTL
colocalisation I utilised the coloc approach (Section 5.2.1.2).
My colocalisation analysis identified 134, 164, and 74 variant-trait associations which
colocalise with atleast one eQTL, pQTL, and disease risk GWAS respectively. Furthermore,
there are 6, 15, and 5 variant-trait associations colocalising with atleast one eQTL and
pQTL, pQTL and disease risk, and eQTL and disease risk association signal. There are no
variant-trait associations with colocalise with a eQTL, pQTL, and disease risk association
signal (Fig. 5.4).
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Figure 5.3: Overview of LD sets which colocalise with loci from different
GWAS analyses.
Heatmap showing colocalisations between LD sets associated with all Sysmex parameters and
pQTL, eQTL, and disease GWAS datasets. Irritable Bowel Disease (IBD), Ulcerative Cholitis
(UC), Multiple Sclerosis (MS), Celiac Disease (Celiac), Systemic Lupus Erythematosus (Lupus),
Atopic Dermatitis (AD), Coronary Artery Disease (CAD), Primary Sclerosing Cholangitis
(PSC), Primary Biliary Cirrhosis (PBC). trans pQTL are associations with the plasma
concentration of a protein encoded by a gene which is further than 1 MB from the association
signal and cis pQTL are associations located within 1 MB of the appropriate gene.
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Figure 5.4: Flow chart showing systematic reduction of candidate genes from
initial association signals through colocalisation.
Colocalisation allows systematic reduction of association signals (or candidate genes) to
smaller sets for which there is evidence for the association signal causally modulating
biological factors (eQTL, pQTL, disease risk).
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5.3.2 Disease aetiology and drug target validation
I have identified 73 associations with Sysmex parameters which colocalise with GWAS
risk for cardiovascular inflammation or immune related disease (PP > 80%) (Table A.1)
(Fig. 5.3). My analysis annotates signals associated with risk for disease and functionally
informative blood cell properties as measured by Sysmex which are discussed below. In
Section 1.6.5 I discussed the challenges of drug development, in particular:
• In the clinical pipeline of AstraZeneca between 2005 - 2010, 88% of drugs failing
at Phase IIb did so due to lack of efficacy. In 40% of these cases the reason for
failure due to efficacy was cited to be target linkage to disease not established or no
validated models available.
• Usually, $1 billion dollars of development costs are incurred prior to Phase II, the
first real chance to test efficacy of a drug compound in man.
During drug development a billion dollars and many years of research may go by before
the first chance to test a purported efficacious drug target in humans. Furthermore, after
a huge commitment of time and resources many candidates are failing because they simply
are not efficacious! It is this context which motivates my thesis and the work of other
statistical geneticists. I do not aim to definitively prove a biological mechanism or provide
overwhelming evidence for a new drug candidate. Instead, my work shows it is possible
to find evidence for a purported efficacious drug target from genetic data derived from a
human cohort living in ‘wild-type’ conditions. This analysis can occur early in the drug
development pipeline, before resources are committed to a candidate pathway or molecule
and can prioritise candidates.
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5.3.2.1 Lymphocyte traits and multiple sclerosis
Five signals associated with lymphocyte parameters colocalised with genetic risk of multiple
sclerosis (MS) (Fig. 5.3). The colocalising associations were located in the transcription
factor encoding gene BACH2, and in the genes encoding receptors for Interleukin(IL)-2
(IL2RA) and IL-7 (IL7R) and in IL-7 itself. The conditionally independent variants
representing these associations are: rs142376788 located in the 5’ untranslated region
(UTR) of IL7R, rs11567705 located in an intron of IL7R, rs72928038 located in an intron
of BACH2, rs10957897 located in an intron of IL7R, and rs3118471 located in an intron of
IL2RA.
5.3.2.2 Interleukin 2 receptor alpha
IL-2RA is a transmembrane protein present on nearly all activated T cells, but not on
resting T cells [172]. IL-2RA is the subject of therapeutic antibody Daclizumab found
effective for treatment of MS by blocking T-lymphocyte IL-2RA receptors. This results
in significant expansion of natural killer (NK) cell population and gradual reduction in
numbers of activated T-lymphocyte cells [24].
It could be expected that a lymphocyte pool with higher numbers of activated cells or
NK cells which are granular will have a higher LY-SSC measurement [32]. Therefore, we
could hypothesise that Daclizumab would raise LY-SSC measurement in patients due to
it’s effect on increasing NK population.
A variant in IL2RA (rs3118471, -Log10P: 8.60, MAF: 29.9%, VEP: intronic IL2RA)
is associated with a reduction in LY-SSC, an increase in LYMPH# and colocalises with
increased risk of MS (PP: 99.9%, Fig. 5.5) [152]. Supporting my aforementioned hypothesis:
at this locus an association annotated to the mechanistic target for Daclizumab is increasing
the risk of MS and decreasing LY-SSC. It is interesting that the variant annotated to
IL2-RA is associated with an increased risk of MS and decreased LY-SSC, because the
variant is acting consistently in the opposite direction to Daclizumab. Daclizumab acts
‘against’ MS aetiology, and increases NK population, a granular subset of lymphocytes
[32] - thus the opposite of this genetic association. This result shows that colocalisation of
Sysmex parameters with disease risk GWAS can identify association signals annotated to
genes which are already validated therapeutic drug targets.
Furthermore, from these results, perhaps it could also be argued that MS patients
with lower LY-SSC are those most likely to benefit from Daclizumab? This would be
supported by the genetic evidence, an association increasing the risk of MS decreases
LY-SSC. However, there doesn’t seem to be a convincing causal relationship between
genome-wide instrumental variables for LY-SSC and MS as assessed by MR (MR-Egger,
P-value: 0.37, causal estimate: 1.60), a full set of MR results are available in Supplementary
file A.3. Separately, a counter-argument could be made that the increase in LY-SSC is
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purely as a function of the increase in lymphocyte count. This is somewhat unlikely
due to the anti-correlation between LY-SSC and LYMPH#, with a Pearson correlation
between phenotypes of -0.183 and a genetic correlation of -0.248 (P-value: 5.13x10−5).
Furthermore, Shirley et al., reported that the clinical effect of Daclizumab is not thought
to result from ‘broad immunodepletion’ of overall lymphocyte cell counts, but instead
through immunomodulation of lymphocyte cell subtypes [156].
However, an interpretation of the LY-SSC parameter, or any lymphocyte scatter
parameter is difficult to make compared to other white cell Sysmex parameters, because of
the heterogeneous nature of the lymphocyte population (Section 6.1.1). It is possible that
a comparison of SSC as an index of granulation between NK cells and other lymphocytes
is confounded by other structural differences between lymphocyte cell types (Section
1.1.3). Therefore, confident interpretations of lymphocyte parameters will require better
understanding of the cytometry properties of different lymphocyte subtypes in isolation.
For example, a SSC comparison between purified NK, T, and B lymphocyte populations.
5.3.2.3 Interleukin 7 receptor
I identified four conditionally significant variants annotated to IL7R, assigned to two
statistically distinct signals (Signal ID: 236 and 237 in Table A.1), which are associated
with seven lymphocyte traits including LYMPH#, LY-SFL, LY-SSC, RE-LYMP%, and
RE-LYMP# (Table A.1). LY-SFL and LY-SSC indicate lymphocyte populations with
higher nucleic acid content and cell granulation respectively. RE-LYMP# is the count of
lymphocyte cells with high SFL values, a reactive and activated lymphocyte sub-population
(Section 3.2.2). The locus of association at IL7R decreased the value of the aforementioned
lymphocyte parameters which include proxies for properties related to cell activation. This
association also reduces the genetic risk for hay fever and rhinitis (PP: 99.1%). This result
between IL7R and hayfever or rhinitis is consistent with a clinical study showing the
expression of IL7R increasing 14% following allergen immunotherapy, and also a decrease
expression following ragweed season, a time of year with high allergen concentrations [19].
Variants in IL7R also colocalised with a range of immune disorders including MS (Fig. 5.6)
[152], and primary biliary cirrhosis (PP: 95.7% and 85.6%) [48]. The targeting of IL-7R
using antibodies in preclinical mouse models of MS shows dramatic therapeutic effects [96].
Our association and colocalisation adds statistical genetic evidence from human cohorts
for the therapeutic effect of this drug target. My finding adds proof of efficacy for this
drug target by leveraging genetic studies of lymphocyte parameters, and risk of multiple
immune disorders (hayfever and rhinitis, MS and primary biliary cirrhosis.
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Figure 5.5: Plot showing colocalisation between disease risk for multiple scle-
rosis and lymphocyte side scatter.
Each data point represents a genetic variant and the position of that data point in the y is the
-Log10P for association with the phenotype. Variants are coloured according to their LD with
the conditionally significant variant in this locus. Colocalisation between the two association
signals occurs with posterior probability of 99.9%, LD between the conditionally significant
variant (rs3118471) and sentinel (rs3118470) in disease risk GWAS is 0.96 r2. The GWAS of MS
is performed by Sawcer et al., 2011 [152].
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Figure 5.6: Plot showing colocalisation between disease risk for multiple scle-
rosis and reactive lymphocyte count.
Each data point represents a genetic variant and the position of that data point in the y axis is
the -Log10P for association with the phenotype. Variants are coloured according to their LD
with the conditionally significant variant in this locus. Colocalisation between the two
association signals occurs with posterior probability of 95.7%. LD between the conditionally
significant variant (rs11567705) and sentinel (rs6881706) in disease risk GWAS is 1.00 r2. The
GWAS of MS was performed by Beecham et al., 2013 [2]. The sparsity in genetic variants in the
disease GWAS figure (bottom) is caused by the difference in genotyping panel between the two
studies.
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5.3.2.4 NE-FSC, IL-18R1 and atopic dermatitis
My GWAS analysis of NE-FSC identifies 70 independent conditionally significant variants,
including an association annotated to the IL-18R1 gene (rs1035127, MAF: 22.3%, -Log10P:
10.9, VEP: downstream IL18-R1 ). The ligand of IL-18R1, IL-18, is a neutrophil activator
and blood samples with higher levels of interleukins such as IL-18 contain neutrophil
populations with higher NE-FSC values [88]. IL-18 expression has been shown to contribute
to aetiology of celiac disease [100], atopic dermatitis [95], and psoriasis [67].
rs1035127 annotated to IL-18R1 associated with a decrease in NE-FSC, which also
colocalises with a pQTL signal for decrease in plasma IL-18R1 (PP: 98.0%), and increased
risk of celiac disease (PP: 93.4%), but decreased risk of eczema and IBD (PP: 93.0%
and 84.1% respectively). This is a confusing result, as celiac disease is considered to
be a differential diagnosis of IBD and shares much of the same disease aetiology [133].
Therefore, this locus is already raising interesting questions about the potential differential
role of IL-18R1 regarding celiac disease and IBD. I found explaining this result difficult, I
hope that by publication of this thesis I may attract colleagues to address this finding.
I previously noted that rs1035127 is associated with a decrease in NE-FSC and increase
in plasma IL-18R1, furthermore, IL-18R1 is expressed with Log2(FPKM) 4.6 in neutrophil
cells [43]. This shows a common genetic determinant between NE-FSC, IL-18R1 expression
in the blood plasma, and the aetiology of immune disorders. From these results it might be
tempting to suggest that that neutrophil cells with lower FSC result in decreased IL-18R1
in blood plasma and changes in risk of immune disorders. This is one possible explanation
which would explain the observed results. However, colocalisation analysis cannot not
show a causal relationship between these factors, only the high probability of a common
genetic determinant, and even this must be interpreted with an understanding of the
limitations of colocalisation (Section 6.1.3).
Mendelian randomisation analysis of NE-FSC as an exposure did not show a significant
causal relationship between NE-FSC and autoimmune disorders: celiac disease (P-value:
0.88) and eczema (P-value: 0.58). This MR included instrumental variables from across
the genome, not just IL-18R1. However, a MR of IL-18R1 blood plasma concentration by
Sun et al. suggested that IL-18R1 may have a causal relationship with atopic dermatitis
(P-value: 1.5× 10−28) [164]. Atopic dermatitis is a diagnosis under the umbrella of eczema
which includes dermatitis syndromes generally [179]. It is unfortunate my colocalisation
analysis was performed with GWAS results of eczema and the MR by Sun et al., was
performed using GWAS results of atopic dermatitis. Further work to explore this signal
of association could begin with repeating the analysis with summary statistics from the
respective outcome.
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5.3.3 Genetic characterisation of white cell granulation
Degranulation of white cells has long been established as an important mechanism of
immune response. My analysis identifies associations annotated to granule proteins by
VEP such as DEF, CTSH, CTSC, ELANE, ARSB, LYZ, RNASE2, RNASE3, and RNASE6
(Appendix A.1). In particular, my analysis is the first GWAS of blood phenotypes to
annotate associations to DEF, CTSH, CTSC, ELANE. This is despite extensive study
showing the importance of such granule proteins in white cell immune function [28].
Many proteins known to be present in granules of white cells have also been identified
as circulating blood plasma proteins [164]. My analysis shows there is often a common
genetic architecture underlying blood plasma protein concentrations and blood cell Sysmex
parameters, in particular SSC an index of cell granulation.
Azurophilic granules are present in a range of white blood cells and most prominent
in neutrophils, where they are loaded with a range of antimicrobial proteins, and play
a critical role in neutrophil immune response [144]. Neutrophil scatter measurements
SFL, SSC, and FSC have been proven to be indicative of neutrophil action and immune
response [103] [146] [188]. GWAS of neutrophil indices identified variants annotated to
MPO, PRTN3, ELANE, BPI, ARSB, CTSC, CTSH, LYZ, and RNASE2, microcidal
proteins which are also known to localise in azurophil granules. Furthermore, signals in
these genes also colocalise with pQTL signals for plasma proteomics of the same granule
proteins (Appendix A.1). An association signal located in ARSB containing conditionally
significant associations with EO-SSC, NE-SSC, NE-SFL, and NE-FSC colocalise (PP: 93%,
98%, 98%, 99%) with a pQTL signal for ARSB in the plasma proteome. Monocyte side
fluorescence is associated with four conditionally independent signals in the RNASE region
on chromosome 14. Associations include rs1045922 (-Log10P: 44.9, MAF: 23.8%, VEP:
missense) located in RNASE6, rs6571511 (-Log10P: 58.9, MAF: 7.7%, VEP: upstream)
located in the RNASE3 gene, rs151169198 (-log10P: 10.7, MAF: 0.80%, VEP: missense)
and rs2771358 (-Log10P: 152.2, MAF: 25.4%, VEP: upstream) both of which are annotated
to RNASE2 by VEP.
RNASE6 has been shown to be localised to the granules of leukocytes and granulocyte
cells. Exocytosis of granules secretes RNASE and other proteins which conduct antimicro-
bial activity [18]. Variant rs1045922 is a conditionally significant association for monocyte
side fluorescence colocalising with eQTL analysis of RNASE6 transcripts in CD14 cells
(PP: 99.4%). Variant rs1045922 also has a pairwise LD of 1.00 r2 and colocalises (PP:
98%) with rs11622942 a conditionally significant pQTL variant for the RNASE6 protein
in the plasma proteome [164].
My analysis of novel blood indices has identified granule proteins which are known to
be crucial in immune function, but remained unidentified by GWAS of traditional blood
cell indices. Furthermore, my integration of data from pQTL analysis by colocalisation
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has shown common genetic architecture modulating white cell granularity indices and
many blood plasma proteins. A likely explanation for these colocalisations is that granule
proteins in plasma are originating from granule proteins in blood cells, this hypothesis
and has been suggested by others [164, 5, 101].
5.3.3.1 ANCA-associated vasculitis
ANCA-associated vasculitis (AAV) is an autoimmune syndrome characterised by vascular
inflammation and autoantibodies against neutrophil granule proteins MPO or proteinase-3
(PR3, encoded by the PRTN3 gene) [107]. It has been shown that genetic variation
which affects PR3 abundance in circulation influences risk of vasculitis with anti-PR3
antibodies [164]. I identified a locus in the PRTN3 region associated with an increase
in neutrophil SSC, SFL, FSC (indices of granule content and of nucleic acid content,
membrane composition, and cell size respectively). This genetic signal also colocalises
with an increase for eQTL in whole blood (GTEX PP: 98.9%) and the pQTL in PR3
plasma concentration (PP: 99.7%). Together, these results suggest that genetic effects on
PRTN3 transcription are reflected in changes in neutrophil granule content and influence
abundance of PR3 in the circulation and thereby disease risk. PR3 is also expressed in
other myeloid cells including eosinophils (Supp. Table 2). Notably this same genetic
signal also colocalises with EO-SFL (a marker of nucleic acid content and membrane
composition), suggesting that the genetic effects on PR3 may also be acting through
eosinophils. Unfortunately, due to the pleiotropic nature of this genetic variant, it is not
possible to identify from these results whether the association in question is acting through
eosinophils, neutrophils, or a combination of both. Intriguingly, a subset of AAV patients
have eosinophilia, although this is more common in the context of antibodies to MPO
rather than to PR3.
5.3.4 Causal association with Mendelian randomisation
Mendelian randomisation can identify casual associations between risk factors and outcomes
of interest using genetic variants as instrumental variables. In the context of MR, Sysmex
parameters are treated as the exposure and disease risk as the outcome. This is testing for
Sysmex parameters as causal mediators of disease risk.
I selected 15 white cell Sysmex parameters to assess for causal relationships with risk
for 23 complex diseases (Table 5.7), summary statistics for disease outcomes were collected
using the MR Base package [80] (Table 5.8). The parameters selected are SSC, SFL, and
FSC measurements of white cells and RE-LYMP#. Genetic variants associated with
each phenotype are selected as ‘instrumental variables’ (IVs) which are used to determine
causality (Section 5.2.2). I began by performing a robust penalised MR-Egger regression,
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the intercept of the MR-Egger models directional pleiotropy of the IVs. If the Wald
statistic of the intercept was less than one, I interpreted the IVs as having balanced
pleiotropy, thus having satisfied the assumptions of inverse variance weighted (IVW)
regression. In such cases I assessed causality with a robust penalised IVW model which
offers greater power than the MR-Egger method [29]. P-values are Bonferroni corrected
for the 15 traits and 23 diseases which are tested for causal association. To assess the
robustness of results I tested causal association with 11 types of Mendelian randomisation
models (Table 5.2.2.2) including IVW models which assume balanced pleiotropy across the
IVs, MR-Egger models which allow for unbalanced pleiotropy across IVs, median based
methods which assume at least 50% of IVs are valid and do not suffer from pleiotropy,
multivariable models to test for association accounting for effects of the instrumental
variables on other Sysmex parameters and traditional blood cell phenotypes. Weighted,
penalised, and robust methods of linear regression were used to account for standard error
of IVs, and heterogeneity of IVs respectively. Three pairs showed statistically significant
causal associations as assessed by MR between Sysmex parameters and complex disease:
NE-SSC and the risk for lung cancer and CAD and EO-FSC and the risk of asthma.
I integrated and visualised results and integrated all MR tests in an interactive report
which includes LD between instrumental variables in the model, integration of LD set data
to annotate instrumental variables, and leave one out analysis (LOO) analysis where the
IVW estimate is recalculated with each of the instrumental variables excluded (Supp. A.3).
Reports are generated in simple hypertext markup language (HTML) format which can
be opened with any electronic device with an internet browser without the need to install
or prepare any additional software. A full set of reports is available in HTML format in
the supplementary (Supp. A.3).
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5.3.4.1 Heterogenity and pleiotropy in instrumental variables
The results indicated a high degree of heterogenity and pleiotropy in the instrumental
variables suggesting multiple pathways contributing to the exposure of interest with
differential association with the disease risk. An example is a test for causality between
NE-SSC and CAD (Fig. 5.7, 5.8). The MR test for causality with an IVW model
resulted in no significance with a P-value of 0.01, compared to a much stronger significance
with Penalised Robust IVW MR model (P-value: 7.26× 10−6). This could be caused by
heterogeneity in the data, as the Penalisation and Robust methods both reduce the influence
of outlying data points on the regression (Chapter 5.2.2). Cochran’s Q statistic suggests
heterogenity for NE-SSC and CAD (Q : 82.2, df : 53,P-value : 6.23 × 10−3) (Section
5.3.4.3), but no heterogenity for NE-SSC and lung cancer (Q : 44.4, df : 53,P-value : 0.773)
(Section 5.3.4.4), and EO-FSC with asthma (Q : 7.22, df : 10,P-value : 0.704) (Section
5.3.4.5).
5.3.4.2 Multivariable Mendelian randomisation
I performed a multivariable MR analysis in order to assess whether causal estimates are
consistent even when considering effects of instrumental variables on other Sysmex and
FBC parameters. I identified Sysmex parameters for which instrumental variables may be
acting through pleiotropy for each of the three identified associations (NE-SSC & CAD or
lung cancer, and EO-FSC with asthma). This was done using the LD clumping approach
(Chapter 2.2.9). If an instrumental variable is in the same clump as associations with other
parameters that parameter is considered to be a potential pleiotropic factor. Furthermore,
I also considered the cell type appropriate FBC count and percentage (of all white blood
cells) measurements for multivariable analysis.
My analysis suggests that NE-SSC and CAD or lung cancer causal associations are
robust for possible pleiotropy with other Sysmex parameters (Fig. 5.9, 5.10). However, in
the case of EO-FSC and asthma the multivariable MR analysis is complicated by high
correlation between the estimated effect size of the instrumental variables on EO-FSC
and other parameters studied in the multivariable analysis such as EO-SSC, EO-SSC-DW,
EO-SFL with r2 correlations of 0.88, 0.79, and 0.71 respectively (Fig. 5.11). It is generally
expected that estimates of covariate effect size in a linear model become unreliable with
collinearities of above 0.8 r2. However, causal estimates for EO-FSC with asthma are
robust to inclusion of eosinophil count and percentage FBC parameters. This suggests
that there is additional information regarding the causal role of eosinophils in asthma
beyond that already proposed by MR of eosinophil count and risk of asthma [15]. More
detailed analysis is required to assess whether EO-FSC is indeed causally mediating risk
of asthma or if there is a potential pleiotropic effect via other eosinophil parameters, or a
combination of both of these factors.
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Figure 5.7: Mendelian randomisation to test for causal association between
NE-SSC and CAD.
A diagram representing the framework of a MR analysis using conditionally independent
variants associated with NE-SSC to test for causal association between NE-SSC and CAD.
Figure 5.8: Scatterplot of instrumental variables and association with NE-SSC
and CAD.
Bars represent 95% confidence intervals for estimate of effect size of instrumental variables with
either the exposure or outcome. Results show good concordance between causal estimates of
sensitivity analyses. The Penalised Robust IVW model predicts causal association between
NE-SSC and CAD (β : 0.0355,P-value : 7.26× 10−6).
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Figure 5.9: Pairwise multivariable IVW MR models for CAD containing NE-
SSC and a covariate.
Each covariate is listed on the y axis with the Pearson correlation between the phenotype of that
covariate and NE-SSC. The x axis is the calculated change in odds ratio for disease risk given 1
SD increase in NE-SSC in a multivariable MR model containing the corresponding covariate.
This is compared to the estimates for causal association from Penalised robust IVW and
Penalised robust MR-Egger containing NE-SSC only. The Pearson correlation (r2) between
instrumental variable effect sizes for each of the covariates is in brackets.
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Figure 5.10: Pairwise multivariable IVW MR models for Lung cancer contain-
ing NE-SSC and a covariate.
Each covariate is listed on the y axis with the Pearson correlation between the phenotype of that
covariate and NE-SSC. The x axis is the calculated change in odds ratio for disease risk given 1
SD increase in NE-SSC in a multivariable MR model containing the corresponding covariate.
This is compared to the estimates for causal association from Penalised robust IVW and
Penalised robust MR-Egger containing NE-SSC only. The Pearson correlation (r2) between
instrumental variable effect sizes for each of the covariates is in brackets.
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Figure 5.11: Pairwise multivariable IVW MR models containing EO-FSC and
a covariate.
Each covariate is listed on the y axis with the Pearson correlation between the phenotype of that
covariate and EO-FSC. The x axis is the calculated change in odds ratio for disease risk given 1
SD increase in EO-FSC in a multivariable MR model containing the corresponding covariate.
This is compared to the estimates for causal association from Penalised robust IVW and
Penalised robust MR-Egger containing EO-FSC only. The Pearson correlation (r2) between
instrumental variable effect sizes for each of the covariates is in brackets.
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5.3.4.3 Neutrophil side scatter and coronary artery disease
Neutrophils play a crucial role in thrombosis and acute coronary syndromes. In a mouse
study of endothelial damage, neutrophils were shown to be the first cells at the site of dam-
age even preceding platelets [51]. In acute coronary syndromes, neutrophil degranulation
damages intact cells, the extracellular matrix,promotes further neutrophil recruitment,
and increases infarct size [69]. In particular, neutrophil recruitment of monocytes by
release of chemoattractants which includes granule proteins has been noted as a cause
for the role of neutrophils in acute coronary syndrome [69]. ARSB is a blood marker of
neutrophil activation correlates with poor prognosis of heart disease [69] [26]. It is notable
that variants in this gene are associated with NE-SSC and colocalise with pQTL of ARSB
in the blood. Two instrumental variables annotated to ARSB inform the aforementioned
MR analysis of NE-SSC and CAD. Furthermore, 11 instrumental variables annotated to
the α-DEFENSIN are present in the MR analysis. To identify if α-DEFENSIN variants
are responsible for the identified causal association I removed all variants within the range
chr8:4,000,000-7,000,000 (hg19). This removal results in no significant association between
NE-SSC and CAD, but simultaneously does now show a significant change in the causal
estimate (Table 5.9). This suggests that instrumental variables in the α-DEFENSIN locus
are consistent with the estimated causality, but do not explain the observation in entirety
5.3.4.4 Neutrophil side scatter and lung cancer
Neutrophils have been suggested to play both pro-tumorigenic and anti-tumorigenic roles
[168]. Serum α-DEFENSIN protein levels have been noted to be elevated in patients
with lung cancer and this has been suggested as a diagnostic tool for lung cancer [12].
IVs located in genes DEFA9P, DEFA3, DEFA1B, DEFA11P are located along the axis
of causality in the robust penalised IVW MR showing that these signals are along the
predicted causal axis. Removal of the 11 IVs located in the α-DEFENSIN locus results in
a loss of significance in the causal estimate between NE-SSC and Lung Cancer, but no
great change in the estimated causal effect (Table 5.9).
Risk Factor Outcome
Robust Penalised IVW
Estimate (P-value)
Removal DEF IVs
Estimate (P-value)
NE-SSC CAD 0.0346 (1.63× 10−5) 0.0273 (0.0369)
NE-SSC Lung Cancer 0.0548 (7.47× 10−5) 0.0571 (0.0109)
Table 5.9: Comparison of MR estimates following removal of α-DEFENSIN
locus instrumental variables.
Removal of instrumental variables in the α-DEFENSIN locus shows that the significant causal
association identified between NE-SSC with CAD and lung cancer is dependent on the
α-DEFENSIN locus.
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Figure 5.12: Scatterplot of instrumental variables and association with NE-
SSC and lung cancer.
Bars represent 95% confidence intervals for estimate of effect size of instrumental variables with
either the exposure or outcome. Results show good concordance between causal estimates of
sensitivity analyses. The Penalised Robust IVW model predicts causal association between
NE-SSC and lung cancer (β : 0.0561,P-value : 4.55× 10−5).
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Figure 5.13: Scatterplot of instrumental variables and association with EO-
FSC and asthma.
Bars represent 95% confidence intervals for estimate of effect size of instrumental variables with
either the exposure or outcome. Results show good concordance between causal estimates of
sensitivity analyses. The Penalised Robust IVW model predicts causal association between
EO-FSC and Asthma (β : 0.232,P-value : 3.68× 10−5).
5.3.4.5 Eosinophil forward scatter and asthma
Eosinophil forward scatter shows a positive causal association with risk of asthma according
to the univariable MR study and associated sensitivity analyses (Fig. 5.13). However,
the associated effect size of instrumental variables for EO-FSC are highly correlated with
EO-SSC (pearson r2 0.93) suggesting pleiotropy. Although, it is interesting to note that
this purported causal relationship seems to be largely independent of the known causal
association between eosinophil count and asthma [15] Fig. 5.11). This suggests two
separate eosinophil properties which causally increase the risk of asthma. More study is
required to understand the effect of these instrumental variables which may be acting
through another intermediary risk factor, but seem independent to the already shown
causal relationship between eosinophil count and asthma [15].
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5.4 Discussion
In this chapter I have detailed my downstream analysis of GWAS results to generate
hypotheses relating to the study of haematology and disease including cardiovascular
disease, immune disorders, and cancer. My colocalisation analysis annotated genetic deter-
minants associated with Sysmex parameters to signals influencing blood cell transcriptome,
blood plasma proteome, and disease risk. This analysis identified genetic determinants as
causally mediating multiple factors and thus helps with interpretation of the gene and
pathways which are mediated by the genetic determinant. My results have identified
disease colocalisations with associated signals in genes which are known drug targets such
as IL-2RA and Daclizumab and evidence for the role of IL-18R1 in aetiology of celiac
disease and IL-7R in a number of autoimmune disorders. Furthermore, I performed a MR
analysis to determine causal associations between the risk factors and disease, the risk
factors of interest being Sysmex parameters which have been shown to be relevant proxies
for cell immune function and activation. Identified associations include NE-SSC and lung
cancer or CAD, and EO-FSC and asthma. MR analysis is limited the assumptions of
MR models, which I address with a sensitivity analysis to assess robust causal estimates.
Interpretation of these results should be made within context of the limitations of genetic
studies and the phenotypes of interest which are discussed further in Chapter 6.
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Chapter 6
Conclusion
I have performed the first ever GWAS of flow cytometry parameters derived from a Sysmex
analyser. Many of these parameters have been shown to be clinically and functionally
relevant readouts of the haematological system (Section 3.2.3). My analysis identified
hundreds of new genetic loci and association signals, many of which are located in genes
known to be relevant for immune cell function and activation (Section 4). Furthermore,
I contribute to the largest ever study of classical FBC haematological parameters and
identify a large number of distinct signals including those which have not previously been
associated with blood cell phenotypes.
In Chapter 2 I describe my contributions to the BCX consortium and our collective
work to perform the largest GWAS of haematological traits. This includes a conditional
analysis of the UK Biobank cohort and subsequent joint modelling to identify distinct
signals identified by a larger meta-analysis.
In Chapter 3 I discuss data collection and QC of extended Sysmex parameters and
associated genotypes. This includes correction of data for technical and environmental
factors. Technical factors included time of day, time since start of study, and time of
year. Environmental factors included, smoking history, age, sex, and weight. Adjustment
for these factors reduced variation in parameters and increased power to detect genetic
associations.
In Chapter 4 I detail my GWAS and conditional analysis of Sysmex parameters, this
includes discussion of multiple testing and population stratification in GWAS studies. I
show that my GWAS and conditional analysis of extended Sysmex parameters identifies
2,142 conditionally independent associations and 849 LD sets across 63 phenotypes.
Finally, in Chapter 5 I outline my downstream analysis of GWAS results, including
disease, eQTL, and pQTL colocalisation. This analysis identifies genetic determinants of
Sysmex parameters which also influence other biological properties including disease risk.
Examples including IL18R1 associated with NE-FSC and atopic dermatitis, and IL2RA
associated with lymphocyte parameters and MS.
161
6.1 Limitations of work
6.1.1 Interpretability of Sysmex parameters
I present Sysmex parameters as ‘functionally relevant’ measurements of blood cell properties
as justified with prior literature (Section 3.2.3) and also by a literature review of genes
identified from annotation of GWAS association signals which identified genes relevant to
white cell function (Section 4.3.1.2). However, the interpretability of these phenotypes
and importantly, the possibility to intervene on these phenotypes as a clinical end point
is limited. For example, neutrophil side scatter (NE-SSC) a known index of granulation
which has been shown to correlate with incidence of disease and visual assessments of
neutrophil granularity. I show evidence from MR analysis that suggests NE-SSC may
be a causal mediator of CAD and lung cancer (Section 5.3.4). However, there is no
currently known clinical intervention that could reduce NE-SSC in patients. Alternatively,
lymphocyte side scatter (LY-SSC) is a measure of the side scatter of lymphocyte cells and
GWAS of this trait identifies a number of association signals located in genes important for
lymphocyte function, often colocalising in diseases with known lymphocyte involvement
such as MS. However, for associations which raise the LY-SSC property, it is not clear by
which lymphocyte subsets the effect is being observed. It could be the granular LGL cells
such as NK or cytotoxic T cells, or some other structural changes in other lymphocyte
subtypes.
In modern GWAS studies, single sets of phenotypes are rarely considered alone because
freely available summary statistics allows more detailed analysis including multiple sets
of phenotypes. Sysmex parameters can be used a intermediate traits and colocalised to
more interpretable outcomes such as disease risk, or eQTL and pQTL measurements. In
this way, Sysmex parameters are yet another layer of information which can be used to
annotate genetic determinants and shouldn’t be used as the sole source of information to
support a hypothesis.
6.1.2 Establishing causality
Establishing causal relationships between biological components is fundamental to our
understanding of biology. However, the hypothesis generating nature of GWAS analysis
presents challenges in proving causality. For example, the identification of an association
signal suggests many, often hundreds, of variants which could be mediating the association
signal (Section 1.4). GWAS analyses are not measuring the change in a phenotype as a
result of an genetic intervention. Therefore it is not easily possible to define which variant
is causally mediating the observed signal. It is possible that the true causal variant may
not have been genotyped or imputed. Such a scenario could be difficult or impossible to
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identify without performing an experiment where the genetic variant is induced and any
changes in phenotype observed.
Establishing causal relationships between phenotypes or traits is similarly difficult.
In many points in my thesis I describe colocalisation analysis which shows a common
genetic determinant between two phenotypes (Sections 5.3.2.1, 5.3.2.4). There are multiple
mechanisms by which a colocalisation between two traits would arise. Firstly there
could be a causal relationship between two traits where mediation of one trait results in
concomitant changes in the other, for example, low density lipoprotein (LDL) and CAD risk.
Alternatively, the genetic variant could be mediating both traits independently, through
different biological pathways. Followup MR studies can determine causality between two
traits, and this approach has been successful in the study of blood cell phenotypes before
[15]. However, MR analysis are burdened with a number of assumptions many of which
are difficult to test. For example, ensuring that instrumental variables are non-pleiotropic
and are not influencing the outcome via a different biological mechanism other than the
intended exposure (Section 5.2.2). This is difficult to prove definitively for any single
instrumental variable.
6.1.3 Limitations of colocalisation
If a locus contains association signals with two phenotypes, colocalisation analysis can
determine if the associations are being caused by the same genetic determinant. An
introduction to colocalisation analysis and an overview of the mathematical implementation
can be found in Sections 1.6.2 and 5.2.1 respectively. Here I focus my discussion on the
limitations of colocalisation which must be held in account when interpreting results
colocalisation analysis:
1. If two distinct associations are caused by a two distinct underlying variants which
are in LD 1.00 r2, colocalisation cannot distinguish between such associations.
2. Colocalisation assumes only one association signal per locus, if multiple association
signals exist they can bias results towards reporting false negatives.
3. It must be stressed that colocalisation simply identifies a common genetic determinant
in a particular locus between two phenotypes, not a causal relationship between the
phenotypes
Situations leading to point 1) cannot be tested properly with a statistical genetics
approach alone, we must always aim to validate with biological experimentation, such as
genetic modification of an animal or tissue model. However, in the case of rare variants
which are less likely to be in high LD with other variants this limitation is ameliorated by
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being less likely to occur. Furthermore, given that most genetic variants in the genome
have almost no effect on a phenotype in question, it would seem unlikely that within a
small set of variants which are in high LD two variants would have distinct effects on
separate phenotypes. Point 2) is less concerning as it can only lead to false negative
results, furthermore an associated locus is unlikely to ever contain a single phenotype
influencing variant. There likely will exist many possible associations nearby which simply
do not reach significance, nearby associations only become problematic when their relative
significance is close to the significance of the ‘main’ association we wish to colocalise. As
GWAS is performed on a greater number of phenotypes, colocalisation analysis will become
more important to allow proper characterisation of the effect of a genetic determinant.
6.1.4 Replication of results
A unique aspect of my work is being the first analysis of functionally relevant white cell
phenotypes. However it follows that my analysis is also lacking in a replication set which
would allow me to further validate my results. Confounding effects such as population
stratification or technical artefacts can lead to spurious associations, validation can help
identify these false positives. I hope my thesis will lead to more interest in Sysmex
parameters and thus spur further GWAS analyses of these phenotypes.
6.2 Recommendations for future research
6.2.1 Validation and meta-analysis with the COMPARE study
The COMPARE study has recruited a cohort of 31,000 healthy donors to compare three
methods for making haemoglobin measurements: blood extraction from the finger, measure-
ment with a spectrometer placed over the skin, Sysmex automated haematology analysis.
At the time of writing genotyping of this cohort has not concluded, in the future this data
could be utilised to validate my GWAS of Sysmex parameters in INTERVAL. Furthermore,
a meta-analysis with both the INTERVAL and COMPARE cohorts would increase the
population cohort to 66,000 individuals. Combining the technical and environmental
correction procedures between these studies would allow for a more accurate statistical
deduction on the effects of covariates on haematological parameters and make a more
effective correction procedure.
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6.2.2 Utilising the second measurement from the INTERVAL
trial
Blood donors in both the INTERVAL and COMPARE cohorts provide a second measure-
ment for haematological analysis, which in the case of INTERVAL is 2 years following
their initial donation, and in the COMPARE study following their first donation. I only
utilised the second time-point of measurement for participants in the INTERVAL trial if
data for the first time point was not available. This was the case for only a small subset of
individuals due to a data storage issue during the trial. A statistical correction procedure
which utilises both first and second measurement in all individuals where available could
significantly increase the effective power to detect genetic associations. This analysis could
be done by firstly performing technical and environmental correction on all measurements
as before, then simply calculating the mean between both time points for each individuals.
This analysis would be complicated by at least two factors:
1. Individuals in INTERVAL would be two years older in their second measurement.
In some participants this may mean they would have experienced menopause which
is known to have a large impact on haematological measurements.
2. Donors in the INTERVAL cohort would have been assigned to different donation
schedules.
These factors could be mitigated by including age and donation schedule as a factor in
the environmental adjustment, menopause status was already included in this adjustment.
Separately, comparing second and first measurement would provide a better sense of
intra-individual variability of these parameters. It is not known, for example if individuals
generally have fairly consistent eosinophil size (EO-FSC) measurements over the course
of time. These observations would be of general interest to haematologists and provide
better characterisation of these haematological properties.
6.2.3 Raw flow cytometry data and predictive models
Haematological parameters have long been used to make diagnoses and predict disease
status. However, there likely exists a greater degree of information in a Sysmex analysis
beyond what is reported as a parameter. The three dimensional position of every cell
in the scattergram is not a useful representation of information for a clinical doctor as
this data would be too difficult for a them to interpret. Instead of relying on parameters
which are inherently a simplification of the rich data available from a scattergram, we
could use modern statistical techniques to consider the entire dataset in order to make
predictions regarding disease status. Machine learning algorithms such as neural networks
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have the ability to consider a high-dimensional input of data, training this algorithm over
time would allow learning of which features in the dataset are the most important with
respect to predicting an outcome. A potential outcome would be to use the raw Sysmex
cytometry data to train a neural network to predict the age, sex, or menopause status of
a participant. This protocol could also be used to predict disease status of participants,
although this would not be possible in using INTERVAL or COMPARE datasets as the
participants are healthy blood donors. More interesting would be to combine the Sysmex
scattergram data with participant age, sex, weight, height, and other information. Neural
networks would effectively integrate these input features and learn relationships which are
useful with respect to the outcome.
6.3 Closing statement
In the introduction of my thesis I presented statistical genetics as not just as a methodology
to better understand human genetics, but also a method by which we can further our
understanding of the biology and disease aetiology. Biology exists as a complex set of
interconnected elements, connected deferentially by time, space, and biological compart-
ment. I propose that statistical geneticists of the future should not narrow their analysis
to a particular set of phenotypes or a disease outcome. Using genetic variants we can
reliably combine data from multiple studies done over time in different sets of individuals,
thus making the massive phenotypic profiling required to develop a comprehensive under-
standing of biological systems tractable. I hope that further study in this field continues
to advance towards mathematically grounded study of biological systems which allow not
only for accurate exchange of information between researchers, but also ability to make
empirical and testable predictions.
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Appendix A
Appendix
A.1 Table of Sysmex parameter conditionally signifi-
cant variants and eQTL, pQTL, disease colocali-
sations
https://figshare.com/s/c8775dc6d85be9b3afa4
A table of 2,172 conditionally independent variant-trait associations identified from GWAS
of the 63 cytometry parameters listed in Table S1. All coordinates are with respect to GRCh37.
Signal ID corresponds to a unique identifier for each signal of association defined by an LD
clumping procedure (r2 > 0.8). Each variant is given marginal (univariable) summary statistics
for association with the corresponding trait and summary statistics for joint association (MULTI)
in a model including all other conditionally independent variants. Fine-mapping of each locus
allows assignment of variants to credible sets indicated by the FINEMAP Credible Set ID column,
the total number of variants in each credible set are also indicated. Further columns include
posterior probabilities for colocalisation with pQTL, eQTL, and disease association signals.
A.2 Table of conditionally significant associations with
FBC phenotypes from the UK Biobank cohort
https://figshare.com/s/0fe1d830cab86dbe095d
A table containing information regarding each of the 17,042 associations ordered by chromo-
some and position (all coordinates are with respect to GRCh37). Locus ID is a unique identifier
for each locus. The column Novel vs Astle et al. 2016 indicates if the variant or any variants
in LD r2 > 0.8 was already found to be associated with the same traits in the cited previously
published meta-analysis including the first release of UK Biobank. The unique variant ID is
constructed from the chromosome, position and the reference and alternative alleles according
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to the human genome reference (build 37 coordinates). Where available, the rsID is also given.
GWAS summary statistics for univariate and multivariate (conditional) model are provided, as
well as the VEP worst consequence annotation.
A.3 Mendelian randomisation reports interactive HTML
format
https://figshare.com/s/207ae098eb2db3172676
A compressed folder containing HTML reports for the MR analyses, the reports can be accessed
by opening the link and pressing the ‘Download’ button, the file must then be decompressed
resulting in a folder titled ‘mendelian randomisation html’. The reports can then be visualised by
opening the ‘index.html’ file in the ‘mendelian randomisation html’ folder using any web-browser.
A.4 Disease Colocalisation Locuszoom Plots
https://figshare.com/s/9f3e9165300d6468db97
A series of plots showing the regions of colocalisation between Sysmex parameters and disease
outcomes. The x axis represents genomic location, the y axis negative log transformed P-value
of association, and each data-point is the significance of association.
A.5 pQTL Colocalisation Locuszoom Plots
https://figshare.com/s/ce075d0f52aff56c67a8
A series of plots showing the regions of colocalisation between Sysmex parameters and blood
plasma protein QTL. The x axis represents genomic location, the y axis negative log transformed
P-value of association, and each data-point is the significance of association.
A.6 eQTL Colocalisation Locuszoom Plots
https://figshare.com/s/103308605dee49d10a3c
A series of plots showing the regions of colocalisation between Sysmex parameters and blood
cell transcript QTL. The x axis represents genomic location, the y axis negative log transformed
P-value of association, and each data-point is the significance of association.
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A.7 Table of Sysmex parameters
https://figshare.com/s/c3ecdcfcad7a39dcba3d
Each row corresponds to one of the 63 cytometry traits studied in this analysis including columns
indicating the most correlated standard FBC hematological measurement and the number of
new loci discovered per cytometry parameter compared to GWAS of standard FBC parameters.
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